

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72961 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US01/09226

(22) International Filing Date: 22 March 2001 (22.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/192,158 24 March 2000 (24.03.2000) US
60/192,668 28 March 2000 (28.03.2000) US
60/200,166 27 April 2000 (27.04.2000) US

(71) Applicants (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19103
(US). **SMITHKLINE BEECHAM P.L.C.** [GB/GB]; New
Horizons Court, Great West Road, Brentford, Middlesex
TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AGARWAL, Pankaj** [IN/US]; 251 West DeKalb Pike, King of Prussia, PA 19406 (US). **MURDOCH, Paul, R.** [GB/GB]; New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **RIZVI, Safia, K.** [PK/US]; 4617 Pine Street, Philadelphia, PA 19143 (US). **SMITH, Randall, F.** [US/US]; 4138 Presidential Drive, Lafayette Hill, PA 19444 (US). **XIANG, Zhaoying** [CN/US]; 2413

Ridgeway, Fort Lee, NJ 07024 (US). **KABNICK, Karen, S.** [US/US]; 4138 Presidential Drive, Lafayette Hill, PA 19444 (US). **LAI, Ying-Ta** [—/US]; 516 Spruce Avenue, Upper Darby, PA 19082 (US).

(74) Agents: **GIMMI, Edward, R.** et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS

(57) Abstract: Polypeptides and polynucleotides of the genes set forth in Table I and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing polypeptides and polynucleotides of the genes set forth in Table I in diagnostic assays.

WO 01/72961 A2

Novel Compounds

Field of Invention

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides. The polynucleotides and polypeptides of the present invention also relate to proteins with signal sequences which allow them to be secreted extracellularly or membrane-associated (hereinafter often referred collectively as secreted proteins or secreted polypeptides).

Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

Proteins and polypeptides that are naturally secreted into blood, lymph and other body fluids, or secreted into the cellular membrane are of primary interest for pharmaceutical research and development. The reason for this interest is the relative ease to target protein therapeutics into their place of action (body fluids or the cellular membrane). The natural pathway for protein secretion into extracellular space is the endoplasmic reticulum in eukaryotes and the inner membrane in prokaryotes (Palade, 1975, Science, 189, 347; Milstein, Brownlee, Harrison, and Mathews, 1972, Nature New Biol., 239, 117; Blobel, and Dobberstein, 1975, J. Cell. Biol., 67, 835). On the other hand, there is no known natural pathway for exporting a protein from the exterior of the cells into the cytosol (with the exception of pinocytosis, a mechanism of snake venom toxin intrusion into cells). Therefore targeting protein therapeutics into cells poses extreme difficulties.

The secreted and membrane-associated proteins include but are not limited to all peptide hormones and their receptors (including but not limited to insulin, growth hormones, chemokines, cytokines, neuropeptides, integrins, kallikreins, lamins,

melanins, natriuretic hormones, neuropeptides, neurotrophins, pituitary hormones, pleiotropins, prostaglandins, secretogranins, selectins, thromboglobulins, thymosins), the breast and colon cancer gene products, leptin, the obesity gene protein and its receptors, serum albumin, superoxide dismutase, spliceosome proteins, 7TM (transmembrane) proteins also called as G-protein coupled receptors, immunoglobulins, several families of serine proteinases (including but not limited to proteins of the blood coagulation cascade, digestive enzymes), deoxyribonuclease I, etc.

Therapeutics based on secreted or membrane-associated proteins approved by FDA or foreign agencies include but are not limited to insulin, glucagon, growth hormone, chorionic gonadotropin, follicle stimulating hormone, luteinizing hormone, calcitonin, adrenocorticotrophic hormone (ACTH), vasopressin, interleukines, interferones, immunoglobulins, lactoferrin (diverse products marketed by several companies), tissue-type plasminogen activator (Alteplase by Genentech), hyaluronidase (Wydase by Wyeth-Ayerst), dornase alpha (Pulmozyme by Genentech), Chymodiactin (chymopapain by Knoll), alglucerase (Ceredase by Genzyme), streptokinase (Kabikinase by Pharmacia) (Streptase by Astra), etc. This indicates that secreted and membrane-associated proteins have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further secreted and membrane-associated proteins which can play a role in preventing, ameliorating or correcting dysfunction or disease, including but not limited to diabetes, breast-, prostate-, colon cancer and other malignant tumors, hyper- and hypotension, obesity, bulimia, anorexia, growth abnormalities, asthma, manic depression, dementia, delirium, mental retardation, Huntington's disease, Tourette's syndrome, schizophrenia, growth, mental or sexual development disorders, and dysfunctions of the blood cascade system including those leading to stroke. The proteins of the present invention which include the signal sequences are also useful to further elucidate the mechanism of protein transport which at present is not entirely understood, and thus can be used as research tools.

Summary of the Invention

The present invention relates to particular polypeptides and polynucleotides of the genes set forth in Table I, including recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, the diseases set forth in Tables III and V,

hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (*e.g.*, inhibitors) using the materials provided by the invention, and treating conditions associated with imbalance of polypeptides and/or polynucleotides of the genes set forth in Table I with the identified compounds. In still a further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels the genes set forth in Table I. Another aspect of the invention concerns a polynucleotide comprising any of the nucleotide sequences set forth in the Sequence Listing and a polypeptide comprising a polypeptide encoded by the nucleotide sequence. In another aspect, the invention relates to a polypeptide comprising any of the polypeptide sequences set forth in the Sequence Listing and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such polypeptides and polynucleotides. Such uses include the treatment of diseases, abnormalities and disorders (hereinafter simply referred to as diseases) caused by abnormal expression, production, function and or metabolism of the genes of this invention, and such diseases are readily apparent by those skilled in the art from the homology to other proteins disclosed for each attached sequence. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with the imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels of the secreted proteins of the present invention.

Description of the Invention

In a first aspect, the present invention relates to polypeptides the genes set forth in Table I. Such polypeptides include:

- (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in the Sequence Listing, herein when referring to polynucleotides or polypeptides of the Sequence Listing, a reference is also made to the Sequence Listing referred to in the Sequence Listing;
- (b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (c) an isolated polypeptide comprising a polypeptide sequence set forth in the Sequence Listing;
- (d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (e) a polypeptide sequence set forth in the Sequence Listing; and

(f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing;

(g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the gene families set forth in Table II. They are therefore of therapeutic and diagnostic interest for the reasons set forth in Tables III and V. The biological properties of the polypeptides and polynucleotides of the genes set forth in Table I are hereinafter referred to as "the biological activity" of polypeptides and polynucleotides of the genes set forth in Table I. Preferably, a polypeptide of the present invention exhibits at least one biological activity of the genes set forth in Table I.

Polypeptides of the present invention also include variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from an amino acid sequence set forth in the Sequence Listing, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from an amino acid sequence set forth in the Sequence Listing. Preferred fragments are biologically active fragments that mediate the biological activity of polypeptides and polynucleotides of the genes set forth in Table I, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

Fragments of a polypeptide of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. A polypeptide of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences,

sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to polynucleotides of the genes set forth in Table I. Such polynucleotides include:

- (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide sequence set forth in the Sequence Listing;
 - (b) an isolated polynucleotide comprising a polynucleotide set forth in the Sequence Listing;
 - (c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide set forth in the Sequence Listing;
 - (d) an isolated polynucleotide set forth in the Sequence Listing;
 - (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
 - (f) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing;
 - (g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
 - (h) an isolated polynucleotide encoding a polypeptide set forth in the Sequence Listing;
 - (i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polynucleotide sequence set forth in the Sequence Listing;
 - (j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing; and
- polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from a sequence set forth in the Sequence Listing, or an isolated polynucleotide comprising a sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from a sequence set forth in the Sequence Listing.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).

Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise an amino acid sequence set forth in the Sequence Listing and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

(a) comprises an RNA transcript of the DNA sequence encoding a polypeptide set forth in the Sequence Listing;

(b) is a RNA transcript of a DNA sequence encoding a polypeptide set forth in the Sequence Listing;

(c) comprises an RNA transcript of a DNA sequence set forth in the Sequence Listing;
or

(d) is a RNA transcript of a DNA sequence set forth in the Sequence Listing;
and RNA polynucleotides that are complementary thereto.

The polynucleotide sequences set forth in the Sequence Listing show homology with the polynucleotide sequences set forth in Table II. A polynucleotide sequence set forth in the Sequence Listing is a cDNA sequence that encodes a polypeptide set forth in the Sequence Listing. A polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing may be identical to a polypeptide encoding a sequence set forth in the Sequence Listing or it may be a sequence other than a sequence set forth in the Sequence Listing, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes a polypeptide set forth in the Sequence Listing. A polypeptide of a sequence set forth in the Sequence Listing is related to

other proteins of the gene families set forth in Table II, having homology and/or structural similarity with the polypeptides set forth in Table II. Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one activity of the genes set forth in Table I.

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA from the tissues set forth in Table IV (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. A polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence set forth in the Sequence Listing, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than) that have a high sequence similarity to sequences set forth in the Sequence Listing, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least

100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than , may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having a sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing the polynucleotide sequence set forth in the Sequence Listing. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to

anneal within the amplified product (typically an adapter specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook *et al. (ibid)*. Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, micro-injection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, *e.g.*, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements,

such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of a gene is characterized by the polynucleotides set forth in the Sequence Listing in the cDNA or genomic sequence and which is associated with a dysfunction. Will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for

detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled nucleotide sequences of the genes set forth in Table I. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

An array of oligonucleotide probes comprising polynucleotide sequences or fragments thereof of the genes set forth in Table I can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M. Chee *et al.*, Science, 274, 610-613 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radio-immunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence set forth in the Sequence Listing, or a fragment or an RNA transcript thereof;
- (b) a nucleotide sequence complementary to that of (a);

- (c) a polypeptide of the present invention, preferably the polypeptide set forth in the Sequence Listing or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide set forth in the Sequence Listing .

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequences set forth in the Sequence Listing are specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, *Nature Genetics* 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (*Hum Mol Genet* 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>.

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include in situ hybridization techniques to clones arrayed on a grid, such as cDNA microarray hybridization (Schena *et al*, Science, 270, 467-470, 1995 and Shalon *et al*, Genome Res, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intra-muscular, intravenous, or intra-dermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore

mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule. Such small molecules preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (*e.g.* agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring an activity of the genes set forth in Table I in the mixture, and comparing activity of the mixture of the genes set forth in Table I to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek *et al*, Anal Biochem., 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and polypeptide of the genes set forth in Table I, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, *e.g.*, a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and the genes set forth in Table I. The art of constructing transgenic animals is well established. For example, the genes set forth in Table I may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host

blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that set forth in the Sequence Listing.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other

recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

"Secreted protein activity or secreted polypeptide activity" or "biological activity of the secreted protein or secreted polypeptide" refers to the metabolic or physiologic function of said secreted protein including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said secreted protein.

"Secreted protein gene" refers to a polynucleotide comprising any of the attached nucleotide sequences or allelic variants thereof and/or their complements.

"Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxribonucleotide (DNA), which may be unmodified or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications

may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, 1-12, in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol*, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci*, 663, 48-62, 1992).

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence set forth in the Sequence Listing.

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino

acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

"Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

"Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA

transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

"Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

"% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide

sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Neddleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990; Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J, G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either

individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \bullet I),$$

in which:

n_a is the number of nucleotide or amino acid differences,

x_a is the total number of nucleotides or amino acids in a sequence set forth in the Sequence Listing,

I is the Identity Index,

\bullet is the symbol for the multiplication operator, and

in which any non-integer product of x_a and I is rounded down to the nearest integer prior to subtracting it from x_a .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 533-A discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, *e.g.*, EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

Table I.

Gene Name	GSK Gene ID	Nucleic Acid SEQ ID NO's	Corresponding Protein SEQ ID NO's
sbg123493SLITa	123493	SEQ ID NO:1	SEQ ID NO:34
sbg14936EGFa	14936	SEQ ID NO:2 SEQ ID NO:3	SEQ ID NO:35 SEQ ID NO:36
SBh80018.cyastin- related	80018	SEQ ID NO:4	SEQ ID NO:37
SBh74552.trypsinogen	74552	SEQ ID NO:5 SEQ ID NO:6	SEQ ID NO:38 SEQ ID NO:39
sbg90060IGFBP	90060	SEQ ID NO:7 SEQ ID NO:8	SEQ ID NO:40 SEQ ID NO:41
sbg97078ANGIOa	97078	SEQ ID NO:9 SEQ ID NO:10	SEQ ID NO:42 SEQ ID NO:43
sbg68091CMP	68091	SEQ ID NO:11 SEQ ID NO:12	SEQ ID NO:44 SEQ ID NO:45
sbg18525LRR	18525	SEQ ID NO:13	SEQ ID NO:46
SBh45597.trypsin inhibitor	45597	SEQ ID NO:14 SEQ ID NO:15	SEQ ID NO:47 SEQ ID NO:48
sbg34640CALa	34640	SEQ ID NO:16 SEQ ID NO:17	SEQ ID NO:49 SEQ ID NO:50
sbg14849LO	14849	SEQ ID NO:18	SEQ ID NO:51
SBh35812.CALGIZZ ARIN	35812	SEQ ID NO:19 SEQ ID NO:20	SEQ ID NO:52 SEQ ID NO:53
sbg37967ECMPa	37967	SEQ ID NO:21 SEQ ID NO:22	SEQ ID NO:54 SEQ ID NO:55
sbg15037SER	15037	SEQ ID NO:23	SEQ ID NO:56
sbg23161EGFa	23161	SEQ ID NO:24 SEQ ID NO:25	SEQ ID NO:57 SEQ ID NO:58
sbg82008TGFa	82008	SEQ ID NO:26	SEQ ID NO:59
sbg82008TGFB	82008	SEQ ID NO:27	SEQ ID NO:60
sbg27142IGBb	27142	SEQ ID NO:28 SEQ ID NO:29	SEQ ID NO:61 SEQ ID NO:62
sbg239881TAGL	239881	SEQ ID NO:30 SEQ ID NO:31	SEQ ID NO:63 SEQ ID NO:64
sbg248602CHP	248602	SEQ ID NO:32	SEQ ID NO:65
sbg219473HNKS	219473	SEQ ID NO:33	SEQ ID NO:66

Table II

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg123493S LITa	Slit-like protein	SC:AL157714 Submitted (20-JAN-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Rat slit1 protein, gi: 4585574 Brose K, Bland KS, Wang KH, Arnott D, Henzel W, Goodman CS, Tessier- Lavigne M, Kidd T. Cell 1999 Mar 19;96(6):795- 806.	Membrane-bound
sbg14936EG Fa	EGF-Like 2 family of polypeptides	GB:Z97832 Submitted (01-FEB-2000) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Mouse EGF-related protein SCUBE1, gi: 10998440 Submitted (08-JUN-2000) by Mammalian Genetics Unit, MRC Harwell, Chilton, Didcot, Oxon OX11 0RD, United Kingdom.	Secreted
SBh80018.c yastin-related	Cystatin-related epididymal spermatogenic protein	GB:AL121894 Submitted (25-OCT-2000) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Mouse cystatin T (Zcys3), geneseq:Y96576 Patented by ZYMOGENETICS INC Patent number and and publication date: WO200031264-A2, 02-JUN-00	Secreted
SBh74552- .trypsinogen	Trypsinogen	GB:U66059 Rowen, L., Koop, B.F. and Hood, L. Science 272 (5269), 1755-1762 (1996).	Mouse Trypsinogen, gi2358070 Rowen, L., Smit, A.F.A. and Hood, L., Submitted (20-JUL-1997) Department of Molecular Biotechnology, Box 357730 University of Washington, Seattle, Washington 98195, USA	Secreted
sbg90060- IGFBP	Insulin-like growth factor binding protein (IGFBP)	GB:AC020916 Direct submitted (12-JAN-2000) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Protein PRO332, geneseq:Y13396 Patented by Genetech Inc Patent Number and publication date: WO9914328-A2, 25-Mar-99	Secreted

Table II (cont).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg97078- ANGIOa	Angiotensin II/vasopressin receptor	GB:AC011476 Direct submitted (07-OCT-1999) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA.	Human hypothetical protein FLJ20510: gi:8923473. Submitted (02-Nov-2000) by Sumio Sugano, Institute of Medical Science, University of Tokyo, Department of Virology; Shirokane-dai, 4-6-1, Minato-ku, Tokyo 108-8639	Membrane-bound
sbg68091- CMP	Cartilage matrix protein	GB:AC006356 Direct Submitted (29-MAY-1999) by Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA	Human zkun5 protein, geneseq: Y52597. Patented by ZYMOGENETICS INC. Patent number and and publication date: WO9961615-A1, 02-Dec-99	Secreted
sbg18525- LRR	Leucine-rich repeat (LLR)	GB:AC016030 Direct submitted (19-NOV-1999) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Human KIAA0416 protein, gi:7662102. Ishikawa,K., Nagase,T., Nakajima,D., Seki,N., Ohira,M., Miyajima,N., Tanaka,A., Kotani,H., Nomura,N. and Ohara,O. 1997. DNA Res. 4:307-313.	Membrane-bound
SBh45597- trypsin inhibitor	Rab subfamily of Ras-like GTPase	SC:Z84479 Submitted (16-OCT-1997) by Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human RAS like GTPASE, gi:3036779. Submitted (16-OCT-1997) Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK.	Cytosolic
sbg34640- CALa	Calgizzarin (endothelial monocyte-activating polypeptide)	GB:AC006483 Sulston,J.E. and Waterston,R Genome Res. 8 (11), 1097-1108 (1998)	Human calgizzarin, gi:1710818. Tanaka,M., Adzuma,K., Iwami,M., Yoshimoto,K., Monden,Y. and Itakura,M. Cancer Lett. 89 (2), 195-200 (1995).	Cytosolic

Table II (cont).

Gene Name	Gene Family	Closest P lynuclotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg14849LO	Lysyl oxidase-like	GB:AC005033 Direct Submitted (12-JUN-1998) by Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA.	Mouse lysyl oxidase-related protein 2, gi:7305239. Jang,W., Hua,A., Spilson,S.V., Miller,W., Roe,B.A. and Meisler,M.H., 1999, Genome Res. 9 : 53-61.	Secreted
SBh35812- CALGIZ- ZARIN	Calgizzarin (endothelial monocyte-activating polypeptide)	GB:AL133399 Submitted (08-FEB-2000) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Mouse calgizzarin, gi:1710819. Submitted (27-NOV-1995) Keith A. Houck, Biomolecular Research, Sphinx Pharmaceuticals Corp., 4615 University Dr., Durham, NC 27707, USA	Cytosolic
sbg37967- ECMPa	Extracellular matrix protein 2	JENA:X57A-X51X57A-X51 found at Jena Genome Sequencing Center	Human extracellular matrix protein 2, gi:4557543. Nishiu,J., Tanaka,T. and Nakamura,Y. Genomics 52, 378-381 (1998)	Secreted
sbg15037- SER	Serine protease	GB:AC005570 Direct submitted (01-SEP-1998) Center for Human Genome Studies, DOE Joint Genome Institute, Los Alamos National Laboratory, MS M888, Los Alamos, NM 87545, USA.	A long isoform of human HELA2 protein, W77297 Patented by Amrad Operations Pty Ltd. Patent number and and publication date: WO9836054-A1, 20-AUG-98	Secreted
sbg23161- EGFa	Extracellular/epidermal growth factor	GB:Z99756, GB:Z82214 Submitted (08-DEC-1999) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Mouse EGF-related protein SCUBE1 gi:10998440. Grimmond,S., Larder,R., Van Hateren,N., Siggers,P., Hulsebos,T.J.M., Arkell,R. and Greenfield, A. Genomics 70 (1), 74-81 (2000)	Secreted
sbg82008- TGFa,b	TGF beta (transforming growth factor beta)	GB:AC008940.frag1. Submitted (03-AUG-1999) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	A novel isolated and purified growth factor (GF), Y16714. Patented by UNIV WASHINGTON. Patent number and and publication date: WO9914235, 25-MAR-99	Secreted

Table II (cont).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg27142-IGBb	Immunoglobulin superfamily	GB:AC011846: Submitted (15-OCT-1999) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA GB:AC068507: Submitted (03-MAY-2000) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Mouse cell adhesion molecule, gi:11862939. Submitted (11-DEC- 2000) Junya Toguchida, Kyoto University, Institute for Frontier Medical Sciences; 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Kyoto 606-8507, Japan	Secreted
sbg239881-TAGL	Tag7-like family protein	GB:AC011492 Direct submitted (07-OCT- 1999) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA.	Mouse TAGL-alpha protein, gi: 10946624. Submitted (11-MAY- 1999) Laboratory of Cancer Molecular Genetics, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, Moscow 117334, Russia	Secreted
sbg248602-CHP	Zinc Carboxypeptidase	GB:AL035460 Direct submitted (20-MAR- 2000) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK	Mouse metallocarboxy- peptidase CPX-1, AAD15985. Lei,Y., Xin,X., Morgan,D., Pintar,J.E. and Fricker,L.D, 1999, DNA Cell Biol. 18:175-185.	Secreted
sbg219473-HNKS	HNK-sulfotransferase	GB:AP001087 Direct submitted (25-JAN- 2000) by the Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center (GSC); Kitasato Univ., 1- 15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan.	Human GalNAc 4-sulfo- transferase, gi:11990885. Habuchi,O. and Okuda,T. J. Biol. Chem. 275 (51), 40605-40613 (2000)	Membrane-bound

Table III.

Gene Name	Uses	Associated Diseases
sbg123493-SLITa	An embodiment of the invention may be the use of sbg123493-SLITa, a secreted protein, to bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance and may be useful for the prevention and treatment of diseases in spinal cord, thyroid gland, ovary, prostate, renal gland, small intestine, heart, trachea, thymus, lymph node, muscular system and colon. sbg123493-SLITa may also be used in the treatment of pineal tumors and alleviation of precocious puberty. Close homologs of sbg123493-SLITa are rat protein-Slit protein and pineal gland specific gene-1 protein.	Diseases in spinal cord, thyroid gland, ovary, prostate, renal gland, small intestine, heart, trachea, thymus, lymph node, muscular system and colon, pineal tumors and alleviation of precocious puberty
sbg14936-EGFa	An embodiment of the invention is the use of sbg14936-EGFa, a secreted protein, to treat colorectal carcinomas, and peptic ulcer healing. The closest homologue to sbg14936-EGFa is high-molecular-weight proteins with multiple EGF-like motifs. Polypeptides with EGF-like and/or cadherin-like repeats have been used to stimulate the growth of various epidermal and epithelial tissues <i>in vivo</i> and <i>in vitro</i> and of some fibroblasts in cell culture.	Neurodegenerative disorders, trauma, natural blinding, colorectal carcinomas and peptic ulcer healing
SBh80018-cyastin-related	An embodiment of the invention is the use of SBh80018-cyastin-related to treat or prevent tissue damage associated with brain hemorrhage.	Autoimmune disorder, hematopoietic disorder, wound healing disorder, viral and bacterial infection, cancer, neurological disorder, brain haemorrhage, tissue damage, inflammation, and protection and remodeling of the eye
SBh74552-trypsinogen	An embodiment of the invention is the use of SBh74552-trypsinogen to treat clot formation induced by myocardial infarction and reocclusion following angioplasty or pulmonary thromboembolism. Close homologues to of SBh74552-trypsinogen are used to treat clot formation and for treating associated gastrointestinal and haematopoietic disorders.	Autoimmune disorder, hematopoietic disorder, wound healing disorder, viral and bacterial infection, cancer, clot formation in myocardial infarction, reocclusion following angioplasty or pulmonary thromboembolism, gastrointestinal disorders

Table III (cont).

Gene Name	Uses	Ass ciated Diseases
sbg90060-IGFBP	An embodiment of the invention is the use of sbg90060-IGFBP, in the treatment of a wide range of disease states including cancer, diabetes, vascular disease, asthma, and growth disorders. Close homologs of sbg90060-IGFBP are Insulin-like growth factor (IGF) binding proteins (IGFBP). IGFBP when occupied by IGF, combines with an acid-labile glycoprotein subunit (ALS) to form a high molecular weight complex. The IGFBPs regulate somatic growth and cellular proliferation both in vivo and in vitro. The IGFBPs also appear to have emerging roles in the mechanisms underlying human cancer. Future research on its physiology may have advancements in the treatment of a wide range of disease states including cancer, diabetes, vascular disease, asthma, and growth disorders (Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P, 1999, Mol Genet Metab 68:161-81).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation, diabetes, vascular disease, asthma, and growth isorders
sbg97078-ANGIOa	An embodiment of the invention is the use of sbg97078-ANGIOa, in treating hypertension, heart disease, and kidney disease, related to unbalanced levels of angiotensin II/vasopressin receptors. A close homolog of sbg97078-ANGIOa is angiotensin II/vasopressin receptors. Angiotensin II/vasopressin receptors couple to adenylate cyclase and responds with equal sensitivity to Ang II and AVP. Ang II receptors respond to the neurotransmitter angiotensin II whilst AVP receptors respond to arginine vasopressin. Vasopressin receptor mediates many central and peripheral actions of vasopressin, including intracellular calcium mobilization. Thus the proteins, antibodies, agonists and antagonists can be used for treating, e.g. hypertension, heart disease, and kidney disease, related to unbalanced levels of angiotensin II/vasopressin receptor (Howl J, Wheatley M, 1995 Gen Pharmacol 26:1143-52; Grazzini E, Boccara G, Joubert D, Trueba M, Durroux T, Guillon G, Gallo-Payet N, Chouinard L, Payet MD, Serradeil Le Gal C, 1998 Adv Exp Med Biol 449:325-34).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation hypertension, heart disease, and kidney disease
sbg68091-CMP	An embodiment of the invention is the use of sbg68091-CMP, in repairing damaged cartilage in joints, such as in osteoarthritis and rheumatoid arthritis. A close homolog of sbg68091-CMP is Matrilin-1. The matrilin family shares a common structure made up of von Willebrand factor A domains, epidermal growth factor-like domains and a coiled coil alpha-helical module (Deak F, Wagener R, Kiss I, Paulsson M, 1999. Matrix Biol 18:55-64). Matrilin-1, cartilage matrix protein (CMP), is a major component of the extracellular matrix of nonarticular cartilage, and it binds to collagen.	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation rheumatoid arthritis, and osteoarthritis.

Table III (cont).

Gene Name	Uses	Associated Diseases
sbg18525-LRR	An embodiment of the invention is the use of sbg18525-LRR a member of the leucine-rich repeat protein family, in immunization, protein-protein interactions, such as cell adhesion or receptor-ligand binding and neuronal LRR may be an important component of the pathophysiological response to brain injury. Close homologs of sbg18525-LRR are leucine-rich repeat (LRR) proteins such as connectin, slit, chaoptin, and toll. These proteins have important roles in neuronal development and the adult nervous system as cell adhesion molecules (Taguchi A, Wanaka A, Mori T, Matsumoto K, Imai Y, Tagaki T, Tohyama M, 1996, Brain Res Mol Brain Res;35:31-4). At least one LRR was shown to be specifically expressed on B cells, suggesting its role in immunization (Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M, 1995. J Immunol 154:3333-40). Some studies have shown that brain injury can cause over expression of neuronal LRR, suggesting that neuronal LRR may be an important component of the pathophysiological response to brain injury (Ishii N, Wanaka A, Tohyama M, 1996, Brain Res Mol Brain Res 40: 148-52)..	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation, gastrointestinal ulceration, and diseases in spinal cord, thyroid gland, heart, trachea, thymus, lymph node, muscular system, and nervous system
SBh45597-trypsin inhibitor	An embodiment of the invention is the use of SBh45597-trypsin inhibitor in vesicle targeting. The Rabs are a subfamily within the large group of small GTP-binding proteins and have been showed to play a role in vesicle targeting. Like RAS, they cycle between active GTP-bound and inactive GDP-bound forms with both transitions to require additional factors: GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs). The GDP-bound form is also a target for a GDI (GDP dissociation inhibitor), a slightly-misnamed but remarkable protein which extracts the GDP-Rab (including its very hydrophobic isoprenoid groups) from the membrane, allowing it to return via the cytosol to its membrane of origin. (Armstrong J. Int J Biochem Cell Biol 2000 Mar;32(3):303-7).	Acute respiratory disease, AIDS, allergy, atherosclerosis, cancer, biabetes, cerebral neoplasm, immune disorder, imflasmatory disorder, rheumatoid arthritis, viral infection.
sbg34640-CALa	An embodiment of the invention is the use of sbg34640-CALa, a secreted protein, in the diagnosis and treatment of cancer. Close homologues to sbg34640-CALa are S100 calcium-binding protein A11 (calgizzarin) and other EF-hand calcium binding proteins and more specifically to s-100/CABP like proteins. S100 calcium-binding protein A11 (calgizzarin) binds two calcium ions per molecule with an affinity similar to that of the s-100 proteins. s-100/CABP like proteins are useful in diagnosis and treatment of cancer. (Fan, Y., Leung, D., Houck, K.A., Yan, S., Kao, J. Calgizzarin (endothelial monocyte-activating polypeptide ((EMAP) Submitted JAN-1996 to the EMBL/GenBank/DBJ databases. ACCESSION NO: P50543.).	Infections, cancers, autoimmune disorders, wound healing disorder and hematopoietic disorder

Table III (cont).

Gene Name	Uses	Associated Diseases
sbg14849LO	An embodiment of the invention is the use of sbg14849LO in the biogenesis of connective tissue matrices by crosslinking the extracellular matrix proteins, collagen and elastin or in the treatment of osteoporotic bone. A close homologue of sbg14849LO is lysyl oxidase (LO). LO is a cuproenzyme that plays a critical role in the biogenesis of connective tissue matrices by crosslinking the extracellular matrix proteins, collagen and elastin. Levels of LO increase in many fibrotic diseases, while expression of the enzyme is decreased in some diseases related to impaired copper metabolism. Transforming growth factor-beta, platelet-derived growth factor, angiotensin II, retinoic acid, fibroblast growth factor, and altered serum conditions can affect LO expression. It has also become increasingly evident that LO may have other important biological functions (Smith-Mungo LI, and Kagan HM, 1998, Matrix Biol 16:387-98). In mineralizing tissues, a relatively low level of lysyl hydroxylation results in low levels of hydroxylysyl pyridinoline, and the occurrence of the largely bone specific lysyl pyridinoline and pyrrolic cross-links (Knott L, and Bailey AJ, 1998, Bone 22:181-7).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation, fibrotic diseases, and metabolic bone diseases
SBh35812-CALGIZ-ZARIN	An embodiment of the invention is the use of SBh35812-CALGIZ-ZARIN to activate host response mechanisms. Close homologues of SBh35812-CALGIZ-ZARIN are cytokines and S-100 PROTEINS.	Autoimmune disorder, hematopoietic disorder, wound healing disorder, viral and bacterial infection, cancer, melanoma cance, cerebral dysfunction
sbg37967-ECMPa	An embodiment of the invention is the use of sbg37967-ECMPa, a secreted protein, in wound healing and treatment of inflammatory diseases. A close homologue to sbg37967-ECMPa is extracellular matrix protein 2 (pECM2). pECM2 expressed predominantly in adipose and female-specific tissues and its chromosomal localization to 9q22.3 and participates in protein-protein interactions and/or cell-ECM recognition processes (Nishiu,J., Tanaka,T. and Nakamura,Y. 1998. Genomics 52, 378-381).	Cancer, autoimmune disease, inflammatory diseases, wound healing and hematopoietic disorder
sbg15037-SER	An embodiment of the invention is the use of sbg15037-SER in the diagnosis of testicular tumors. sbg15037-SER is a membrane-type serine protease which shows a trypsin-like cleavage activity. A close homologue to sbg15037-SER is testisin, a new human serine proteinase, which is abundantly expressed only in the testis and is lost in testicular tumors. These findings about testisin demonstrate a new cell surface serine proteinase, loss of which may have a role in the progression of testicular tumors of germ cell origin. (Hooper JD, Nicol DL, Dickinson JL, Eyre HJ, Scarman AL, Normyle JF, Stuttgen MA, Douglas ML, Loveland KA, Sutherland GR, and Antalis TM, 1999, Cancer Res 59:3199-205).	Cancer, including testicular tumors, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation

Table III (cont).

Gene Name	Uses	Associated Diseases
sbg23161-EGFa	An embodiment of the invention is the use of sbg23161-EGFa, a secreted protein, in regulating vascular smooth muscle cell proliferation, e.g. for enhancing neurological functions or treating neoplasia and other disorders. A close homologue to sbg23161-EGFa is human extracellular/epidermal growth factor-like protein(EEGF). This EEGF protein is useful for regulating vascular smooth muscle cell proliferation, e.g. for enhancing neurological functions or treating neoplasia and other disorders (LI HS and OLSEN H, New isolated extracellular/epidermal growth factor, Accession Number W79739, HUMAN GENOME SCI INC).	Cancer, autoimmune disorders, wound healing disorders, infections, and hemotopoietic disorders
sbg82008-TGFa,b	An embodiment of the invention is the use of sbg82008-TGFa,b in growth control and hence the etiology of cancer, cell differentiation and development. sbg82008-TGFa,b contains the Prosite consensus pattern (PDOC00223) for TGF beta family members. Close homologues of sbg82008-TGFa,b are TGF-beta proteins. TGF-beta proteins are known to be involved in growth control and hence the etiology of cancer (<i>Anticancer Res</i> 1999 Nov-Dec;19(6A):4791-807), cell differentiation and development. A TGF-beta signaling pathway constitutes a tumor suppressor path (<i>Cytokine Growth Factor Rev</i> 2000 Apr 1;11(1-2):159-168).	Cancer (eg., lymphoma, leukemia, renal cell carcinoma, melanoma, lung cancer), infection (viral disease, (eg hepatitis A and C), parasitic disease, bacterial disease), inflammation, autoimmune disorder (eg multiple sclerosis, Type I diabetes), infertility, miscarriage, hematopoietic disorder, wound healing disorder, inflammatory diseases, inflammatory bowel disease, cystic fibrosis, immune deficiency, thrombocytopenia, chronic obstructive pulmonary disease
sbg27142-IGBb	An embodiment of the invention is the use of sbg27142-IGBb in the diagnosis and/or treatment of cancer and autoimmune disorders of the nervous system. A close homologue to sbg27142-IGBb is the mouse cell adhesion molecule (gi:11862939) that has been associated with transformation of osteoblasts and the mouse gene Punc that is expressed predominantly in the developing nervous system (Salbaum, J.M. 1998 Mech. Dev. 71 (1-2), 201-204).	Cancer, infection diseases, autoimmune disorder, wound healing disorder and hematopoietic disorder
sbg239881-TAGL	An embodiment of the invention is the use of sbg239881-TAGL to inhibit tumor growth and induce apoptosis and/or may also be useful as probes for gene mapping and detection of tag7 gene expression. Close homologues to sbg239881-TAGL and its promoter region are genes of the tumor necrosis factor (TNF). The tag7 coding sequences are also useful as probes for gene mapping and detection of tag7 gene expression (Kiselev SL, Kustikova OS, Korobko EV, Prokhortchouk EB, Kabishev AA, Lukanidin EM, Georgiev GP, 1998, J Biol Chem 273:18633-9).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders

Table III (cont).

Gene Name	Uses	Associated Diseases
sbg248602- CHP	Due to the carboxypeptidase activity required for processing of various neuropeptides and hormones, an embodiment of the invention is the use of sbg248602-CHP in treatments of neurodegenerative disorders and developmental abnormalities. Close homologues to sbg248602-CHP are peptidases that catalyze the removal of c-terminal basic amino acid residues, and is involved in processing of neuropeptides and hormones in secretory vesicles (Manser E, Fernandez D, Loo L, Goh PY, Monfries C, Hall C, and Lim L, 1990, Biochem J 267:517-25). Some enzymes from this family have been isolated in multiple forms from both soluble and membrane-bound compartments, and are demonstrated to co-secrete with peptides from pancreatic and adrenal cells. Single mRNA species have been shown to yield multiple forms of similar peptidases (Manser E, Fernandez D, and Lim L, 1991, Biochem J 280:695-701).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, neurodegenerative disorders, and developmental abnormalities
sbg219473- HNKS	An embodiment of the invention may be the use of sbg219473-HNKS in the development of the nervous system, and may also be involved in the preferential reinnervation of muscle nerves by motor axons after lesion. Close homologues to sbg219473-HNKS are sulfotransferases. Sulfotransferase is considered to be the key enzyme in the biosynthesis of the HNK-1 carbohydrate epitope, which is expressed on several neural adhesion glycoproteins and as a glycolipid, and is involved in cell interactions (Bakker,H., Friedmann,I., Oka,S., Kawasaki,T., Nifant'ev,N., Schachner,M., and Mantei,N., 1997, J. Biol. Chem. 272:29942-29946). The HNK-1 epitope is spatially and temporally regulated during the development of the nervous system. The biological function of the HNK-1 sulfotransferase may be related to the development of the nervous system, and also may be involved in the preferential reinnervation of muscle nerves by motor axons after lesion (Jungalwala FB, 1994, Neurochem Res 19:945-57).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, and peripheral neuropathies

Table IV. Quantitative, Tissue-specific mRNA expression detected using SybrMan

Quantitative, tissue-specific, mRNA expression patterns of the genes were measured using SYBR-Green Quantitative PCR (Applied Biosystems, Foster City, CA; see Schmittgen T.D. et al., Analytical Biochemistry 285:194-204, 2000) and human cDNAs prepared from various human tissues. Gene-specific PCR primers were designed using the first nucleic acid sequence listed in the Sequence List for each gene. Results are presented as the number of copies of each specific gene's mRNA detected in 1ng mRNA pool from each tissue. Two replicate mRNA measurements were made from each tissue RNA.

Table IV Cont

Gene Name	Tissue-Specific mRNA Expression (copies per ng mRNA; avg. \pm range for 2 data points per tissue)									
	Brain	Heart	Lung	Liver	Kid- ney	Skele- tal muscle	Intes- tine	Spleen /lymph	Pla- centa	Testis
sbg123493- SLITa	9 \pm 3	70 \pm 31	13 \pm 3	-1 \pm 1	41 \pm 16	132 \pm 21	6 \pm 2	5 \pm 10	9 \pm 4	959 \pm 80
sbg14936- EGFa	516 \pm 3 4	2424 \pm 72	550 \pm 56	129 \pm 7	1825 \pm 6	1503 \pm 168	218 \pm 26	423 \pm 4	629 \pm 39	1765 \pm 40
SBh80018- .cyastin- related	1 \pm 0	2 \pm 1	0 \pm 0	-7 \pm 4	2 \pm 3	6 \pm 4	-3 \pm 3	2 \pm 0	0 \pm 1	5258 \pm 259
SBh74552- .trypsinogen	-1 \pm 1	7 \pm 1	9 \pm 1	-10 \pm 1	1 \pm 3	4 \pm 1	3 \pm 0	10 \pm 3	5 \pm 0	5159 \pm 907
sbg90060- IGFBP	366 \pm 17	659 \pm 36	784 \pm 64	53 \pm 7	1035 \pm 189	119 \pm 15	109 \pm 4	531 \pm 12	582 \pm 8	207 \pm 13
sbg97078- ANGIOa	15 \pm 1	16 \pm 7	58 \pm 3	-6 \pm 1	18 \pm 1	4 \pm 1	37 \pm 2	91 \pm 5	244 \pm 3	688 \pm 18
sbg68091- CMP	1360 \pm 30	3596 \pm 59	1846 \pm 271	248 \pm 18	2596 \pm 146	2351 \pm 5	1646 \pm 112	486 \pm 4	3228 \pm 327	3204 \pm 42
sbg18525- LRR	4290 \pm 157	367 \pm 6	47 \pm 4	7 \pm 0	263 \pm 10	69 \pm 7	401 \pm 62	39 \pm 3	119 \pm 17	307 \pm 1
SBh45597- .trypsin inhibitor	59 \pm 12	58 \pm 7	44 \pm 1	22 \pm 1	106 \pm 21	45 \pm 6	36 \pm 6	49 \pm 16	57 \pm 9	219 \pm 55
sbg34640- CALa	3006 \pm 11	30001 \pm 197	98054 \pm 1290	4166 \pm 228	39196 \pm 1674	9611 \pm 323	31417 \pm 619	70617 \pm 2786	203542 \pm 4017	20011 \pm 2747
sbg14849- LO	508 \pm 23	862 \pm 13	631 \pm 8	51 \pm 5	251 \pm 24	125 \pm 12	348 \pm 38	662 \pm 17	1404 \pm 138	721 \pm 69
SBh35812.- CALGIZ- ZARIN	345 \pm 1	20 \pm 1	11 \pm 1	-3 \pm 7	45 \pm 1	8 \pm 7	5 \pm 2	15 \pm 4	20 \pm 5	136 \pm 20
sbg37967- ECMPa	72 \pm 5	26 \pm 10	24 \pm 8	3 \pm 9	45 \pm 0	18 \pm 1	4 \pm 3	34 \pm 10	593 \pm 62	57 \pm 5
sbg15037- SER	291 \pm 9	256 \pm 24	284 \pm 18	302 \pm 7	312 \pm 6	298 \pm 8	264 \pm 17	256 \pm 4	277 \pm 14	316 \pm 55
sbg23161- EGFa	150 \pm 1	142 \pm 9	2063 \pm 68	348 \pm 20	1184 \pm 80	79 \pm 13	809 \pm 41	1276 \pm 17	831 \pm 22	2635 \pm 156

Table IV Cont

Gene Name	Tissue-Specific mRNA Expression (copies per ng mRNA; avg. \pm range for 2 data points per tissue)									
	Brain	Heart	Lung	Liver	Kidney	Skeletal muscle	Intestine	Spleen /lymph	Placenta	Testis
sbg82008-TGFa,b	1542 ± 96	651 ± 49	858 ± 37	555 ± 30	818 ± 248	829 ± 47	321 ± 28	721 ± 108	1037 ± 51	670 ± 110
sbg2714-2IGBb	526 ± 3 7	505 ± 8	115 ± 5	-6 ± 9	91 ± 3	3783 \pm 80	173 ± 1	211 ± 3 7	5218 \pm 240	354 ± 3 9
sbg23988-1TAGL	3 ± 1	2 ± 0	6 ± 1	2816 ± 28	6 ± 1	0 ± 0	3 ± 1	-2 ± 5	4 ± 0	780 ± 20
sbg248602-CHP	134 ± 10	989 ± 16	539 ± 3	3 ± 5	1335 ± 16	80 ± 17	385 ± 18	730 ± 43	15644 ± 309	921 ± 9
sbg219473-HNKS	175 ± 32	1075 ± 81	2522 ± 91	473 ± 35	453 ± 57	74 ± 18	98 ± 1	1121 ± 12	10 ± 6	2813 ± 148

Table V. Additional diseases based on mRNA expression in specific tissues

Tissue Expression	Additional Diseases
Brain	Neurological and psychiatric diseases, including Alzheimers, parasupranuclear palsey, Huntington's disease, myotonic dystrophy, anorexia, depression, schizophrenia, headache, amnesias, anxiety disorders, sleep disorders, multiple sclerosis
Heart	Cardiovascular diseases, including congestive heart failure, dilated cardiomyopathy, cardiac arrhythmias, Hodgson's Disease, myocardial infarction, cardiac arrhythmias
Lung	Respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease, cystic fibrosis, acute bronchitis, adult respiratory distress syndrome
Liver	Dyslipidemia, hypercholesterolemia, hypertriglyceridemia, cirrhosis, hepatic encephalopathy, fatty hepatocirrhosis, viral and nonviral hepatitis, Type II Diabetes Mellitis, impaired glucose tolerance
Kidney	Renal diseases, including acute and chronic renal failure, acute tubular necrosis, cystinuria, Fanconi's Syndrome, glomerulonephritis, renal cell carcinoma, renovascular hypertension
Skeletal muscle	Eulenburg's Disease, hypoglycemia, obesity, tendinitis, periodic paralyses, malignant hyperthermia, paramyotonia congenita, myotonia congenita
Intestine	Gastrointestinal diseases, including Myotonia congenita, Ileus, Intestinal Obstruction, Tropical Sprue, Pseudomembranous Enterocolitis
Spleen/lymph	Lymphangiectasia, hypersplenism, angiomas, ankylosing spondylitis, Hodgkin's Disease, macroglobulinemia, malignant lymphomas, rheumatoid arthritis
Placenta	Choriocarcinoma, hydatidiform mole, placenta previa
Testis	Testicular cancer, male reproductive diseases, including low testosterone and male infertility
Pancreas	Diabetic ketoacidosis, Typ 1 & 2 diabetes, obesity, impaired glucose tolerance

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
 - (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in Table I;
 - (b) an isolated polypeptide comprising a polypeptide sequence set forth in Table I; and
 - (c) a polypeptide sequence of a gene set forth in Table I.
2. An isolated polynucleotide selected from the group consisting of:
 - (a) an isolated polynucleotide comprising a polynucleotide sequence set forth in Table I;
 - (b) an isolated polynucleotide of a gene set forth in Table I;
 - (c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in Table I;
 - (d) an isolated polynucleotide encoding a polypeptide set forth in Table I;
 - (e) a polynucleotide which is an RNA equivalent of the polynucleotide of (a) to (d); or a polynucleotide sequence complementary to said isolated polynucleotide.
3. An expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.
4. A process for producing a recombinant host cell which comprises the step of introducing an expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 into a cell such that the host cell, under appropriate culture conditions, produces said polypeptide.
5. A recombinant host cell produced by the process of claim 4.
6. A membrane of a recombinant host cell of claim 5 expressing said polypeptide.
7. A process for producing a polypeptide which comprises culturing a host cell of claim 5 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.

SEQUENCE LISTING

<110> SMITHKLINE BEECHAM CORPORATION
SMITHKLINE BEECHAM p.l.c.

<120> NOVEL COMPOUNDS

<130> GP50018

<140> TO BE ASSIGNED

<141> 2001-03-22

<150> 60/192,158

<151> 2000-03-24

<150> 60/192,668

<151> 2000-03-27

<150> 60/200,166

<151> 2000-04-27

<160> 66

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 771

<212> DNA

<213> Homo sapiens

<400> 1

atgtcccttg	cttcaggccc	tggccctggg	tggttactct	tttcctttgg	aatggggctg	60
gtatcagggt	caaagtgtcc	aaataattgt	ctgtgtcaag	cccaagaagt	aatctgcaca	120
gggaagcagt	taaccgaata	cccccttgac	ataccctga	acaccggag	gctgttctg	180
aacgagaaca	gaatcactag	tttgccagca	atgcatctag	gactcctcag	tgacctgtt	240
tatttggact	gtcagaacaa	ccggattcga	gaggtgatgg	attatacctt	catcggggtc	300
ttcaaaactca	tctaccttga	cctcagctcc	aacaacctaa	cctcgatctc	cccatcact	360
ttctcgggtgc	tcagcaaacct	ggtgcagctg	aacattgccca	acaaccctca	cctgttatcg	420
cttcacaagt	tcacctttgc	caacaccacc	tctttgaggt	acctggacct	cagaaatacc	480
ggcttgacaga	ccctggacag	tgctgcctta	taccacctca	ctactctgga	gaccctgttt	540
ctgagtggaa	acccctggaa	gtgcaactgc	tctttcctgg	acttcgccat	cttcttaata	600
gtgttcata	tggacccctc	aggtgagggc	ttgattgggt	gtggggaaga	ggatgtgatt	660
gaagtggctc	cagaaaaggt	gaactcaaaa	gatggtcaga	atgggagaaa	aagttgggtg	720
aagctgattg	aatgcattct	tattactctg	cagggccac	ccttgggttg	a	771

<210> 2

<211> 2694

<212> DNA

<213> Homo sapiens

<400> 2

atgggctcgg	ggcgcgctacc	cgggctctgc	ctgcttgctc	tgctgggtcca	cgcccgcgcc	60
gccagctaca	gcaaagccgc	gcaagatgtg	gatgagtgtg	tggaggggac	tgacaactgc	120
cacatcgatg	ctatctgcca	gaacaccccg	aggtcataca	agtgcactctg	caagtctggc	180
tacacagggg	acggcaaaca	ctgcaaagac	gtggatgagt	gcgagcgaga	ggataatgca	240
ggttggtgtg	atgactgtgt	caacatccct	ggcaattacc	ggtgtacctg	ctatgatgga	300
ttccacctgg	cacatgacgg	acacaactgt	ctggatgtgg	acgagtgtgc	cgagggcaac	360
ggcggctgtc	agcagagctg	tgtcaacatg	atgggcagct	atgagtgccca	ctgccgggaa	420

ggcttcttcc	tcagcgacaa	ccagcatacc	tgtatccagc	ggccagaaga	aggaaatgaat	480
tgcatgaaca	agaaccacgg	ctgtgcccac	atttgccggg	agacacccaa	gggggggtatt	540
gcctgtgaat	gccgtcctgg	ctttgagctt	accaagaacc	aacgggactg	taaattgtgag	600
ataattggga	tggcagtgac	atgcaactat	ggtaacggcg	gctgccagca	cacgtgtgat	660
gacacagagc	aggggtccccg	gtgcggctgc	catatcaagt	ttgtgctcca	taccgacggg	720
aagacatgca	tcgagacctg	tgctgtcaac	aacgggggct	gtgacagtaa	gtgccatgat	780
gcagcgactg	gtgtccactg	cacctgccct	gtgggcttca	tgctgcagcc	agacaggaag	840
acgtgcaaag	atatagatga	gtgccgctta	aacaacgggg	gctgtgacca	tatttgccgc	900
aacacagtgg	gcagcttcga	atgcagttgc	aagaaaggct	ataagcttct	catcaatgag	960
aggaactgcc	aggatataga	cgagtgttcc	tttgatcgaa	cctgtgacca	catatgtgtc	1020
aacacaccag	gaagcttcca	gtgtctctgc	catcgtggct	acctgttgta	tggtatcacc	1080
caactgtggg	atgtggatga	atgcagcatc	aaccggggag	gttgccgctt	tggctgcac	1140
aacactcctg	gcagctacca	gtgtacctgc	ccagcaggcc	agggtcggct	gcactggaat	1200
ggcaaagatt	gcacagagcc	actgaagtgt	cagggcagtc	ctggggcctc	gaaagccatg	1260
ctcagctgca	accggtctgg	caagaaggac	acctgtgccc	tgacctgtcc	ctccagggcc	1320
cgatTTTTTgc	cagagtctga	gaatggcttc	acggtgagct	gtgggacccc	cagccccagg	1380
gctgctccag	cccagctggg	ccacaatggg	aacagcacca	actccaacca	ctgcatgag	1440
gctgcagtgc	tgtccattaa	acaacggggc	tccttcaaga	tcaaggatgc	caaagtccgt	1500
ttgcacctgc	gaaacaaagg	caaaaacagag	gaggctggca	gaatcacagg	gccaggtggt	1560
gccccctgct	ctgaatgccat	ggtcaccttc	atccacctta	agtgtgactc	ctctcggaag	1620
ggcaaggggc	gacggggccc	gacccctcca	ggcaaagagg	tcacaaggct	caccctggaa	1680
ctggaggcag	agcaactctt	tctctccct	gatacacacg	gccatccacc	accagccagc	1740
tgtgggctgc	cctgcctccg	acagcgaatg	gaacggcggc	tgaaaggatc	cctgaagatg	1800
ctcagaaagt	ccatcaacca	ggaccgcttc	ctgctgcgcc	tggcaggcct	tgattatgag	1860
ctggcccaca	agccgggect	ggtagccggg	gagcgagcag	agccgatgga	gtcctgtagg	1920
cccgggcagc	accgtgctgg	gaccaagtgt	gtccagtgtc	ccccagggca	ctactacaac	1980
accagcatcc	accgtgtgat	tcgctgtgcc	atgggctcct	atcagcccga	cttccgtcag	2040
aacttctgca	gccgctgtcc	aggaaacaca	agcacagact	ttgatggctc	taccagtgtg	2100
gcccacatgca	agaatcgta	gtgtgggtgg	gagctgggtg	agttcactgg	ctatatgag	2160
tcceccaaact	acccgggcaa	ctaccagct	gggtgtggagt	gcactctggaa	catcaacccc	2220
ccacccaaagc	gcaagatcct	tatcgtggta	ccagagatct	tcctgccatc	tgaggatgag	2280
tgtggggagc	tcctcgtcat	gagaaagaac	tcacccccat	cctccattac	cacttatgag	2340
acctgccaga	cctacgagcg	tcccattgcc	ttcactgccc	gttccaggaa	gctctggatc	2400
aacttcaaga	caagcgaggc	caacagcgcc	cgtggcttcc	agattcccta	tgttacctat	2460
gatgaggact	atgagcagct	ggtagaagac	attgtgcag	atggccggct	ctatgcctct	2520
gaaaaccacc	aggagatttt	aaaggacaag	aagctcatca	aggccttctt	tgagggtgcta	2580
gccaccccc	agaactactt	caagtaacaca	gagaaacaca	aggagatgct	gccaaaatcc	2640
ttcatcaagc	tgctccgctc	caaagtttcc	agcttcctga	ggccctacaa	atag	2694

<210> 3

<211> 2982

<212> DNA

<213> Homo sapiens

<400> 3

atgggctcgg	ggcgcgtaac	cgggctctgc	ctgcttgttc	tgctgggtcca	cgcccgcgcc	60
gcccagtaga	gcaaagccgc	gcaggatgtg	gatgagtgtg	tgagggggac	tgacaactgc	120
cacatcgatg	ctatctgcca	gaacaccccg	aggtcataca	agtgcactctg	caagtctggc	180
tacacagggg	acggcaaaca	ctgcaaagac	gtggatgagt	gcgagcgaga	ggataatgca	240
ggttgtgtgc	atgactgtgt	caacatccct	ggcaattacc	gggtgtacctg	ctatgatgga	300
ttccacctgg	cacatgacgg	acacaactgt	ctggatgtgg	acgagtgtgc	cgaggggcaac	360
ggcggtgtgc	agcagagctg	tgtcaacatg	atgggcagct	atgagtgcc	ctgcccgggaa	420
ggcttcttcc	tcagcgacaa	ccagcatacc	tgtatccagc	ggccagaaga	aggaaatgaat	480
tgcatgaaca	agaaccacgg	ctgtgcccac	atttgccggg	agacacccaa	gggggggtatt	540
gcctgtgaat	gccgtcctgg	ctttgagctt	accaagaacc	aacgggactg	taaattgaca	600
tgcaactatg	gtaacggcgg	ctgccagcac	acgtgtgatg	acacagagca	gggtccccgg	660
tgggctgcc	atatcaagtt	tgtgtcccat	accgacggga	agacatgcat	cgagacctgt	720
gctgtcaaca	acgggggctg	tgacagtaag	tgccatgatg	cagcgactgg	tgtccactgc	780
acctgccctg	tgggcttcat	gctgcagcca	gacaggaaga	cgtgcaaaga	tatagatgag	840

tgccgcttaa	acaacggggg	ctgtgaccat	atttgccgca	acacagtggg	cagcttcgaa	900
tgcagttgca	agaaaggcta	taagcttctc	atcaatgaga	ggaactgcc	ggatatagac	960
gagtgttcct	ttgatcgaac	ctgtgaccac	atatgtgtca	acacaccagg	aagcttccag	1020
tgtctctgcc	atcgtggcta	cctgttgat	ggtatcacc	actgtgggga	tgtggatgaa	1080
tgcagcatca	accggggagg	ttgccgcttt	ggctgcatca	acactcctgg	cagctaccag	1140
tgtacctgcc	cagcaggcca	gggtcggctg	cactggaatg	gcaaagattg	cacagagcca	1200
ctgaagtgtc	agggcagtc	tggggcctcg	aaagccatgc	tcagctgcaa	ccggtctggc	1260
aagaaggaca	cctgtgccct	gacctgtccc	tccaggggccc	gattttttgcc	agagtctgag	1320
aatggcttca	cgggtgagctg	tgggaccccc	agccccagg	ctgctccagc	ccgagctggc	1380
cacaatggga	acagcaccaa	ctccaaccac	tgccatgagg	ctgcagtgtc	gtccattaaa	1440
caacgggcct	ccttcaagat	caaggatgcc	aaatgccgtt	tgcacctgcg	aaacaaaggc	1500
aaaacagagg	aggctggcag	aatcacagg	ccagggtggtg	ccccctgctc	tgaatgccag	1560
gtcaccttca	tccaccttaa	gtgtgactcc	tctcggaagg	gcaagggccg	acggggcccgg	1620
acccctccag	gcaaagaggt	cacaaggctc	accctggaac	tggaggcaga	ggtcagagcc	1680
gaagaaacca	cagccagctg	tgggctgccc	tgccctccgac	agcgaatgga	acggcggctg	1740
aaaggatccc	tgaagatgct	cagaaagtcc	atcaaccagg	accgcttcct	gctgcgctg	1800
gcaggccttg	attatgagct	ggcccacaag	ccgggccttg	tagccgggga	gcgagcagag	1860
ccgatggagt	cctgtaggcc	cgggcagcac	cgtgctggga	ccaagtgtgt	cagctgcccc	1920
cagggaaagt	attaccacgg	ccagacggag	cagtgtgtgc	catgcccagc	gggcaccttc	1980
caggagagag	aagggcagct	ctcctgcgac	ctttgccctg	ggagtgatgc	ccacgggcct	2040
cttggagcca	ccaacgtcac	cacgtgtgca	ggtcagtgcc	cacctggcca	acactctgta	2100
gatgggttca	agccctgtca	gccatgcccc	cgtggcacct	accaacctga	agcaggacgg	2160
accctatgct	tcccttgttg	tgggggcctc	accaccaagc	atgaaggggc	catttccttc	2220
caagactgtg	acaccaaagt	ccagtgtctc	ccagggcact	actacaacac	cagcatccac	2280
cgctgtattc	gctgtgccat	gggctcctat	cagcccgact	tccgtcagaa	cttctgcagc	2340
cgctgtccag	gaaacacaag	cacagacttt	gatggctcta	ccagtgtggc	ccaatgcaag	2400
aatcgtcagt	gtggtgggga	gctgggtgag	ttcactggct	atattgagtc	ccccaaactac	2460
ccgggcaact	accagctgg	tgtggagtgc	atctggaaca	tcaaccccc	acccaagcgc	2520
aagatcctta	togtgggtacc	agagatcttc	ctgccatctg	aggatgagtg	tggggacgtc	2580
ctcgtcatga	gaaagaactc	atccccatcc	tccattacca	cttatgagac	ctgccagacc	2640
tacgagcgtc	ccattgcctt	cactgcccgt	tccaggaagc	tctggatcaa	cttcaagaca	2700
agcgaggcca	acagcgccc	tggcttcctg	attccctatg	ttacctatga	tgaggactat	2760
gagatctgg	tagaagacat	tgtgcgagat	ggccgctct	atgcctctga	aaaccaccag	2820
gagattttta	aggacaagaa	gctcatcaag	gccttctttg	aggtgctagc	ccacccccag	2880
aactacttca	agtacacaga	gaaacacaag	gagatgctgc	caaaatcctt	catcaagctg	2940
ctccgctcca	aagtttccag	cttcctgagg	ccctacaaat	ag		2982

<210> 4

<211> 417

<212> DNA

<213> Homo sapiens

<400> 4

atgggtccggc	tctgccaggc	cctgctgctg	ttagtggcca	ctgtggccct	tgcattccaga	60
agattccaag	cctggggctc	aacaaagggtg	gtgaggacat	tccaagatat	ccctcaaaac	120
tacgtctatg	tgcagcaggc	actctggttc	gccatgaagg	agtataacaa	ggccagcttt	180
agtataacaa	gttcagcttt	agggaaagaa	tacaaattaa	aggtgacaga	tagttttggag	240
tactatattg	aggtcaaaat	tgcccgaaca	atttgcaaga	aaatttcaga	agatgaaaac	300
tgtgcatttc	aagaggatcc	caaaatgcaa	aaggtgggtt	tttgtacttt	tattgttgca	360
tctaaaccat	ggaaatttga	actcaccatg	ctgaagaaac	aatgcaaaga	tatgtag	417

<210> 5

<211> 726

<212> DNA

<213> Homo sapiens

<400> 5

atgaagttta	tcctcctctg	ggccctcttg	aatctgactg	ttgctttggc	ctttaatcca	60
gattacacag	tcagctccac	tcccccttac	ttgggtctatt	tgaaatctga	ctacttgccc	120

tgcgctggag	tcttgatcca	cccgccttgg	gtgatcacag	ctgcacactg	caatttacca	180
aagcttcggg	tgatattggg	ggttacaatc	ccagcagact	ctaataaaaa	gcattctgca	240
gtgattggct	atgagaagat	gattcatcat	ccacacttct	cagtcacttc	tattgatcat	300
gacatcatgc	taatcaagct	gaaaacagag	gctgaactca	atgactatgt	gaaattagcc	360
aacctgccct	accaaactat	ctctgaaaat	accatgtgct	ctgtctctac	ctggagctac	420
aatgtgtgtg	atatctacaa	agagcccgat	tcaactgcaa	ctgtgaacat	ctctgtaatc	480
tccaagcctc	agtgtcgcca	tgcctataaa	acctacaaca	tcacggaaaa	tatgtgtgtg	540
gtgggcattg	tgccaggaag	gaggcagccc	tgcaaggaag	tttctgtctg	cccggaatc	600
tgcaatggga	tgcttcaagg	aatcctgtct	tttgcggtatg	gatgtgtttt	gagagccgat	660
gttggcattc	atgccaaaat	tttttactat	ataccctgga	ttgaaaatgt	aatccaaaat	720
aactga						726

<210> 6

<211> 732

<212> DNA

<213> Homo sapiens

<400> 6

atgactgaga	aatcttggaa	tttcttgtct	atgcttctct	ttccagttgc	tttggccttt	60
aatccagatt	acacagtcag	ctccactccc	ccttacttgg	tctatttgaa	atctgactac	120
ttgccctgcg	ctggagtcct	gatccaccgc	ctttgggtga	tcacagctgc	acactgcaat	180
ttaccaaagc	ttcgggtgat	attgggggtt	acaatcccag	cagactctaa	tgaaaagcat	240
ctgcaagtga	ttggctatga	gaagatgatt	catcatccac	acttctcagt	cacttctatt	300
gatcatgaca	tcatgctaata	caagctgaaa	acagaggctg	aactcaatga	ctatgtgaaa	360
ttagccaacc	tgccctacca	aactatctct	gaaaatacca	tgtgctctgt	ctctacctgg	420
agctacaatg	tgtgtgatat	ctacaaagag	cccgattcac	tgcaaactgt	gaacatctct	480
gtaatctcca	agcctcagtg	tcgcgatgcc	tataaaacct	acaacatcac	ggaaaatatg	540
ctgtgtgtgg	gcattgtgcc	aggaaggagg	cagccctgca	aggaaagttc	tgctgccccg	600
gcaatctgca	atgggatgct	tcaaggaatc	ctgtcttttg	cggatggatg	tgttttgaga	660
gccgatgttg	gcattctatgc	caaaattttt	tactatatac	cctggattga	aaatgtaatc	720
caaaataact	ga					732

<210> 7

<211> 1452

<212> DNA

<213> Homo sapiens

<400> 7

atgtacccag	gctggccccg	gcagggcatg	tgggagagcg	gacagcgctt	gcctgacgag	60
gccttcgagt	ccctcaccca	gctgcagcac	ctctgcgtgg	ctcacaacaa	gctctcagtg	120
gcccctcagt	ttctgccccg	gtccctccgt	gtcgcggatc	tggtgcca	ccaagtgatg	180
gagatcttcc	ccctcacctt	tggggagaag	ccggcactca	ggtccgtgta	cctccacaac	240
aaccagctga	gcaacgctgg	cctgcccccc	gacgccttcc	gcggctccga	ggccatcgcc	300
accctcagcc	tctccaacaa	ccagctcagc	tacctgcgc	ccagcctgcc	gccctcactc	360
gagcggctcc	acctgcagaa	caatctcacc	tccaaggtgc	cccagaggagc	cctgagccgc	420
cagactcaac	tccgtgagct	ctacctccag	cacaaccagc	tgacagacag	tggcctggat	480
gccaccacct	tcagcaagct	gcatagcctt	gaataacctg	atctctccca	caaccagctg	540
accacagtgc	ccgcgggcct	gccccggacc	ctggctatcc	tgcacctggg	ccgcaaccgc	600
atccggcagg	tggaggcggc	tcggctgcac	ggggcgcgctg	gtctgcgcta	tttgttgctg	660
cagcacaacc	agctggggag	ctcagggctg	cccgcggggg	ctctgcggcc	gctgcggggc	720
ctgcacacgc	tgcacctcta	tggcaatggg	ctggaccgcg	tgccctccagc	cctgccccgc	780
cgctgcgtg	ccctgggtgt	gccccacaa	cacgtggccg	cgctgggtgc	ccgtgacctg	840
gtcgccacac	cgggcctgac	ggagcttaac	ctggcctata	accgcctggc	cagcggcgt	900
gtgcaccacc	gggccttcgc	ccggttgctg	gcccctgcga	gcctcgacct	ggcagggaa	960
cagctaaccc	ggctgcccac	gggcctgccc	actggcctgc	gcacctgca	gctgcaacgc	1020
aaccagctgc	ggatgctega	gcccagacct	ctggccggcc	tggaccaact	gcgggagctc	1080
agcctggcgc	acaaccggct	ccgggtcggc	gacatcgggc	caggcacctg	gcattgagctc	1140
caagccctcc	agatgctgga	cctcagccac	aatgagctgt	cctttgtgcc	cccgacctg	1200
cctgaggccc	tagaggagct	gcacctcgag	ggcaaccgca	tcggccacgt	gggccccgag	1260

gccttcctca	gcacaccccg	cctgcgtgcc	ctcttcctca	gggccaacag	gcttcacatg	1320
acgagcatcg	cggctgaggg	cttcctgggg	ctcccaaacc	tgctgtgtgt	ggacacggga	1380
gggaatccgg	agcaggtcct	gatccggctg	cctcccacca	ccccacgtgg	gccacgggca	1440
gggggcccct	ga					1452

<210> 8
 <211> 1818
 <212> DNA
 <213> Homo sapiens

<400> 8

atggcagagt	cagggctggc	catggagggg	atgctccagt	caccatggcg	accctgcgcc	60
cagcctggag	acacgctgac	cctccctccc	ccgcagtggc	cgagcctgct	gctgctcctg	120
ctgttgccgg	ggcccccgcc	cgtegccggc	ttggaagacg	ctgccttccc	ccacctgggg	180
gagagcttgc	agccccctgcc	ccgggcctgt	cccctgcgct	gctcctgccc	ccgagtcgac	240
actgtggact	gtgatggctt	ggaccttcga	gtgttcccgg	acaacatcac	cagagccgct	300
cagcacctct	ccctgcagaa	caaccagctc	caggaactcc	cctacaatga	gctgtcccgc	360
ctcagtggcc	tgcgaaacct	caacctccac	aacaacctca	tctcctccga	aggcctgcct	420
gacgaggcct	tcgagtccct	caccagctg	cagcacctct	gcgtggctca	caacaagctc	480
tcagtggccc	ctcagtttct	gccccggctc	ctccgtgtcg	cggatctggc	tgccaaccaa	540
gtgatggaga	tcttccccct	cacctttggg	gagaagccgg	cactcaggte	cgtgtacctc	600
cacaacaacc	agctgagcaa	cgctggcctg	ccccccgacg	ccttcgcggg	ctccgaggcc	660
atcgccaccc	tcagcctctc	caacaaccag	ctcagctacc	tgccgcccag	cctgccgccc	720
tcactcgagc	ggctccacct	gcagaacaat	ctcatctcca	aggtgccccg	aggagccctg	780
agccgccaga	ctcaactccg	tgagctctac	ctccagcaca	accagctgac	agacagtggc	840
ctggatgcca	ccaccttcag	caagctgcat	agccttgaat	acctggatct	ctcccacaa	900
cagctgacca	cagtgccegc	cggcctgccc	cggacctggg	ctatcctgca	cctggggccgc	960
aaccgcatcc	ggcaggtgga	ggcggtctcg	ctgcacgggg	cgctggtct	gcgctatttg	1020
ttgctgcagc	acaaccagct	ggggagctca	gggtgccccg	ccggggctct	gcggccgctg	1080
cggggcctgc	acacgctgca	cctctatggc	aatgggctgg	accgcgtgcc	tccagccctg	1140
ccccgcggcc	tgctgtccct	ggtgctgccc	cacaaccacg	tgccgcgct	gggtgcccgt	1200
gacctggctg	ccacaccggg	cctgacggag	cttaacctgg	cctataaccg	cctggccagc	1260
gcccgtgtgc	accaccgggc	cttcgcggcg	ttgctgtccc	tgccgagcct	cgacctggca	1320
gggaatcagc	taaccgggct	gcccattggc	tgcccactg	gcctgcgcac	cctgcagctg	1380
caacgcaacc	agctgcggat	gctcgagccc	gagcctctgg	ccggcctgga	ccaactgcgg	1440
gagctccaag	ccctccagat	gctggacctc	agccacaatg	agctgtcctt	tgtgcccccg	1500
gacctgcctg	aggccctaga	ggagctgcac	ctcgagggca	accgcacggg	ccacgtgggc	1560
cccgaggcct	tcctcagcac	acccgcctg	cgtgccctct	tcctcagggg	caacaggcct	1620
cacatgacga	gcctcgcggc	tgaggccttc	ctggggctcc	caaacctgcg	tgtggtggac	1680
acggcaggga	atccggagca	ggtcctgac	cggctgcctc	ccaccacccc	acgtggggca	1740
cgggcagggg	gcccctga					1800
						1818

<210> 9
 <211> 3150
 <212> DNA
 <213> Homo sapiens

<400> 9

atggtaactc	gtgaactgtt	tttctttttt	tccccccagt	tcttcagcct	taacctaaag	60
tctcatactc	ggagcactat	gacatcgccc	cagctagagt	ggactctgca	gaccttctg	120
gagcagctga	acgaggatga	attaaagagt	ttcaaattccc	ttttatgggc	ttttccctc	180
gaagcagtg	tacagaagac	cccatggtct	gaggtggaag	aggctgatgg	caagaaactg	240
gcagaaattc	tggtaaacac	ctcctcagaa	aattggataa	ggaatgcgac	tgtgaacatc	300
ttggaagaga	tgaatctcac	ggaattgtgt	aagatggcaa	aggctgagat	gatggaggac	360
ggacagggtg	aagaaataga	taatcctgag	ctgggagatg	cagaagaaga	ctcggagtta	420
gcaaagccag	gtgaaaagga	aggatggaga	aattcaatgg	agaaacagtc	tttgggtctg	480
aagaacacct	tttggaagg	agacattgac	aatttccatg	acgacgtcac	tctgagaaac	540
caacggttca	ttccattctt	gaatcccaga	acaccagga	agctaacacc	ttacacgggt	600

gtgctgcacg	gccccgcagg	cgtgggggaaa	accacgctgg	ccaaaaagtg	tatgctggac	660
tggacagact	gcaacctcag	cccgacgctc	agatacgctg	tctacctcag	ctgcaaggag	720
ctcagccgca	tgggcccctg	cagttttgca	gagctgatct	ccaaagactg	gcctgaattg	780
caggatgaca	ttccaagcat	cctagcccaa	gcacagagaa	tcctgttcgt	ggctgatggc	840
cttgatgagc	tgaagtccc	acctggggcg	ctgatccagg	acatctgcgg	ggactgggag	900
aagaagaagc	cggtgcccgt	cctcctgggg	agtttgctga	agaggaagat	gttaccagg	960
gcagccttgc	tggtcaccac	gcgggcccagg	gcactgaggg	acctccagct	cctgggcgag	1020
cagccgatct	acgtaagggg	ggagggcctt	ctggaggagg	acaggagggc	ctatttcctg	1080
agacactttg	gagacgagga	ccaagccatg	cgtgcctttg	agctaattgag	gagcaacgcg	1140
gccctgttcc	agctgggctc	ggcccccgcg	gtgtgctgga	ttgtgtgcac	gactctgaag	1200
ctgcagatgg	agaaggggga	ggaccccggtc	cccacctgcc	tcaccgcgac	ggggctgttc	1260
ctgcgtttcc	tctgcagccg	gttcccgcag	ggcgacagc	tgcggggcg	gctgcggacg	1320
ctgagcctcc	tggccgcgca	gggcctgtgg	gcgcagatgt	ccgtgttcca	ccgagaggac	1380
ctggaaaggg	tgggggtgca	ggagtccgac	ctccgtctgt	tcctggacgg	agacatcctc	1440
cgccaggaca	gagtctccaa	aggctgctac	tccttcatcc	acctcagctt	ccagcagttt	1500
ctcactgccc	tgttctacgc	cctggagaag	gaggaggggg	aggacaggga	cggccacgcc	1560
tgggacatcg	gggacgtaca	gaagctgctt	tccggagaag	aaagactcaa	gaaccccgac	1620
ctgattcaag	taggacactt	cttattcggc	ctcgctaacg	agaagagagc	caaggagctg	1680
gaggccactt	ttggctgccc	gatgtcaccg	gacatcaaac	aggaattgct	gcaatgcaaa	1740
gcacatcttc	atgcaataaa	gcccttatcc	gtgaccgacc	tgaaggagggt	cttgggctgc	1800
ctgtatgagt	ctcaggagga	ggagctggcg	aagggtgggtg	tggccccgtt	caaggaaatt	1860
tctattcacc	tgacaaatac	ttctgaagtg	atgcattgtt	ccttcagcct	gaagcattgt	1920
caagacttgc	agaaactctc	actgcaggta	gcaaaggggg	tgttcctgga	gaattacatg	1980
gattttgaac	tggacattga	atttgaaagc	tcaaacagca	acctcaagtt	tctggaagtg	2040
aaacaaagct	tcctgagtga	ctcttctgtg	cggattcttt	gtgaccacgt	aacccgtagc	2100
acctgtcatc	tgcagaaaagt	ggagattaaa	aacgtcaccc	ctgacaccgc	gtaccgggac	2160
ttctgtcctg	ctttcatttg	gaagaagacc	ctcacgcacc	tgaccctggc	agggcacatc	2220
gagtgggaac	gcacgatgat	gctgatgctg	tgtgacctgc	tcagaaatca	taaagtcaac	2280
ctgcagtacc	tgaggttggg	aggtcactgt	gccaccccg	agcagtgggc	tgaattcttc	2340
tatgtcctca	aagccaacca	gtccctgaag	cacctgcgtc	tctcagccaa	tgtgtcctg	2400
gatgaggggtg	ccatgttgct	gtacaagacc	atgacacgcc	caaaacactt	cctgcagatg	2460
ttgtcgttgg	aaaactgtcg	tcttacagaa	gccagttgca	aggaccttgc	tgctgtcctg	2520
gttgtcagca	agaagctgac	acacctgtgc	ttggccaaga	accccatagg	ggatacaggg	2580
gtgaagtttc	tgtgtgaggg	cttgagttac	cctgattgta	aactgcagac	cttgggtgtg	2640
gtgtcttgtt	ccgctaccac	tcagcagtg	gctgatctct	ccttggccct	tgaagtcaac	2700
cagtccctga	cgtgcgtaaa	cctctccgac	aatgagcttc	tggatgaggg	tgctaagtgt	2760
ctgtacacaa	ctttgagaca	ccccaaagtgc	tttctgcaga	ggttgtcgtt	ggaaaactgt	2820
caccttcaag	aagccaattg	caaggacctt	gctgctgtgt	tggttgtcag	ccgggagctg	2880
acacacctgt	gcttggccaa	gaaccccat	gggaatacag	gggtgaagtt	tctgtgtgag	2940
ggcttgaggt	accccgagtg	taaactgcag	accttgggtg	tacagcaatg	cagcataacc	3000
aagcttggct	gtagatatct	ctcagaggcg	ctccaagaag	cctgcagcct	cacaaacctg	3060
gacttgagta	tcaaccagat	agctcgtgga	ttgtggattc	tctgtcaggc	attagagaat	3120
ccaaactgta	acctaaaaca	cctacggtag				3150

<210> 10

<211> 3189

<212> DNA

<213> Homo sapiens

<400> 10

atggtgtctt	cggcgagat	gggcttcaac	ctgcaggtc	tcctggagca	gctcagccag	60
gatgagttga	gcaagttcaa	gtatctgac	acgaccttct	ccctggcaca	cgagctccag	120
aagatcccc	acaaggagg	agacaaggct	gatgggaagc	aactggtaga	aatcctcacc	180
acccattgtg	acagctactg	ggtggagatg	gcgagcctcc	aggtctttga	aaagatgcac	240
cgaatggatc	tgtctgagag	agcaaaggat	gaagtcagag	aagcagcttt	gaaatccttt	300
aataaaaagg	agcctctatc	attagggata	acacggaaag	aacgaccacc	tctagacgtg	360
gacgaaatgc	tggagcgctt	caaaacagaa	gcacaagcgt	ttacagaaac	gaaaggaaat	420
gtcatctgcc	tgggtaaaga	agtctttaaa	ggaaaaaagc	cagacaaaga	caataggtgc	480
aggtatatat	tgaagacgaa	gttccgggag	atgtggaaga	gctggcctgg	agatagcaaa	540

gaggtccagg	ttatggctga	gagatacaag	atgctgatcc	cattcagcaa	ccccaggggtg	600
cttccccgggc	ccttctcata	cacgggtgggtg	ctgtatgggtc	ctgcaggcct	tgggaaaacc	660
acgctggccc	agaaactaat	gctagactgg	gcagaggaca	acctcatcca	caaattcaaaa	720
tatgctgttct	acctcagctg	cagggagctc	agccgcctgg	gcccgtgcag	ttttgcagag	780
ctggctcttca	gggactggcc	tgaattgcag	gatgacattc	cacacatcct	agcccaagca	840
cggaaaatct	tggtcgtgat	tgacggcttt	gatgagctgg	gagccgcacc	tggggcgctg	900
atcgaggaca	tctgcgggga	ctgggagaag	aagaagccgg	tgcccgtcct	cctggggagt	960
ttgctgaaca	gggtgatgtt	acccaaggcc	gccctgctgg	tcaccacgcg	gccccggggcc	1020
ctgagggacc	tccggtatcct	ggcggaggag	ccgatctaca	taagggtgga	gggcttctctg	1080
gaggaggaca	ggagggccta	tttcttgaga	cacttttgag	acgaggacca	agccatgcgt	1140
gcctttgagc	taatgaggag	caacgcggcc	ctgttccagc	tgggctcggc	ccccgcgggtg	1200
tgctggatcg	tgtgcacgac	tctgaagctg	cagatggaga	agggggagga	cccgggtcccc	1260
acctgcctca	cccgcacggg	gctgttctctg	cgtttctct	gcagccggtt	cccgcaggggc	1320
gcacagctgc	ggggcgcgct	gcgagcgtg	agcctcctgg	ccgcgcaggg	cctgtggggcg	1380
cagacgtccg	tgcttcaccg	agaggatctg	gaaaggctcg	gggtgcagga	gtccgacctc	1440
cgtctgttcc	tggaaggaga	catcctccgc	caggacagag	tctccaaagg	ctgctactcc	1500
ttcatccacc	tcagcttcca	gcagtttctc	actgccctgt	tctacacct	ggagaaggag	1560
ggagaagagg	atagggacgg	ccacacctgg	gacattgggg	acgtacagaa	gctgctttcc	1620
ggagtagaaa	gactcaggaa	ccccgacctg	atccaagcag	gctactactc	ctttggcctc	1680
gctaacgaga	agagagccaa	ggagttggag	gccacttttg	gctgccggat	gtcaccggac	1740
atcaaacagg	aattgctgcg	atgcgacata	agttgtaagg	gtggacattc	aacggtgaca	1800
gacctgcagg	agctcctcgg	ctgtctgtac	gagtcctcag	aggaggagct	ggtgaaggag	1860
gtgatggctc	agttcaaaga	aatatccctg	cacttaaattg	cagtagacgt	tgtgccatct	1920
tcattctgcg	tcaagcactg	tcgaaacctg	cagaaaatgt	cactgcagg	aataaaggag	1980
aatctccccg	agaatgtcac	tgctctgtaa	tcagacgcgc	aggttgagag	atccaggat	2040
gatcagcaca	tgcttctctt	ctggacggac	ctttgttcca	tatttggtatc	aaataaggat	2100
ctgatgggtc	tagcaatcaa	tgatagcttt	ctcagtgcc	ccctagtaag	gatcctgtgt	2160
gaacaaatag	cctctgacac	ctgtcatctc	cagagagtgg	tggtcaaaaa	catttcccca	2220
gctgatgctc	atcggaacct	ctgcctagct	cttcgagggtc	acaagactgt	aacgtatctg	2280
acccttcaag	gcaatgacca	ggatgatatg	tttcccgcac	tggtgtgagg	cttgagacat	2340
ccagaatgta	acctgcgata	tctcgggttg	gtgtcttgtt	ccgctaccac	tcagcagtgg	2400
gctgatctct	ccttggccct	tgaagtcaac	cagtcctctga	cgtgcgtaaa	cctctccgac	2460
aatgagcttc	tggatgaggg	tgctaagttg	ctgtacacaa	ctttgagaca	ccccaaagtgc	2520
tttctgcaga	gggtgtcgtt	ggaaaactgt	caccttacag	aagccaattg	caaggacctt	2580
gctgctgtgt	tggttgtcag	ccgggagctg	acacacctgt	gcttggccaa	gaacccatt	2640
gggaatacag	gggtgaagtt	tctgtgtgag	ggcttgaggt	accccgagt	taaactgcag	2700
accttgggtg	tttggaaactg	cgacataact	agcgatggct	gctgcgatct	cacaaagctt	2760
ctccaagaaa	aatcaagcct	gttgtgtttg	gatctggggc	tgaatcacat	aggagttaag	2820
ggaatgaagt	tcctgtgtga	ggctttgagg	aaacctactgt	gcaacttgag	atgtctgtgg	2880
ttgtggggat	gttccatccc	tccgttcagt	tgtgaagacc	tctgctctgc	cctcagctgc	2940
aaccagagcc	tcgtcactct	ggacctgggt	cagaatccct	tggggtctag	tggagtgaag	3000
atgctgtttg	aaaccttgac	atgttccagt	ggcaccctcc	ggacactcag	gttgaaaatc	3060
gatgacttta	atgatgaact	caataagctg	ctggaagaaa	tagaagaaaa	aaaccacaaa	3120
ctgattattg	atactgagaa	acatcatccc	tgggcagaaa	ggccttcttc	tcatgacttc	3180
atgatctga						3189

<210> 11

<211> 1062

<212> DNA

<213> Homo sapiens

<400> 11

atgacaattt	ttcatcccat	tacttcatcc	attggccagc	ctggttgtgg	gccccaaatgc	60
aaagagactc	cactagagct	gggtgtttgtg	atcgacagct	cagaaagcgt	ggggccagag	120
aactttcaga	tcattaaaaa	ttttgtgaag	actatggctg	accgggttgc	tctggacctt	180
gccacggccc	gcataggcat	aatcaactat	agccataagg	tggagaagg	ggctaatttg	240
aagcagttct	ccagcaagga	tgacttcaag	ttggctgtgg	acaacatgca	gtatctgggg	300
gaaggcacat	acacagccac	tgctctgcaa	gcagccaacg	acatgtttga	agatgcaagg	360
ccaggtgtaa	aaaaagtggc	cttgggtcatc	atgatggac	agacagattc	tcgtgataaa	420

gagaaactga	cagaggtggt	gaagaatgcc	agtgacacca	atgtggagat	atttgtgata	480
ggggtggtga	agaaaaatga	tcccaacttt	gaaatattcc	acaaagaaat	gaatctaatt	540
gctactgacc	cagagcatgt	ttaccagttt	gatgatttct	ttaccctgca	agacaccctg	600
aagcaaaaat	tgtttcaaaa	aattttgtgag	gattttgatt	cctatctcgt	tcaaattttt	660
ggttcacgt	cacctcaacc	tggatttggg	atgtcagggg	aagaactcag	tgaatctact	720
ccagagcctc	aaaaagaaat	ttctgagtca	ttgagtgtca	ccagagacca	ggatgaagat	780
gataaggctc	cagagccaac	gtgggctgat	gatctgcctg	ccactacctc	atctgaggcc	840
accaccaccc	ccaggccact	gctcagcacc	cctgtggatg	gggcagagga	tcctagatgt	900
ttggaagcct	tgaagcctgg	aaactgtggt	gaatatgtgg	ttcgatggta	ttatgacaaa	960
caggtcaact	cttgtgcccg	attttggttc	agtggctgta	atggctcagg	aaatagattc	1020
aacagtgaat	aggaatgtca	agaaacctgc	attcaaggat	ga		1062

<210> 12
 <211> 1347
 <212> DNA
 <213> Homo sapiens

<400> 12						
atgcatgagg	taattgaatc	tgactatgag	gggagagata	aaaccttgct	ctgccttgtg	60
gtgggtgtgt	gtgactactc	cactcggatg	cttggttagaa	atgatcacac	tgctgttact	120
ggccaacaag	gagcctgggtc	agagtctgcc	tccttggacc	acagtcccat	cctcagtttc	180
ctgccccagg	aattcccagc	agatcgagat	ggttccttgg	ctctccatag	cacttatgaa	240
agtcttcgtt	tgtctgcttc	ttcctggact	gtgaatcctt	tgaggggtat	aaatatgatg	300
ccttcacat	tggcaccaag	tagccaaggt	tgtgggcccc	aatgcaaaga	gactccacta	360
gagctgggtg	ttgtgatcga	cagctcagaa	agcgtggggc	cagagaactt	tcagatcatt	420
aaaaattttg	tgaagactat	ggctgaccgg	gttgctctgg	acettgccac	ggcccgcata	480
ggcataatca	actatagcca	taagggtggag	aagggtggcta	atttgaagca	gttctccagc	540
aaggatgact	tcaagttggc	tgtggacaac	atgcagtatc	tgggggaagg	cacatacaca	600
gccactgctc	tgcaagcagc	caacgacatg	tttgaagatg	caaggccagg	tgtaaaaaaaa	660
gtggccttgg	tcatcactga	tggacagaca	gattctcgtg	ataaagagaa	actgacagag	720
gtggtgaaga	atgccagtg	caccaatgtg	gagatatttg	tgataggggt	ggtgaagaaa	780
aatgatccca	actttgaaat	attccacaaa	gaaatgaatc	taattgctac	tgaccagag	840
catgtttacc	agtttgatga	tttctttacc	ctgcaagaca	ccctgaagca	aaaattgttt	900
caaaaaattt	gtgaggattt	tgattcctat	ctcgttcaaa	tttttggttc	atcgtcacct	960
caacctggat	ttgggatgtc	aggggaagaa	ctcagtgaat	ctactccaga	gcctcaaaaa	1020
gaaattttctg	agtcattgag	tgtcaccaga	gaccaggatg	aagatgataa	ggctccagag	1080
ccaacgtggg	ctgatgatct	gcctgccact	acctcatctg	aggccaccac	cacccccagg	1140
ccactgctca	gcacccctgt	ggatggggca	gaggatccta	gatgtttgga	agccttgaag	1200
cctggaaact	gtggtgaata	tgtggttcga	tggatttatg	acaaacaggt	caactcttgt	1260
gcccgatatt	ggttcagtg	ctgtaatggc	tcaggaaata	gattcaacag	tgaaggaa	1320
tgtcaagaaa	cctgcattca	aggatga				1347

<210> 13
 <211> 1482
 <212> DNA
 <213> Homo sapiens

<400> 13						
atgtgccccg	ccgccccag	cgggtgcccc	cagctgtgcc	ggtgagagg	gggctgctg	60
tactgcgagg	cgctcaacct	caccgaggcg	ccccacaacc	tgccggcct	gctgggcttg	120
tccctgcgct	acaacagcct	ctcggagctg	cgcgcgggcc	agttcacggg	gttaatgcag	180
ctcacgtggc	tctatctgga	tcacaatcac	atctgctccg	tgcaggggga	cgctttcag	240
aaactgcgcc	gagttaagga	actcacgtg	agttccaacc	agatcaccca	actgccaac	300
accaccttcc	ggcccatgcc	caacctgcgc	agcgtggacc	tctcgtacaa	caagctgcag	360
gcgctcgcgc	ccgacctctt	ccacgggctg	cggaagctca	ccacgtgca	tatgcggggc	420
aacgccatcc	agttttgtgc	cgtgcgcac	ttccaggact	gccgcagcct	caagtttctc	480
gacatcggat	acaatcagct	caagagtctg	gcgcgcaact	ctttcgccgg	cttgtttaag	540
ctcaccgagc	tgcacctcga	gcacaacgac	ttggtcaagg	tgaacttcgc	ccactccccg	600
cgctcatct	ccctgcactc	gctctgcctg	cggaggaca	aggtggccat	tgtggtcagc	660

tcgctggact	gggttttgaa	cctggagaaa	atggacttgt	cgggcaacga	gatcgagtac	720
atggagcccc	atgtgttcga	gaccgtgccg	cacctgcagt	ccctgcagct	ggactccaac	780
cgcctcacct	acatcgagcc	ccggatcctc	aactcttggg	agtccttgac	aagcatcacc	840
ctggccggga	acctgtggga	ttgcggggcg	aacgtgtgtg	ccctagcctc	gtggctcaac	900
aacttccagg	ggcgctacga	tggcaacttg	cagtgcgcca	gcccggagta	cgcacagggc	960
gaggacgtcc	tggacgccgt	gtacgccttc	cacctgtgcg	aggatggggc	cgagcccacc	1020
agcggggcacc	tgtctctggc	cgtcaccaac	cgcagtgatc	tggggccccc	tgaaggcgg	1080
gccaccacgg	cctcgcggac	cgggggggag	gggcagcacg	acggcacatt	caagcctgcc	1140
accggggggt	ttccagccgg	ggagcacggg	aagaaccccg	tgcagatcca	caaggtggtc	1200
acggggacca	tggccttcat	tttttctttc	ctcatgggtg	tcctgggtgt	ctacgtgtcc	1260
tgggaagtgt	tcccagccag	cctcaggcag	ctcagacagt	gctttgtcac	gcagcgcagg	1320
aagcaaaagc	agaaacagac	catgcatcag	atggctgcc	tgtctgccc	ggaatactac	1380
gttgattaca	aaccgaacca	cattgagggg	gccctgggtg	tcatcaacga	gtatggctcg	1440
tgtacctgcc	accagcagcc	cgcgagggaa	tgcgaggtgt	ga		1482

<210> 14

<211> 1647

<212> DNA

<213> Homo sapiens

<400> 14

atgcccgc	tacgtccact	cctgccgctc	ctgctcctcc	tccggctgac	ctcgggggct	60
ggcttgctgc	cagggctggg	gagccacccg	ggcgtgtgcc	ccaaccagct	cagccccaac	120
ctgtgggtgg	acgccagag	cacctgtgag	cgcgagtgtg	gcagggacca	ggactgtgcg	180
gctgctgaga	agtgtgtcat	caacgtgtgt	ggactgcaca	gctgcgtggc	agcacgcttc	240
cccggcagcc	cagctgcgcc	gacgacagcg	gcctcctgcg	agggctttgt	gtgcccacag	300
cagggctcgg	actgcgacat	ctgggacggg	cagccctgtg	gccgctgccg	cgaccgctgt	360
gagaaggagc	ccagcttcac	ctgcgcctcg	gacggcctca	cctactacaa	ccgctgctat	420
atggacgccc	aggcctgcct	gcggggcctg	cacctccaca	tcgtgccctg	caagcacgtg	480
ctcagctggc	cgcccagcag	cccggggccg	ccggagacca	ctgcccgc	cacacctggg	540
gccgcgccc	tgcctcctgc	cctgtacagc	agcccctccc	cacaggcggt	gcagggtggg	600
ggtacggcca	gcctccactg	cgacgtcagc	ggccgcccgc	cgctgtgtgt	gacctgggag	660
aagcagagtc	accagcgaga	gaacctgatc	atgcgcctgt	atcagatgta	tggcaacgtg	720
gtggtcacca	gcacggggca	gctggtgctc	tacaacgcgc	ggcccgaaga	cgccggcctg	780
tacacctgca	ccgcgcgcaa	cgctgctggg	ctgctgcggg	ctgacttccc	actctctgtg	840
gtccagcgag	agccggccag	ggacgcagcc	cccagcatcc	cagccccggc	cgagtgcctg	900
ccggatgtgc	aggcctgcac	gggccccact	tccccacacc	ttgtcctctg	gcactacgac	960
ccgcagcggg	gcggctgcat	gaccttccc	gcccgtggct	gtgatggggc	ggcccgcggc	1020
tttgagacct	acgaggcatg	ccagcaggcc	tgtgcccgcg	gccccggcga	cgctgtcgtg	1080
ctgcctgccg	tgcagggccc	ctgccggggc	tgggagccgc	gctgggccta	cagcccgtg	1140
ctgcagcagt	gccatccctt	cgtgtacggg	ggctgcgagg	gcaacggcaa	caacttccac	1200
agccgcgaga	gctgcgagga	tgcctgcccc	gtgccgcgca	caccgccttg	ccgcgcctgc	1260
cgctcccgga	gcaagctggc	gctgagcctg	tgccgcagcg	acttcgccat	cgtggggcgg	1320
ctcacggagg	tgttgaggga	gcccagggcc	gccggcgcca	tgcggcgctg	ggcgctcgag	1380
gacgtgctca	aggatgacaa	gatgggcctc	aagttcttgg	gcaccaagta	cctggagggtg	1440
acgttgagtg	gcattggactg	ggcctgcccc	tgccccaaca	tgacggcggg	cgacggggccg	1500
ctggctcatca	tgggtgaggt	gcgcgatggc	gtggccgtgc	tggacgccc	cagctacgtc	1560
cgcgccgcca	gcgagaagcg	cgtcaagaag	atcttggagc	tgctggagaa	gcaggcctgc	1620
gagctgctca	accgcttcca	ggactag				1647

<210> 15

<211> 861

<212> DNA

<213> Homo sapiens

<400> 15

atggcctttg	tggcaatcgt	ggtgtccaac	tttggcctct	caggtcagcc	tcatgggggc	60
ttcaacagcc	aggacaaaa	tgaccaaggc	ccctccgtcc	ctgtgtccct	gcttgacaga	120
accaccggag	gagggagcgc	cctgtgcttc	ctcgcaggga	tgcactacaa	gaccaccacc	180

atcctgctgg	acggccggcg	cgtgaagctg	gagctctggg	acacgtcggg	ccagggccgg	240
ttctgcacca	tcttcaggte	ctactccagg	ggcgctcagg	ggatcctctt	ggtgtatgac	300
atcaccaacc	gctggtcctt	tgacggcatc	gaccgctgga	tcaaggagat	cgatgagcat	360
gcacccggag	tccccggat	cttggttggg	aaccggctgc	acctggcctt	caagcggcag	420
gtccccgacg	agcaggcccc	cgcgtacgca	gagaagaact	gcatgacctt	ctttgaggte	480
agccccctgt	gcaacttcaa	cgtcatcgag	tccttcacgg	agctatcccc	catcgtgctc	540
atgcggcacg	gcatggagaa	gatctggagg	cccaaccgag	tgttcagcct	gcaggacctc	600
tgctgccggg	ccatcgtctc	ctgcaccccc	gtgcacctca	tcgacaagct	tccactgccc	660
gtcaccatca	agagccacct	caagtccttc	tcgatggcca	acggcatgaa	cgcgggtcatg	720
atgcacggcc	gttccctactc	cctggccagc	ggggccgggg	gcggcggcag	caagggcaac	780
agcctcaaga	ggtccaagtc	catccgtcca	ccccagagcc	ccccccagaa	ctgctcgcgg	840
agtaactgca	agatctccta	g				861

<210> 16
 <211> 519
 <212> DNA
 <213> Homo sapiens

<400> 16						
atgggcatcc	ccatcccaat	catccctcac	cacccccagg	ctcgggtcgc	gtccccccag	60
gctttgatgg	acaagtggcc	atggaaagca	tcctcagctg	ccccagggtt	ctgccatcac	120
ccatccacta	aatggtccag	ggaccctggg	aggcaccctg	agtctccaca	tcggggtggc	180
tctggggtac	acagacgaag	cagagagccg	gcaccccatc	ctgcgtctga	ggaatccagc	240
tttccctggc	tggaagacct	ggatcatgaag	tatgtgggaa	aggggtggtta	taactgcaact	300
ctctccaaga	cggagttoct	aagcttcatg	aatgcagaac	tggctgcctt	cacaaagaac	360
cagaaggacc	ccggggtoct	tcaccgcatg	atgaagaaac	tgggcaccaa	caatgacggg	420
cagctagatt	tctcagaatt	tcttaatctg	attggcggcc	tagctatggc	ttgccatgac	480
tccttctcctca	aggctgtccc	ttcccagaag	cggacctga			519

<210> 17
 <211> 312
 <212> DNA
 <213> Homo sapiens

<400> 17						
ctgcaaaaat	ctccagccct	gcagagactg	agcatcgagt	ccctgatttc	tcttttccag	60
aagtatgtgg	gaaagggtgg	ttataactgc	actctctcca	agacggaggt	cctaagcttc	120
atgaatgcag	aactggctgc	cttcacaaag	aaccagaagg	accccggggt	ccttcaccgc	180
atgatgaaga	aactgggcac	caacaatgac	gggcagctag	atttctcaga	atttcttaat	240
ctgattggcg	gcctagctat	ggcttgccat	gactccttcc	tcaaggctgt	cccttcccag	300
aagcggacct	ga					312

<210> 18
 <211> 2262
 <212> DNA
 <213> Homo sapiens

<400> 18						
atgcgacctg	tcagtgtctg	gcagtggagc	ccctgggggc	tgctgctgtg	cctgctgtgc	60
agttcgtgct	tggggtctcc	gtcccccttc	acgggccctg	agaagaaggc	cgggagccag	120
gggcttcggg	tccggctggc	tggtctcccc	aggaagccct	acgagggccg	cgtggagata	180
cagcgagctg	gtgaatgggg	caccatctgc	gatgatgact	tcacgctgca	ggctgcccac	240
atcctctgcc	gggagctggg	cttcacagag	gccacaggct	ggaccacag	tgccaaatat	300
ggccctggaa	caggccgcat	ctggctggac	aacttgagct	gcagtgggac	cgagcagagt	360
gtgactgaat	gtgcctcccg	gggctggggg	aacagtgact	gtacgcacga	tgaggatgct	420
ggggctcatct	gcaaagacca	gcgcctccct	ggcttctcgg	actccaatgt	cattgaggta	480
gagcatcacc	tgcaagtggg	ggaggtgcga	attcgacccg	ccgttgggtg	gggcagacga	540
cccctgcccc	tgacggaggg	gctgggtggg	gtcaggcttc	ctgacggctg	gtcgcaagtg	600
tgcgacaaaag	gctggagcgc	ccacaacagc	cacgtggtct	gcgggatgct	gggcttcccc	660

agcgaaaaga	gggtcaacgc	ggccttctac	aggctgctag	cccaacggca	gcaacactcc	720
tttgggtctgc	atgggggtggc	gtgcgtgggc	acggaggccc	acctctccct	ctgttccctg	780
gagttctatc	gtgccaatga	caccgccagg	tgccctgggg	ggggccctgc	agtggtgagc	840
tgtgtgccag	gccctgtcta	cgcgccatcc	agtggccaga	agaagcaaca	acagtcgaag	900
cctcaggggg	aggcccgtgt	ccgtctaaag	ggcggcgccc	accctggaga	gggccgggta	960
gaagtcctga	aggccagcac	atggggcaca	gtctgtgacc	gcaagtggga	cctgcatgca	1020
gccagcgtgg	tgtgtcggga	gctgggcttc	gggagtgtct	gagaagctct	gagtggcgct	1080
cgcatggggc	agggcagggg	tgctatccac	ctgagtgaag	ttcgctgtct	tggacaggag	1140
ctctccctct	ggaagtggcc	ccacaagaac	atcacagctg	aggattgttc	acatagccag	1200
gatggccggg	tccggtgcaa	cctaccttac	actggggcag	agaccaggat	ccgactcagt	1260
gggggcccga	gccaacatga	ggggcgagtc	gaggtgcaaa	taggggggacc	tgggcccctt	1320
cgctggggcc	tcactctgtg	ggatgactgg	gggaccctgg	aggccatggg	ggcctgtagg	1380
caactgggtc	tgggctacgc	caaccacggc	ctgcaggaga	cctggtactg	ggactctggg	1440
aatataacag	aggtgggtgat	gagtggagtg	cgctgcacag	ggactgagct	gtccctggat	1500
cagtgtgccc	atcatggcac	ccacatcacc	tgcaagagga	cagggaccgc	cttcaactgt	1560
ggagtcatct	gttctgagac	tgcatcagat	ctggttgcct	actcagcact	ggtgcaggag	1620
accgcctaca	tcgaagaccg	gcccctgcat	atggttgact	gtgctgcgga	agagaactgc	1680
ctggccagct	cagcccgtct	agccaactgg	ccctatggtc	accggcgtct	gctccgattc	1740
tcctcccaga	tccacaacct	gggacgagct	gacttcaggc	ccaaggctgg	gcgccactcc	1800
tgggtgtggc	acgagtggca	tgggcattac	cacagcatgg	acatcttcac	tcactatgat	1860
atcctcacc	caaatggcac	caaggtggct	gagggccaca	aagctagttt	ctgtctcgaa	1920
gacactgagt	gtcaggagga	tgtctccaag	cggtatgagt	gtgccaactt	tggagagcaa	1980
ggcatcactg	tgggttgctg	ggatctctac	cggcattgaca	ttgactgtca	gtggattgac	2040
atcacggatg	tgaagccagg	aaactacatt	ctccagggtt	tcatcaaccc	aaactttgaa	2100
gtagcagaga	gtgactttac	caacaatgca	atgaaatgta	actgcaaata	tgatggacat	2160
agaatctggg	tgcacaactg	ccacattggt	gatgccttca	gtgaagaggc	caacaggagg	2220
tttgaacgct	accctggcca	gaccagcaac	cagattatct	aa		2262

<210> 19

<211> 355

<212> DNA

<213> Homo sapiens

<400> 19

atggagagcg	cagcacagtt	aggccccag	gtcccagtg	ctctcagttg	gatgagggac	60
caagggcagg	gccattgcat	cacgaccctg	tgctgttttc	cagagaggta	tgctggacgg	120
gaccataaca	gctgcaaaact	ctcccagagg	gggttcctaa	acttcatgaa	cactgtactg	180
gttgcccttca	caaagaacca	gaagggtctt	ggtgcccttg	actgcatgat	gaagaaactg	240
gacttcaact	gtgatgggca	ggattttcag	gactttctca	gtcttactga	tgggtgtagct	300
gtggcttgcc	ctgactcctt	catcccggct	ggccatgccc	catgagagaa	tctga	355

<210> 20

<211> 321

<212> DNA

<213> Homo sapiens

<400> 20

atggcaaaaa	tctccggctg	cacagagatt	gcatgggtgt	gcatcacgac	cctgtgctgt	60
tttccagaga	ggtatgctgg	acgggaccat	aacagctgca	aactctccca	gaggggggtc	120
ctaaacttca	tgaacactgt	actggttgcc	ttcacaaga	accagaaggg	ctctgggtgcc	180
cttgactgca	tgatgaagaa	actggacttc	aactgtgatg	ggcagctaga	ttttcaggac	240
tttctcagtc	ttactgatgg	tgtagctgtg	gcttgccctg	actccttcat	cccggctggc	300
catgcccctg	agagaatctg	a				321

<210> 21

<211> 1932

<212> DNA

<213> Homo sapiens

<400> 21

atggcccttg	cgggcccttg	ccccctctec	actgcttccc	ttctcccctc	cacccaagcc	60
ttgcccacaa	tttaactcatt	tcttaagatc	gcttccaaac	ctaagtcaac	gctggacagg	120
gctgtaggaa	aagcttcctc	aatactggcc	ctgaagagcc	gagccagcgc	caagaggagt	180
gtgctgctcc	ccatcctggc	actgtgggcg	gggagctgct	caggaggggc	cccaccaacc	240
cccatgggct	tggctacctt	gcagctgctg	cccagcccac	caggggcccc	cgacggtcag	300
ctgcagccca	tccctggcat	cggccaccca	gacaagcctg	aggctgggaa	gctggaccag	360
ttgcgggatc	agcccacccc	gaagcaggga	gctcaaggaa	ccccaccca	gtccccctcc	420
actggctgga	aagcgcttcc	caggccaggg	ctggccctga	ggaaggagtc	acccccagt	480
accttggagc	aggagcaggg	tcacaacaag	ggcctggctg	ctgagtgggc	tcagccccag	540
gccacagctg	ccatgagggc	tggggcaggg	aagcccagag	ccttgaagct	gaggccctgg	600
caggccggca	gggacctca	agctcaagag	ggggcagcag	tcaccgagga	ggaccagggc	660
cagaggacag	gaggccggga	agacaaggga	aggggcctga	aaccaggag	gcccccaaaa	720
gggacctccc	atcaacctgg	gctgaggatc	cggcgcccac	agaaggaccg	cagccgaggc	780
caggggtggcg	gcggcagcac	ctccaagacc	ccaggccatg	ggtggaaaag	accaggaagc	840
acacatgggc	acaggcacag	gcacgcagac	ctgggcacca	cccagcaggc	catgccctct	900
ctgccggcct	cgtgcctcct	ggcccaggca	gtcatcgctt	gtggcaatgt	caagatgaag	960
catgtccctg	ccctgaccca	ccctggctct	accacactct	acctggcaga	gaatgaaatt	1020
gccaagatcc	cagcccacac	gttccctggg	ctgcccaccc	tggagtggct	ggatctcagc	1080
aagaacaagc	tggatccccg	aggcctgcac	ccccatgcct	tcaagaatct	gatgcgctg	1140
aagcggctga	acctgggttg	gaactcgctg	accacagtcc	cggccctacc	tgccctccctg	1200
caggagctca	aactcaacga	caacctcctg	cagggcttgc	aaggcagcag	cttccgtggg	1260
ctcagccagc	tggtgacgct	ggaggagctg	cacctgggca	ccaacctcat	cgaggagggtg	1320
gcggaggggc	cactgagcca	catccacagc	ctcagcgtgc	tggtgctcag	ccacaactgg	1380
cttcaggagc	actggctggc	accccagacc	tggattcatc	tcccgaagct	ggagaccctt	1440
gacctgtcct	acaaccggct	ggtgcacgtg	ccccgcttcc	tgcgcggggg	cctgaggcgc	1500
ctgacgctgc	accacgacca	catcgagcgc	atccctggct	acgcgttcgc	gcacatgaag	1560
ccaggccctag	agttcctgca	cctgtcccac	aacaggtctg	aggctgacgc	catccacagc	1620
gtgtccttcc	tgggcctgcg	cgcctcgctg	gcggagctgc	tcctggatca	taaccagggtg	1680
caggccatcc	cacgcggcct	cctgggcctc	aagggactgc	aggtgctggg	cctgagccac	1740
aacaggatca	gacaagtgcc	cttgaattcc	atctgtgaca	tgcgcgtggc	tcaggactcc	1800
aaccttacct	ccacacacct	ggagaacaac	ctcattgacc	ggcgcgcgat	cccggccact	1860
gccttctcct	gcacccgagc	ctatcacagc	gtggtcctcc	agccccagcg	gcggggggag	1920
gagggctcct	ag					1932

<210> 22

<211> 1962

<212> DNA

<213> Homo sapiens

<400> 22

atggccgggt	gccctgggac	tggacagagt	gggcagcagg	agtaccactc	cccagggggcc	60
cacccagcca	agaggagtgt	gctgctcccc	atcctggcac	tgtgggcggg	gagctgctca	120
ggagggggcc	caccaacccc	catgggcttg	gctaccctgc	agctgctgcc	cagcccacca	180
ggggcccccg	acggtcagct	gcagcccac	cctggcatcg	gccaccaga	caagcctgag	240
gctgggaagc	tggaccagtt	gcgggatcag	cccaccccga	agcaggagc	tcaaggaacc	300
cccacccagt	ccccctccac	tggctggaaa	gcgcttccca	ggccagggct	ggcctgagg	360
aaggagtac	ccccagtgc	cttggagcag	gagcagggtc	acaacaagg	cctggctcgt	420
gagtgggctc	agccccaggc	cacagctgcc	atgagggtcg	gggcagggaa	gcccagggcc	480
ttgaagctga	ggccttgcca	ggccggcagg	gaccctcaag	ctcaagagg	ggcagcagtc	540
accgaggagg	accagggcca	gaggacagga	ggccgggaag	acaagggaa	gggcctgaaa	600
cccaggaggc	cccccaaagg	gacctcccat	caacctgggc	tgaggatcdg	gcgcccacag	660
aaggaccgca	gccgaggcca	gggtggcggc	ggcagcacct	ccaagacccc	aggccatggg	720
tggaaaagac	caggaagcac	acatgggcac	aggcacaggc	acgcagacct	gggcaccacc	780
cagcaggcca	tgccctctct	gccggcctcg	tgctccttgg	cccaggcagt	catgcctgt	840
ggcaatgtca	agatgaagca	tgtccctgcc	ctgaccaccc	ctggtctgac	cacactctac	900
ctggcagaga	atgaaattgc	caagatccca	gcccacacgt	tcctggggct	gcccacacct	960
gagtggctgg	atctcagcaa	gaacaagctg	gatccccgag	gcctgcaccc	ccatgccttc	1020
aagaatctga	tgcggctgaa	gcggctgaac	ctggttggga	actcgtgac	cacagtcccc	1080

gccetacctg	cctccctgca	ggagctcaaa	ctcaacgaca	acctcctgca	gggcttgcaa	1140
ggcagcagct	tccgtgggct	cagccagctg	ttgacgctgg	aggtggaagg	gaaccagctg	1200
cgtagacagg	acatctcccc	cctggccttc	cagccctctt	gcagcctgct	ctatctgagg	1260
ctggaccgga	accggctgcg	ggccatccca	cggggcctgc	cgctcctcct	gcaggaactg	1320
cacctgggca	ccaacctcat	cgaggaggtg	gcggaggggcg	cactgagcca	catccacagc	1380
ctcagcgtgc	tgggtgctcag	ccacaactgg	cttcaggagc	actggctggc	accccgagcc	1440
tggattcatc	tcccgaagct	ggagaccctt	gacctgtcct	acaaccggct	gggtgcacgtg	1500
ccccgcttcc	tgccgcgggg	cctgaggcgc	ctgacgctgc	accacgacca	catcgagcgc	1560
atccctggct	acgcgttcgc	gcacatgaag	ccaggcctag	agttcctgca	cctgtccac	1620
aacaggctgc	aggctgacgg	catccacagc	gtgtccttcc	tgggcctgcg	cgctcgctg	1680
gcggagctgc	tcctggatca	taaccagggtg	caggccatcc	cacgcggcct	cctgggcctc	1740
aagggactgc	aggtgctggg	cctgagccac	aacaggatca	gacaagtggc	cttgaattcc	1800
atctgtgaca	tgcgcgtggc	tcaggactcc	aaccttacct	ccacacacct	ggagaacaac	1860
ctcattgacc	ggcgccgcat	cccgccact	gccttctcct	gcacccgagc	ctatcacagc	1920
gtggctcctcc	agccccagcg	gcggggggag	gagggctcct	ag		1962

<210> 23

<211> 918

<212> DNA

<213> Homo sapiens

<400> 23

atggggcgcg	gcggggcgct	gctgctggcg	ctgctgctgg	ctcgggctgg	actcgggaag	60
ccggagtgcg	aggaggagga	gctgttgctca	gaggcctgcg	gccaccggga	aattcacgcg	120
ctgggtggcg	gcggagtggg	gtccgcgcgc	gggcgctggc	catggcaggc	cagcctgcgc	180
ctgaggagac	gccaccgatg	tggagggagc	ctgctcagcc	gccgctgggt	gctctcggct	240
gcgcactgct	tccaaaagca	ctactatccc	tccgagtggg	cggctccagct	gggcgagctg	300
attccaggc	caactccttg	gaacctgcgg	gcctacagca	gtcggtacaa	agtgcaggac	360
atcattgtga	accctgacgc	acttgggggtt	ttacgcaatg	acattgccct	gctgagactg	420
gcctcttctg	tcacctacaa	tgcgtacatc	cagcccattt	gcacgagtc	ttccaccttc	480
aacttcgtgc	accggccgga	ctgctgggtg	accggctggg	ggttaatcag	ccccagtggc	540
acacctctgc	cacctcctta	caacctccgg	gaagcacagg	tcaccatctt	aaacaacacc	600
aggtgtaatt	acctgtttga	acagccctct	agccgtagta	tgatctggga	ttccatgttt	660
tgtgctgggtg	ctgaggatgg	cagtgtagac	acctgcaaag	gtgactcagg	tggacccttg	720
gtctgtgaca	aggatggact	gtggtatcag	gttggaatcg	tgagctgggg	aatggactgc	780
ggtcaaccca	atcggcctgg	tgtctacacc	aacatcagtg	tgtacttcca	ctggatccgg	840
aggggtgatgt	cccacagtac	accagggcca	aacctctccc	agctgttgct	gctccttgcc	900
ctgctgtggg	ctccctga					918

<210> 24

<211> 1164

<212> DNA

<213> Homo sapiens

<400> 24

atgaggggtca	cctggaacca	cggggccgcca	tgtccctccc	ccgacagctt	gacaataacc	60
tgtaattatg	gaaacggagg	ctgccagcac	agctgtgagg	acacagacac	aggccccacg	120
tgtgggttgc	accagaagta	cgccctccac	tcagacggtc	gcacgtgcat	cgagaaggat	180
gaggctgcaa	ttgagcgctc	tcagttcaat	gccacgtcag	tagctgatgt	ggacaagcgg	240
gtgaaacggc	ggctactcat	ggcaccctct	gactgggggc	agaagctagg	tcttttccag	300
cttgggtgcc	cccctcaggg	cacagcacag	ggccttgccc	agagcgggag	catggagtcc	360
ctgctcatta	atctagtcac	tgagcacaac	tcattagaca	cctccgcccgt	gctggtcacc	420
ttgacgtgc	cctgcccaga	tagcgtgtgg	tcagtgggag	aggcctctgc	acacacagac	480
agcgtgccc	tgtggggcag	aagcccaggg	gtgagcgctc	tccccaccag	ctggaggagg	540
aagccagggt	accagcgggt	gcagacctca	cgtcccaggc	gcctgagccg	ccctccacaa	600
gtgtgtttca	gggtggggga	gattcctcat	gaggccataa	tgtagcccc	tgagacgtgc	660
gcagtcaata	acggaggctg	cgaccggaca	tgcaaggaca	cagccactgg	cgtagcatgc	720
agctgccccg	ttggattcac	actgcagccg	gacgggaaga	catgcaaaga	catcaacgag	780
tgccctgggtca	acaacggagg	ctgcgaccac	ttctgcccga	acaccgtggg	cagcttcgag	840

tgcggtgcc	ggaagggcta	caagctgtctc	accgacgagc	gcacctgcc	ggacatcgac	900
gagtgtcct	tcgagcggac	ctgtgaccac	atctgcatca	actccccggg	cagcttccag	960
tgctgtgtc	accgcggcta	catcctctac	gggacaaccc	actgcgagga	tgtggacgag	1020
tgacgcatga	gcaacgggag	ctgtgaccag	ggctgcttca	acaccaaggg	cagctacgag	1080
tgctgtgtc	ccccggggag	gcggtctccac	tggaaacggga	aggattgcgt	gggcagaggt	1140
tctctgtgt	tggggtatgg	ctga				1164

<210> 25
 <211> 2895
 <212> DNA
 <213> Homo sapiens

<400> 25						
atggggcgcg	cgcccggtgc	ctggcacttg	tgctgtgtgc	tggccctggg	cacacgcggg	60
cggctggccg	ggggcagcgg	gctcccaggt	tcagtcgacg	tggatgagtg	ctcagagggc	120
acagatgact	gccacatcga	tgccatctgt	cagaacacgc	ccaagtccta	caaatgcctc	180
tgcaagccag	gctacaaggg	ggaaggcaag	cagtgtgaag	acattgacga	gtgtgagaat	240
gactactaca	atgggggctg	tgtccacgag	tgcatcaaca	tcccggggaa	ctacaggtgt	300
acctgctttg	atggcttcat	gctggcacac	gatggacaca	actgcctgga	tgtggacgag	360
tgtcaggaca	ataatggtgg	ctgccagcag	atctgcttca	atgccatggg	cagctacgag	420
tgctagtgcc	acagtggctt	cttccttagt	gacaaccagc	atacctgcat	ccaccgctcc	480
aatgagggtg	tgaactgcat	gaacaaagac	catggctgtg	cccacatctg	ccgggagacg	540
cccaaagggtg	gggtggcctg	cgactgcagg	cccggctttg	accttgccca	aaaccagaag	600
gactgcacac	taacctgtaa	ttatggaaac	ggaggctgcc	agcacagctg	tgaggacaca	660
gacacaggcc	ccacgtgtgg	ttgccaccag	aagtacgccc	tccactcaga	cggtcgcacg	720
tgcatcgaga	cgtgcgcagt	caataacgga	ggctgcgacc	ggacatgcaa	ggacacagcc	780
actggcgtgc	gatgcagctg	ccccgttggg	ttcacactgc	agccggacgg	gaagacatgc	840
aaagacatca	acgagtgcct	ggtcaacaac	ggaggctgcg	accacttctg	ccgcaacacc	900
gtgggcagct	tcgagtgcgg	ctgccggaag	ggctacaagc	tgctcaccga	cgagcgcacc	960
tgccaggaca	tcgacgagtg	ctccttcgag	cggacctgtg	accacatctg	catcaactcc	1020
ccgggcagct	tccagtgcct	gtgtcaccgc	ggctacatcc	tctacgggac	aaccactgc	1080
ggagatgtgg	acgagtgcag	catgagcaac	gggagctgtg	accagggctg	cgtcaacacc	1140
aagggcagct	acgagtgcgt	ctgtcccccg	gggaggcgcc	tccactggaa	cggaaggat	1200
tgctgggaga	caggcaagtg	tctttctcgc	gccaagacct	ccccccgggc	ccagctgtcc	1260
tgacgcaagg	caggcggtgt	ggagagctgc	ttcctttcct	gcccggctca	cacactcttc	1320
gtgccagact	cggaaaatag	ctacgtcctg	agctgcggag	ttccaggggc	gcagggcaag	1380
gcgctgcaga	aacgcaacgg	caccagctct	ggcctcgggc	ccagctgtct	agatgcccc	1440
accaccccca	tcaaacagaa	ggcccgttcc	aagatccgag	atgccaaagt	ccacctccgg	1500
ccccacagcc	aggcacgagc	aaaggagacc	gccaggcagc	cgctgctgga	ccactgccat	1560
gtgactttcg	tgacctcaa	gtgtgactcc	tccaagaaga	ggcgccgtgg	ccgcaagtcc	1620
ccatccaagg	aggtgtccca	catcacagca	gagtttgaga	tcgagacaaa	gatggaagag	1680
gcctcagaca	catgcgaagc	ggactgcttg	cggaagcgag	cagaacagag	cctgcaggcc	1740
gccatcaaga	ccctgcgcaa	gtccatcggc	cggcagcagt	tctatgtcca	ggtctcaggg	1800
actgagtacg	aggtagccca	gaggccagcc	aaggcgctgg	aggggcaggg	ggcatgtggc	1860
gcaggccagg	tgctacagga	cagcaaatgc	gttgctgtg	ggcctggcac	ccacttcggt	1920
ggtgagctcg	gccagtgtgt	gtcatgtatg	ccaggaaacat	accaggacat	ggaaggccag	1980
ctcagttgca	caccgtgccc	cagcagcgac	gggcttgggtc	tgcttgggtc	ccgcaacgtg	2040
tcggaatgtg	gaggccagtg	ttctccaggg	ttcttctcgg	ccgatggctt	caagccctgc	2100
caggcctgcc	ccgtgggcac	gtaccagcct	gagcccgggc	gcaccggctg	cttcccctgt	2160
ggaggggggtt	tgctcaccaa	acacgaaggc	accacctcct	tccaggactg	cgaggctaaa	2220
gtgcaactgt	cccccgcca	ccactacaac	accaccaccc	accgtgcat	ccgtgcccc	2280
gtcggcacct	accagcccga	gtttggccag	aaccactgca	tcacctgtcc	gggcaacacc	2340
agcacagact	tcgatggctc	caccaacgtc	acacactgca	aaaaccagca	ctgcggcgcc	2400
gagcttggtg	actacaccgg	ctacatcgag	tcccccaact	accctggcga	ctaccagcc	2460
aacgttgaat	gcgtctggga	catcgccct	cccccaaagc	gcaggatcct	catcggtgtc	2520
cctgagatct	tccctgccc	cgaggatgag	tgccggcgatg	ttctgggtcat	gaggaagagt	2580
gcctctccca	cgtccatcac	cacctatgag	acctgccaga	cctacgagag	gcccacgccc	2640
ttcacctccc	gctcccga	gctctggatc	cagttcaaat	ccaatgaagg	caacagcgcc	2700
aaaggcttcc	aagtgcctta	tgtcacctac	gatggtaaga	tccactgtct	tcacggccca	2760

ctgtgcacgg	ctcaggcggg	gccctggaga	cacagagatg	agtcgcacgt	ccccgccctc	2820
agggagctgc	gacctggcag	gtacagacct	ggaagcagaa	cgaacactgt	cagggggccag	2880
agccagacag	gctga					2895

<210> 26
 <211> 640
 <212> DNA
 <213> Homo sapiens

<400> 26						
aatgggtttta	ccctcatatt	caaaatcaga	gggaggggtca	ttattggata	tctactgttt	60
actcacgtat	tggatggagg	tgggtgccac	cctcttggca	gagacaaaga	ttccagccac	120
tgatgtcgct	gatgccagcc	tgaatgaatg	ttccagtacc	gaaaggaaac	aagacgtagt	180
gttgctgttc	gtgacctgt	cccacacaca	gccacctctg	tttcacctgc	cttatgtcca	240
gaaaccttta	atctctaata	tggagcagct	gacccctggg	atccccgggc	agaatcgccg	300
ggagataggc	catggccagg	atatctttcc	agcagagaag	ctctgccatc	tcgaggatcg	360
caaggtgaac	cttcacagag	ctgcctgggg	cgagtgtatt	gttgcaccca	agactctcag	420
cttctcttac	tgtcagggga	cctgcccgcc	cctcaacagt	gagctccgtc	attccagctt	480
tgagtgtctat	aagagggcag	tacctacctg	tccttggttc	ttccagacct	gccgtcccac	540
catggtcaga	ctcttctccc	tgatgggtcca	ggatgacgaa	cacaagatga	gtgtgcacta	600
tgtgaacact	tccttggtgg	agaagtgtgg	ctgctcttga			640

<210> 27
 <211> 568
 <212> DNA
 <213> Homo sapiens

<400> 27						
batggaggtg	gtgcccaccc	tcttggcaga	gacaaagatt	ccagccactg	atgtcgctga	60
tgccagcctg	aatgaatgtt	ccagtaccga	aaggaaacaa	gacgtagtgt	tgctgttcgt	120
gaccttgtcc	cacacacagc	cacctctgtt	tcacctgcct	tatgtccaga	aaccttaata	180
ctctaattgt	gagcagctga	tcctgggggat	cccggggccag	aatcgccggg	agataggcca	240
tggccaggat	atctttccag	cagagaagct	ctgccatctg	caggatcgca	aggtgaacct	300
tcacagagct	gcctggggcg	agtgtattgt	tgcacccaag	actctcagct	tctcttactg	360
tcaggggacc	tgcccggccc	tcaacagtga	gtcccgctcat	tccagctttg	agtgtataaa	420
gagggcagta	cctacctgtc	cctggctctt	ccagacctgc	cgccccacca	tggtcagact	480
cttctccctg	atgggtccagg	atgacgaaca	caagatgagt	gtgcactatg	tgaacacttc	540
cttggtggag	aagtgtggct	gctcttga				568

<210> 28
 <211> 2223
 <212> DNA
 <213> Homo sapiens

<400> 28						
atgggtgact	caggagcaga	ggctgtggga	ggtgggggga	catacactga	tggccccgtg	60
ctcctcctct	atgcagggga	gctgctgttg	ccccaggaga	cgactgtgga	gctgagctgt	120
ggagtggggc	cactgcaagt	gatcctgggc	ccagagcagg	ctgcagtgtc	aaactgtagc	180
ctgggggctg	ctgccgctgg	acccccacc	aggggtgacct	ggagcaagga	tggggacacc	240
ctgctggagc	acgaccactt	acacctgctg	cccaatggtt	ccctgtggct	gtcccagcca	300
ctagcaccca	atggcagtga	cgagtcagtc	cctgaggctg	tgggggtcat	tgaaggcaac	360
tattcgtgcc	tagcccacgg	ccccctggga	gtgctggcca	gccagactgc	tgtcgtcaag	420
cttgccacac	tcgcagactt	ctctctgcac	ccggagtctc	agacgggtgga	ggagaacggg	480
acagctcgct	ttgagtgcc	cattgaagg	ctgccagctc	ccatcattac	ttgggagaag	540
gaccaggtga	cattgcctga	ggagcctcgg	ctcatcgtgc	ttcccaacgg	cgctccttcag	600
atcctggatg	ttcaggagag	tgatgcaggc	ccctaccgct	gcgtggccac	caactcagct	660
cgccagcact	tcagccagga	ggccctactc	agtgtggccc	acagaggggtc	cctggcgctcc	720
accagggggc	aggacgtgg	cattgtggca	gccccagaga	acaccacagt	ggtgtctggc	780
cagagtgtgg	tgatggaatg	tgtggcctca	gctgacccca	ccccttttgt	gtcctgggtc	840

cgacaagacg	ggaagcccat	ctccacagat	gtcatcgctc	tgggcccgcac	caacctacta	900
attgccaacg	cgcagccctg	gcactccggc	gtctatgtct	gccgcgccaa	caagccccgc	960
acgcgcgact	tcgccactgc	agccgctgag	ctccgtgtgc	tggcggctcc	cgccatcact	1020
caggcgcccg	aggcgctgtc	gcggacgcgg	gcgagcacag	cgcgcttcgt	gtgccgcgcg	1080
tcggggggagc	cgcggccagc	gctgcgctgg	ctgcacaacg	gggcgcgcgt	gcgcccaac	1140
gggcgcgtca	aggtccaggg	cggcgggtgg	agcctggtca	tcacacagat	cggcctgcag	1200
gacgccggct	actaccagt	cgtggctgag	aacagcgcg	gaatggcggt	cgctgccgcg	1260
tcgctggccg	tgggtggtgcg	cgaggggctg	cccagcgccc	ccacgcgggt	cactgctacg	1320
ccactgagca	gctccgctgt	gttgggtggc	tgggagcggc	ccgagatgca	cagcgagcag	1380
atcatcggt	tctctctcca	ctaccagaag	gcacggggca	tggacaatgt	ggaataccag	1440
tttgagtgta	acaacgacac	cacagaacta	caggttcggg	acctggaacc	caacacagat	1500
tatgagttct	acgtggtggc	ctactcccag	ctgggagcca	gccgcacctc	caccccagca	1560
ctgggtgcaca	cactggatga	tggtagggcc	tctgaactcg	cagtgggcag	cttggggcctg	1620
agcaatgggc	aggtggtgaa	gtacaagata	gaatacgggt	tgggaaagga	agatcagatt	1680
ttctctactg	aggtgcgagg	aaatgagaca	cagcttatgc	tgaactcgct	tcagccaaac	1740
aaggtgtatc	gagtacggat	ttcggctggt	acagcagccg	gcttcggggc	ccccctccag	1800
tggatgcac	acaggacgcc	cagtatgcac	aaccagagcc	atgtcccttt	tggccctgca	1860
gagttgaagg	tgcaggcaaa	gatggagtcc	ctggtcgtgt	catggcagcc	acccccctac	1920
cccacccaga	tctctggcta	caaactatat	tggcgggagg	tgggggctga	ggaggaggcc	1980
aatggcgatc	gcctgccagg	gggccgtgga	gaccagcctt	gggatgtggg	gcctgtccgg	2040
ctcaagaaga	aagtgaagca	gtatgagctg	acccagctag	tccctggccg	gctgtacgag	2100
gtgaagctcg	tggctttcaa	caaacatgag	gatggctatg	cagcagtggt	gaagggcaag	2160
acggagaagg	cgccggcacc	aggtgagggc	ggtgggggaa	gaaggcgggg	agggctcagg	2220
tga						2223

<210> 29
 <211> 3753
 <212> DNA
 <213> Homo sapiens

<400> 29						
atggcgccggg	gggacgccgg	ccgcggccgc	gggctcctcg	cgttgacctt	ctgcctgttg	60
gccgcgcgcg	gggagctgct	gttgccccag	gagacgactg	tggagctgag	ctgtggagtg	120
gggcccactgc	aagtgatcct	gggcccagag	caggctgcag	tgctaaactg	tagcctgggg	180
gctgctgccg	ctggaccccc	caccaggggtg	acctggagca	aggatgggga	caccctgctg	240
gagcacgacc	acttacacct	gctgcccaat	ggttccctgt	ggctgtccca	gccactagca	300
cccaatggca	gtgacgagtc	agtccttgag	gctgtggggg	tcattgaagg	caactattcg	360
tgcctagccc	acggccccct	cggagtgcgt	gccagccaga	ctgctgtcgt	caagcttgcc	420
acactcgagc	acttctctct	gcacccggag	tctcagacgg	tggaggagaa	cgggacagct	480
cgctttgagt	gccacattga	agggctgcca	gctcccatca	ttacttggga	gaaggaccag	540
gtgacattgc	ctgaggagcc	tcggctcate	gtgcttccca	acggcgctcct	tcagatcctg	600
gatgttcagg	agagtgatgc	aggcccctac	cgtgcgctgg	ccaccaactc	agctcgccag	660
cacttcagcc	aggaggccct	actcagtgtg	gcccacagag	ggtccctggc	gtccaccagg	720
gggcaggacg	tggtcattgt	ggcagcccca	gagaacacca	cagtgggtgc	tggccagagt	780
gtggtgatgg	aatgtgtggc	ctcagctgac	cccaccctt	ttgtgtcctg	ggtccgacaa	840
gacgggaagc	ccatctccac	agatgtcate	gtcctggggc	gcaccaacct	actaattgcc	900
aacgcgcagc	cctggcactc	cggcgcttat	gtctgccgcg	ccaacaagcc	ccgcacgcgc	960
gacttcgcca	ctgcagccgc	tgagctccgt	gtgctggcgg	ctccccccat	cactcaggcg	1020
cccagggcgc	tgtcgcggac	gcgggcgagc	acagcgcgct	tcgtgtgccc	cgcgtcgggg	1080
gagccgcggc	cagcgtgcg	ctggctgcac	aacggggcgc	cgctgcggcc	caacgggcgc	1140
gtcaaggtcc	agggcgggcg	tggcagcctg	gtcatcacac	agatcggcct	gcaggacgcc	1200
ggctactacc	agtgcgtggc	tgagaacagc	gcgggaatgg	cgtgcgctgc	cgcgtcgtg	1260
gccgtgggtg	tgcgcgaggg	gctgcccagc	gccccacgc	gggtcactgc	tacgccactg	1320
agcagctccg	ctgtgttggg	ggcctggggg	cggcccagag	tgcacagcga	gcagatcatc	1380
ggcttctctc	tccactacca	gaaggcacgg	ggcatggaca	atgtggaata	ccagtttgca	1440
gtgaacaacg	acaccacaga	actacagggt	cgggacctgg	aacccaacac	agattatgag	1500
ttctacgtgg	tggcctactc	ccagctggga	gccagccgca	cctccacccc	agcactgggtg	1560
cacacactgg	atgatgtccc	cagtgcagca	ccccagctct	ccctgtccag	ccccaacctt	1620
tcggacatca	gggtggcggtg	gctgcccctg	ccccccagcc	tgagcaatgg	gcagggtgggtg	1680

aagtacaaga	tagaatacgg	tttgggaaag	gaagatcaga	ttttctctac	tgaggtgcga	1740
ggaaatgaga	cacagcttat	gctgaactcg	cttcagccaa	acaaggtgta	tcgagtacgg	1800
atttcggctg	gtacagcagc	cggcttcggg	gccccctccc	agtggatgca	tcacaggacg	1860
cccagtatgc	acaaccagag	ccatgtccct	tttgcccctg	cagagttgaa	ggtgcaggca	1920
aagatggagt	ccctggtcgt	gtcatggcag	ccacccccctc	acccccacca	gatctctggc	1980
tacaaactat	attggcggga	ggtgggggct	gaggaggagg	ccaatggcga	tcgcctgcca	2040
ggggggccgtg	gagaccagge	ttgggatgtg	gggcctgtcc	ggctcaagaa	gaaagtgaag	2100
cagtatgagc	tgaccagct	agtccctggc	cggctgtacg	aggtgaagct	cgtggctttc	2160
aacaaacatg	aggatggcta	tgacagcagc	tgggaaggga	agacggagaa	ggcgccggca	2220
ccagacatgc	ctatccagag	gggaccaccc	ctgcctccag	cccacgtcca	tcggaatca	2280
aacagctcca	catccatctg	gcttcgggtg	aaaaagccag	atttcaccac	agtcaagatt	2340
gtcaactaca	ctgtgcgctt	cagcccctgg	gggctcagga	atgcctccct	ggtcacctat	2400
tacaccagtt	ctggagaaga	catcctcatt	ggcggcttga	agccattcac	caaatacag	2460
tttgagtgac	agtctcacgg	cgtggacatg	gatgggcctt	tcggctctgt	ggtggagcgc	2520
tccaccctgc	ctgaccggcc	ctccacaccc	ccatccgacc	tgcgactgag	ccccctgaca	2580
ccgtccacgg	ttcggctgca	ctggtgcccc	cccacagagc	ccaacgggga	gatcgtggag	2640
tatctgatcc	tgtacagcag	caaccacacg	cagcctgagc	accagtggac	cttgctcacc	2700
acgcagggaa	acatcttcag	tgtgaggtg	catggcctgg	agagcgacac	tcgggtacttc	2760
ttcaagatgg	gggcgcgcac	agaggtggga	cctgggcctt	tctcccgctt	gcaggatgtg	2820
atcacgctcc	aggagaagct	gtcagactcg	ctggacatgc	actcagtcac	gggcatcatc	2880
gtgggtgtct	gcctgggcct	cctctgcctc	ctggcctgca	tgtgtgctgg	cctgcgcgcg	2940
agccccaca	gggaatccct	cccaggcctg	tctccaccg	ccacccccgg	gaatccccgcg	3000
ctgtactcca	gagctcggct	tggccccccc	agccccccag	ctgcccata	attggagtcc	3060
cttgtgcacc	cccatcccca	ggactgggtc	ccgccaccct	cagacgtgga	ggacagggct	3120
gaagtgcaca	gccttatggg	tggcgggtgt	tctgaaggcc	ggagtcactc	caaaagaaa	3180
atctcctggg	ctcaaccaag	cgggctgagc	tgggctgggt	cctgggcagg	ctgtgagctg	3240
ccccaggcag	gccccggg	ggctctgacc	cgggccctgc	tgccccctgc	tggaaactggg	3300
cagacgctgt	tgtctgcaggc	tctgggtgtac	gacgccataa	agggcaatgg	gaggaagaag	3360
tcacccccag	cctgcaggaa	ccagggtggag	gctgaagtca	ttgtccactc	tgactttagt	3420
gcacttaacg	ggaaccctga	cctccatctc	caagacctgg	agcctgagga	ccccctgcct	3480
ccagaggctc	ctgatctcat	ctcgggtgtt	ggggatccag	ggcagggggc	agcctggctg	3540
gacagggagt	tgggagggtg	tgagctggca	gccccggggc	cagacagact	tacctgcttg	3600
ccagaggcag	ccagtgcctc	ctgctcctac	ccggacctcc	agccaggcga	ggtgctagag	3660
gagacccctg	gagatagctg	ccagctcaaa	tccccctgcc	ctctaggagc	cagcccaggc	3720
ctgcccagat	ccccgggtctc	ctcctctgcc	tag			3753

<210> 30

<211> 1905

<212> DNA

<213> Homo sapiens

<400> 30

atggcccagg	gtgtcctctg	gactctactc	ggattgctac	tgtggtcaga	cccagggaca	60
gcctccctgc	ccctgctcat	ggactctgtc	atccaggccc	tggctgagct	ggagcagaaa	120
gtgccagctg	ccaagaccag	acacacagct	tctgcgtggc	tgatgtcagc	tccaaactct	180
ggccccaca	atgcctcta	ccacttctct	ctgggggcat	ggagcctcaa	tgctacagag	240
ttggatccct	gcccactaag	cccagagctg	ttaggcctga	ccaaggaggt	ggccccacat	300
gacgtacgag	aagggaagga	atatgggggtg	gtgctggcac	ctgatggctc	gaccgtggct	360
gtggagcctc	tgtctggcggg	gctggaggca	gggctgcaag	ggcgagggt	cataaatttg	420
cccttgga	gcattggctg	cccttgggag	actggagata	cctttccaga	tgttgtggcc	480
attgctccag	atgtaagagc	cacctcctcc	ccaggactca	gggatggctc	tccagatgtc	540
accactgcag	atattggagc	caacactcca	gatgtacaaa	aaggctgtcc	agatgtccaa	600
gcttccttgc	cagatgccaa	agccaagtcc	ccaccgacca	tggtaggacag	cctcctggca	660
gtcaccctgg	ctggaaacct	gggcctgacc	tccctccgag	gttcccagac	ccagagccat	720
ccagacctgg	gaactgaggg	ctgctgggac	cagctctctg	cccctcggac	ctttacgctt	780
ttggacccca	aggcatctct	gttaaccatg	gccttcctca	atggcgccct	ggatgggggtc	840
atccttggag	actacctgag	ccggactcct	gagccccggc	catccctcag	ccacttgctg	900
agccagtact	atggggctgg	ggtggccaga	gacccagggt	tccgcagcaa	cttcgcagcg	960
cagaacgggtg	ctgctctgac	ttcagcctcc	atcctggccc	agcaggtgtg	gggaaccctt	1020

gtccttctac	agaggctgga	gccagtagac	ctccagcttc	agtgcattgag	ccaagaacag	1080
ctggcccagg	tggctgccaa	tgctaccaag	gaattcactg	aggccttctc	gggatgcccg	1140
gccatccacc	cccgtgccc	ctggggagcg	gcgccttata	ggggccgccc	gaagctgctg	1200
cagctgccgc	tgggattctt	gtacgtgcat	cacacctacg	tgcttgacac	accctgcacg	1260
gacttcacgc	gctgcgacg	caacatgcgc	tccatgcagc	gctaccacca	ggacacgcaa	1320
ggctggggag	acatcggcta	cagtttcgtg	gtgggctcgg	acggctacgt	gtacgagggg	1380
cgcggtggtg	actgggtggg	cgcccacacg	ctcgggccaca	actcccgggg	cttcggcgctg	1440
gccatagtgg	gcaactacac	cgcggtgctg	cccaccgagg	ccgctctgcg	cacggtgcgc	1500
gacacgctcc	cgagttgtgc	ggtgcgcgccc	ggcctcctgc	ggccagacta	cgcgctgctg	1560
ggccaccgccc	agctggtgcg	caccgactgc	cccggcgacg	cgctcttcga	cctgctgcgc	1620
acctggccgc	acttcaccgc	ggtgagtctt	cgcagcctgc	actacacggc	ccgccgcccc	1680
tccgtctaca	caagctccac	gaggcccttg	ccccctgctt	gtaacagctg	tgcccgcaca	1740
gcctcagcca	ggcccccaac	ttcccggcgg	cacgtctatt	caggaaacct	aggcccagcc	1800
tttgccgggtc	actctgcggg	caacatccct	gatcctgtga	cttctgccta	tgacgcctca	1860
gctcagcccc	agaccagcc	agcctgtcct	ttccccagct	cctaa		1905

<210> 31

<211> 1731

<212> DNA

<213> Homo sapiens

<400> 31

atggcccagg	gtgtcctctg	gactcctactc	ggattgctac	tgtggctcaga	cccagggaca	60
gcctccctgc	ccctgctcat	ggactctgtc	atccaggccc	tggctgagct	ggagcagaaa	120
gtgccagctg	ccaagaccag	acacacagct	tctgcgtggc	tgatgtcagc	tccaaactct	180
ggccccccaca	atcgccctcta	ccacttcctg	ctgggggcat	ggagcctcaa	tgctacagag	240
ttggatccct	gcccactaag	cccagagctg	ttaggcctga	ccaaggaggt	ggcccgcacat	300
gacgtacgag	aagggaaggga	atatgggggtg	gtgctggcac	ctgatggctc	gaccgtggct	360
gtggagcctc	tgctggcggg	gctggaggca	gggctgcaag	ggcgcagggt	cataaatttg	420
cccttgagaca	gcatggctgc	cccttgaggag	actggagata	cctttccaga	tggttgaggcc	480
attgctccag	atgtaagagc	cacctcctcc	ccaggactca	gggatggctc	tccagatgtc	540
accactgcag	atattggagc	caacactcca	gatgctacaa	aaggctgtcc	agatgtccaa	600
gcttccttgc	cagatgccaa	agccaagtcc	ccaccgacca	tgggtggacag	cctcctggca	660
gtcaccctgg	ctggaaacct	gggcctgacc	ttcctccgag	gttcccagac	ccagagccat	720
ccagaccttg	gaactgaggg	ctgctgggac	cagctctctg	cccctcggac	ctttacgctt	780
ttggacccca	aggcatctct	gttaaccatg	gccttcctca	atggcgccct	ggatggggctc	840
atccttggag	actacctgag	ccggactcct	gagccccggc	catccctcag	ccacttgcctg	900
agccagtact	atggggctgg	ggtggccaga	gaccagggt	tccgcagcaa	cttcgcagcg	960
cagaacgggtg	ctgctctgac	ttcagcctcc	atcctggccc	agcaggtgtg	gggaaccctt	1020
gtccttctac	agaggctgga	gccagtagac	ctccagcttc	agtgcattgag	ccaagaacag	1080
ctggcccagg	tggctgccaa	tgctaccaag	gaattcactg	aggccttctc	gggatgcccg	1140
gccatccacc	cccgtgccc	ctggggagcg	gcgccttata	ggggccgccc	gaagctgctg	1200
cagctgccgc	tgggattctt	gtacgtgcat	cacacctacg	tgcttgacac	accctgcacg	1260
gacttcacgc	gctgcgacg	caacatgcgc	tccatgcagc	gctaccacca	ggacacgcaa	1320
ggctggggag	acatcggcta	cagtttcgtg	gtgggctcgg	acggctacgt	gtacgagggg	1380
cgcggtggtg	actgggtggg	cgcccacacg	ctcgggccaca	actcccgggg	cttcggcgctg	1440
gccatagtgg	gcaactacac	cgcggtgctg	cccaccgagg	ccgctctgcg	cacggtgcgc	1500
gacacgctcc	cgagttgtgc	ggtgcgcgccc	ggcctcctgc	ggccagacta	cgcgctgctg	1560
ggccaccgccc	agctggtgcg	caccgactgc	cccggcgacg	cgctcttcga	cctgctgcgc	1620
acctggccgc	acttcaccgc	gactgttaag	ccaagacctg	ccaggagtgt	ctctaagaga	1680
tccaggaggg	agccaccccc	aaggaccctg	ccagccacag	acctccaata	a	1731

<210> 32

<211> 2205

<212> DNA

<213> Homo sapiens

<400> 32

atgtggggggc	tcctgctcgc	cctggccgccc	ttcgcgcccg	ccgtcggccc	ggctctgggg	60
-------------	------------	-------------	------------	------------	------------	----

gcgcccagga	actcggtgct	gggcctcgcg	cagcccggga	ccaccaaggt	cccaggctcg	120
accccgggcc	tgcatagcag	cccggcacag	ccgcccggcg	agacagctaa	cgggacctca	180
gaacagcatg	tccggattcg	agtcatcaag	aagaaaaagg	tcattatgaa	gaagcgggaag	240
aagctaactc	taactcgccc	caccccactg	gtgactgccg	ggccccctgt	gacccccact	300
ccagcagggg	ccctcgaccc	cgtcgagaaa	caagaaacag	gctgtcctcc	tttgggtctg	360
gagtccctgc	gagtttcaga	tagccggctt	gaggcatcca	gcagccagtc	ctttgggtctt	420
ggaccacacc	gaggacggct	caacattcag	tcaggcctgg	aggacggcga	tctatatgat	480
ggagcctggg	gtgctgagga	gcaggacgcc	gatccatggg	ttcagggtgga	cgtcgggcac	540
cccacccgct	tctcggtgtg	tatcacacag	ggcaggaact	ctgtctggag	gtatgactgg	600
gtcacatcat	acaaggtcca	gttcagcaat	gacagtcgga	cctgggtggg	aagtaggaac	660
cacagcagtg	ggatggacgc	agtatttcct	gccaatcag	accagaaac	tccagtgtcg	720
aacctcctgc	cggagcccca	ggtggccccg	ttcattcgcc	tgctgcccc	gacctggctc	780
cagggaggcg	cgccttgctt	ccgggcagag	atcctggcct	gcccagtcct	agaccccaat	840
gacctattcc	ttgaggcccc	tgcgtcgga	tcctctgacc	ctctagactt	tcagcatcac	900
aattacaagg	ccatgaggaa	gctgatgaag	caggtacaag	agcaatgcc	caacatcacc	960
cgcattctaca	gcattgggaa	gagctaccag	ggcctgaagc	tgatgtgat	ggaaatgtcg	1020
gacaagcctg	gggagcatga	gctgggggag	cctgaggtgc	gctacgtggc	tggtatgcat	1080
gggaacgagg	ccctggggcg	ggagttgctt	ctgctcctga	tgagttcct	gtgccatgag	1140
ttcctgcgag	ggaacccacg	ggtgaccg	ctgctctctg	agatgcgcac	tcacctgctg	1200
ccctccatga	accctgatgg	ctatgagatc	gcctaccacc	ggggttcaga	gctgggtggg	1260
tgggcccagg	gccgctggaa	caaccagagc	atcgatctta	accataattt	tgctgacctc	1320
aacacaccac	tgtgggaagc	acaggacgat	gggaaggtgc	cccacatcgt	cccccaaccat	1380
cacctgccat	tgcccactta	ctacaccctg	cccaatgcca	ccgtggctcc	tgaaacgcgg	1440
gcagtaatca	agtggatgaa	gcggatcccc	tttgtgctaa	tgccaacct	ccacgggggt	1500
gagctcgtgg	tgctctaccc	attcgacatg	actcgacccc	cgtgggctgc	ccgcgagctc	1560
acgcccacac	cagatgatgc	tgtgtttcgc	tggctcagca	ctgtctatgc	tggtcagta	1620
ctggccatgc	aggacaccag	ccgccgaccc	tgccacagcc	aggacttctc	cgtgcacggc	1680
aacatcatca	acggggctga	ctggcacacg	gtccccggga	gcataaatga	cttcagctac	1740
ctacacacca	actgctttga	ggtcactgtg	gagctgtcct	gtgacaagtt	ccctcacgag	1800
aatgaattgc	cccaggagtg	ggagaacaac	aaagacgccc	tcctcaccta	cctggagcag	1860
gtgcgcatgg	gcattgcagg	agtgggtgag	gacaaggaca	cggagcttgg	gattgctgac	1920
gctgtcattg	ccgtggatgg	gattaaccat	gacgtgacca	cggcggtggg	cggtgattat	1980
tggcgcttgc	tgaccccagg	ggactacatg	gtgactgcca	gtgccgaggg	ctaccattca	2040
gtgacacgga	actgtcgggt	cacctttgaa	gagggccctt	tcctctgcaa	tttctgtgctc	2100
accaagactc	ccaaacagag	gctgcgcgag	ctgctggcag	ctggggccaa	ggtgcccccg	2160
gaccttcgca	ggcgccctgga	gcggctaagg	ggacagaagg	attga		2205

<210> 33

<211> 1077

<212> DNA

<213> Homo sapiens

<400> 33

atgcctgagg	atgtacgaga	aaaaaaggaa	aattcttctac	tcaattctga	gagatctact	60
aggctcttaa	caaagaccag	tcattcacaa	ggaggggatc	aagctttaag	taagtcacaa	120
gggtcaccaa	cagagaagtt	gattgaaaaa	cgtcaaggag	ctaagactgt	ttttaacaag	180
ttcagcaaca	tgaattggcc	agtggacatt	caccctttaa	acaaaagttt	agtcaaagat	240
aataaatgga	agaaaactga	ggagacccaa	gagaaacgaa	ggtctttcct	tcaggagttt	300
tgcaagaaat	acgggtgggg	gagtcacatc	cagtcacatc	tttttcatac	agtatccaga	360
atctatgtag	agataaaaca	caaaatctta	tattgtgagg	tacctaaagg	tggtgtttcc	420
aattggaaaa	gaattctgat	ggtactaaat	ggattggctt	cctctgcata	caacatctcc	480
cacaatgctg	tccactacgg	gaagcatttg	aagaagctag	atagctttga	cctaaaagg	540
atatataccc	gcttaaatac	ttacacccaa	gctgtgtttg	ttcgtgatcc	catggaaaga	600
ttagtatcag	ccttttaggga	caaatttgaa	caccccaata	gttattacca	tccagtattc	660
ggaaaggcaa	ttatcaagaa	atatcgacca	aatgcctgtg	aagaagcatt	aattaatgga	720
tctggagtc	agttcaaaga	gtttatccac	tacttgctgg	attcccaccg	tccagtagga	780
atggacattc	actgggaaaa	ggtcagcaaa	ctctgctatc	cgtgtttgat	caactatgat	840
tttgtaggga	aatttgagac	tttggaagaa	gatgccaat	actttttaca	gatgatcggt	900
gctccaaagg	agctgaaatt	tcccaacttt	aaggataggc	actcttccga	tgaagaacc	960

aatgctcaag tcgtgagaca gtattttaaag gatctgacta gaactgagag acaattaatc 1020
 tatgactttt attacttgga ctatttaatg tttaattata caactccatt tttgtag 1077

<210> 34
 <211> 256
 <212> PRT
 <213> Homo sapiens

<400> 34
 Met Ser Leu Ala Ser Gly Pro Gly Pro Gly Trp Leu Leu Phe Ser Phe
 1 5 10 15
 Gly Met Gly Leu Val Ser Gly Ser Lys Cys Pro Asn Asn Cys Leu Cys
 20 25 30
 Gln Ala Gln Glu Val Ile Cys Thr Gly Lys Gln Leu Thr Glu Tyr Pro
 35 40 45
 Leu Asp Ile Pro Leu Asn Thr Arg Arg Leu Phe Leu Asn Glu Asn Arg
 50 55 60
 Ile Thr Ser Leu Pro Ala Met His Leu Gly Leu Leu Ser Asp Leu Val
 65 70 75 80
 Tyr Leu Asp Cys Gln Asn Asn Arg Ile Arg Glu Val Met Asp Tyr Thr
 85 90 95
 Phe Ile Gly Val Phe Lys Leu Ile Tyr Leu Asp Leu Ser Ser Asn Asn
 100 105 110
 Leu Thr Ser Ile Ser Pro Phe Thr Phe Ser Val Leu Ser Asn Leu Val
 115 120 125
 Gln Leu Asn Ile Ala Asn Asn Pro His Leu Leu Ser Leu His Lys Phe
 130 135 140
 Thr Phe Ala Asn Thr Thr Ser Leu Arg Tyr Leu Asp Leu Arg Asn Thr
 145 150 155 160
 Gly Leu Gln Thr Leu Asp Ser Ala Ala Leu Tyr His Leu Thr Thr Leu
 165 170 175
 Glu Thr Leu Phe Leu Ser Gly Asn Pro Trp Lys Cys Asn Cys Ser Phe
 180 185 190
 Leu Asp Phe Ala Ile Phe Leu Ile Val Phe His Met Asp Pro Ser Gly
 195 200 205
 Glu Gly Leu Ile Gly Cys Gly Glu Glu Asp Val Ile Glu Val Ala Pro
 210 215 220
 Glu Lys Val Asn Ser Lys Asp Gly Gln Asn Gly Arg Lys Ser Trp Val
 225 230 235 240
 Lys Leu Ile Glu Cys Ile Leu Ile Thr Leu Gln Gly Pro Pro Leu Gly
 245 250 255

<210> 35
 <211> 897
 <212> PRT
 <213> Homo sapiens

<400> 35
 Met Gly Ser Gly Arg Val Pro Gly Leu Cys Leu Leu Val Leu Leu Val
 1 5 10 15
 His Ala Arg Ala Ala Gln Tyr Ser Lys Ala Ala Gln Asp Val Asp Glu
 20 25 30
 Cys Val Glu Gly Thr Asp Asn Cys His Ile Asp Ala Ile Cys Gln Asn
 35 40 45
 Thr Pro Arg Ser Tyr Lys Cys Ile Cys Lys Ser Gly Tyr Thr Gly Asp
 50 55 60
 Gly Lys His Cys Lys Asp Val Asp Glu Cys Glu Arg Glu Asp Asn Ala
 65 70 75 80
 Gly Cys Val His Asp Cys Val Asn Ile Pro Gly Asn Tyr Arg Cys Thr

					85					90					95				
Cys	Tyr	Asp	Gly	Phe	His	Leu	Ala	His	Asp	Gly	His	Asn	Cys	Leu	Asp				
			100					105					110						
Val	Asp	Glu	Cys	Ala	Glu	Gly	Asn	Gly	Gly	Cys	Gln	Gln	Ser	Cys	Val				
		115					120					125							
Asn	Met	Met	Gly	Ser	Tyr	Glu	Cys	His	Cys	Arg	Glu	Gly	Phe	Phe	Leu				
		130				135					140								
Ser	Asp	Asn	Gln	His	Thr	Cys	Ile	Gln	Arg	Pro	Glu	Glu	Gly	Met	Asn				
145					150					155					160				
Cys	Met	Asn	Lys	Asn	His	Gly	Cys	Ala	His	Ile	Cys	Arg	Glu	Thr	Pro				
			165						170					175					
Lys	Gly	Gly	Ile	Ala	Cys	Glu	Cys	Arg	Pro	Gly	Phe	Glu	Leu	Thr	Lys				
		180						185					190						
Asn	Gln	Arg	Asp	Cys	Lys	Cys	Glu	Ile	Ile	Gly	Met	Ala	Val	Thr	Cys				
		195					200					205							
Asn	Tyr	Gly	Asn	Gly	Gly	Cys	Gln	His	Thr	Cys	Asp	Asp	Thr	Glu	Gln				
		210				215					220								
Gly	Pro	Arg	Cys	Gly	Cys	His	Ile	Lys	Phe	Val	Leu	His	Thr	Asp	Gly				
225					230					235					240				
Lys	Thr	Cys	Ile	Glu	Thr	Cys	Ala	Val	Asn	Asn	Gly	Gly	Cys	Asp	Ser				
			245						250					255					
Lys	Cys	His	Asp	Ala	Ala	Thr	Gly	Val	His	Cys	Thr	Cys	Pro	Val	Gly				
		260						265					270						
Phe	Met	Leu	Gln	Pro	Asp	Arg	Lys	Thr	Cys	Lys	Asp	Ile	Asp	Glu	Cys				
		275					280					285							
Arg	Leu	Asn	Asn	Gly	Gly	Cys	Asp	His	Ile	Cys	Arg	Asn	Thr	Val	Gly				
		290				295					300								
Ser	Phe	Glu	Cys	Ser	Cys	Lys	Lys	Gly	Tyr	Lys	Leu	Leu	Ile	Asn	Glu				
305					310					315					320				
Arg	Asn	Cys	Gln	Asp	Ile	Asp	Glu	Cys	Ser	Phe	Asp	Arg	Thr	Cys	Asp				
			325						330					335					
His	Ile	Cys	Val	Asn	Thr	Pro	Gly	Ser	Phe	Gln	Cys	Leu	Cys	His	Arg				
		340						345					350						
Gly	Tyr	Leu	Leu	Tyr	Gly	Ile	Thr	His	Cys	Gly	Asp	Val	Asp	Glu	Cys				
		355					360					365							
Ser	Ile	Asn	Arg	Gly	Gly	Cys	Arg	Phe	Gly	Cys	Ile	Asn	Thr	Pro	Gly				
		370				375					380								
Ser	Tyr	Gln	Cys	Thr	Cys	Pro	Ala	Gly	Gln	Gly	Arg	Leu	His	Trp	Asn				
385					390					395					400				
Gly	Lys	Asp	Cys	Thr	Glu	Pro	Leu	Lys	Cys	Gln	Gly	Ser	Pro	Gly	Ala				
			405						410					415					
Ser	Lys	Ala	Met	Leu	Ser	Cys	Asn	Arg	Ser	Gly	Lys	Lys	Asp	Thr	Cys				
		420						425					430						
Ala	Leu	Thr	Cys	Pro	Ser	Arg	Ala	Arg	Phe	Leu	Pro	Glu	Ser	Glu	Asn				
		435					440					445							
Gly	Phe	Thr	Val	Ser	Cys	Gly	Thr	Pro	Ser	Pro	Arg	Ala	Ala	Pro	Ala				
		450				455					460								
Arg	Ala	Gly	His	Asn	Gly	Asn	Ser	Thr	Asn	Ser	Asn	His	Cys	His	Glu				
465					470					475					480				
Ala	Ala	Val	Leu	Ser	Ile	Lys	Gln	Arg	Ala	Ser	Phe	Lys	Ile	Lys	Asp				
			485						490					495					
Ala	Lys	Cys	Arg	Leu	His	Leu	Arg	Asn	Lys	Gly	Lys	Thr	Glu	Glu	Ala				
		500						505					510						
Gly	Arg	Ile	Thr	Gly	Pro	Gly	Gly	Ala	Pro	Cys	Ser	Glu	Cys	Gln	Val				
		515				520						525							
Thr	Phe	Ile	His	Leu	Lys	Cys	Asp	Ser	Ser	Arg	Lys	Gly	Lys	Gly	Arg				
		530				535					540								
Arg	Ala	Arg	Thr	Pro	Pro	Gly	Lys	Glu	Val	Thr	Arg	Leu	Thr	Leu	Glu				
545					550					555					560				

Leu Glu Ala Glu Gln Leu Phe Leu Leu Pro Asp Thr His Gly His Pro
 565 570 575
 Pro Pro Ala Ser Cys Gly Leu Pro Cys Leu Arg Gln Arg Met Glu Arg
 580 585 590
 Arg Leu Lys Gly Ser Leu Lys Met Leu Arg Lys Ser Ile Asn Gln Asp
 595 600 605
 Arg Phe Leu Leu Arg Leu Ala Gly Leu Asp Tyr Glu Leu Ala His Lys
 610 615 620
 Pro Gly Leu Val Ala Gly Glu Arg Ala Glu Pro Met Glu Ser Cys Arg
 625 630 635 640
 Pro Gly Gln His Arg Ala Gly Thr Lys Cys Val Gln Cys Ser Pro Gly
 645 650 655
 His Tyr Tyr Asn Thr Ser Ile His Arg Cys Ile Arg Cys Ala Met Gly
 660 665 670
 Ser Tyr Gln Pro Asp Phe Arg Gln Asn Phe Cys Ser Arg Cys Pro Gly
 675 680 685
 Asn Thr Ser Thr Asp Phe Asp Gly Ser Thr Ser Val Ala Gln Cys Lys
 690 695 700
 Asn Arg Gln Cys Gly Gly Glu Leu Gly Glu Phe Thr Gly Tyr Ile Glu
 705 710 715 720
 Ser Pro Asn Tyr Pro Gly Asn Tyr Pro Ala Gly Val Glu Cys Ile Trp
 725 730 735
 Asn Ile Asn Pro Pro Pro Lys Arg Lys Ile Leu Ile Val Val Pro Glu
 740 745 750
 Ile Phe Leu Pro Ser Glu Asp Glu Cys Gly Asp Val Leu Val Met Arg
 755 760 765
 Lys Asn Ser Ser Pro Ser Ser Ile Thr Thr Tyr Glu Thr Cys Gln Thr
 770 775 780
 Tyr Glu Arg Pro Ile Ala Phe Thr Ala Arg Ser Arg Lys Leu Trp Ile
 785 790 795 800
 Asn Phe Lys Thr Ser Glu Ala Asn Ser Ala Arg Gly Phe Gln Ile Pro
 805 810 815
 Tyr Val Thr Tyr Asp Glu Asp Tyr Glu Gln Leu Val Glu Asp Ile Val
 820 825 830
 Arg Asp Gly Arg Leu Tyr Ala Ser Glu Asn His Gln Glu Ile Leu Lys
 835 840 845
 Asp Lys Lys Leu Ile Lys Ala Phe Phe Glu Val Leu Ala His Pro Gln
 850 855 860
 Asn Tyr Phe Lys Tyr Thr Glu Lys His Lys Glu Met Leu Pro Lys Ser
 865 870 875 880
 Phe Ile Lys Leu Leu Arg Ser Lys Val Ser Ser Phe Leu Arg Pro Tyr
 885 890 895
 Lys

<210> 36
 <211> 993
 <212> PRT
 <213> Homo sapiens

<400> 36
 Met Gly Ser Gly Arg Val Pro Gly Leu Cys Leu Leu Val Leu Leu Val
 1 5 10 15
 His Ala Arg Ala Ala Gln Tyr Ser Lys Ala Ala Gln Asp Val Asp Glu
 20 25 30
 Cys Val Glu Gly Thr Asp Asn Cys His Ile Asp Ala Ile Cys Gln Asn
 35 40 45
 Thr Pro Arg Ser Tyr Lys Cys Ile Cys Lys Ser Gly Tyr Thr Gly Asp
 50 55 60

Gly Lys His Cys Lys Asp Val Asp Glu Cys Glu Arg Glu Asp Asn Ala
 65 70 75 80
 Gly Cys Val His Asp Cys Val Asn Ile Pro Gly Asn Tyr Arg Cys Thr
 85 90 95
 Cys Tyr Asp Gly Phe His Leu Ala His Asp Gly His Asn Cys Leu Asp
 100 105 110
 Val Asp Glu Cys Ala Glu Gly Asn Gly Gly Cys Gln Gln Ser Cys Val
 115 120 125
 Asn Met Met Gly Ser Tyr Glu Cys His Cys Arg Glu Gly Phe Phe Leu
 130 135 140
 Ser Asp Asn Gln His Thr Cys Ile Gln Arg Pro Glu Glu Gly Met Asn
 145 150 155 160
 Cys Met Asn Lys Asn His Gly Cys Ala His Ile Cys Arg Glu Thr Pro
 165 170 175
 Lys Gly Gly Ile Ala Cys Glu Cys Arg Pro Gly Phe Glu Leu Thr Lys
 180 185 190
 Asn Gln Arg Asp Cys Lys Leu Thr Cys Asn Tyr Gly Asn Gly Gly Cys
 195 200 205
 Gln His Thr Cys Asp Asp Thr Glu Gln Gly Pro Arg Cys Gly Cys His
 210 215 220
 Ile Lys Phe Val Leu His Thr Asp Gly Lys Thr Cys Ile Glu Thr Cys
 225 230 235 240
 Ala Val Asn Asn Gly Gly Cys Asp Ser Lys Cys His Asp Ala Ala Thr
 245 250 255
 Gly Val His Cys Thr Cys Pro Val Gly Phe Met Leu Gln Pro Asp Arg
 260 265 270
 Lys Thr Cys Lys Asp Ile Asp Glu Cys Arg Leu Asn Asn Gly Gly Cys
 275 280 285
 Asp His Ile Cys Arg Asn Thr Val Gly Ser Phe Glu Cys Ser Cys Lys
 290 295 300
 Lys Gly Tyr Lys Leu Leu Ile Asn Glu Arg Asn Cys Gln Asp Ile Asp
 305 310 315 320
 Glu Cys Ser Phe Asp Arg Thr Cys Asp His Ile Cys Val Asn Thr Pro
 325 330 335
 Gly Ser Phe Gln Cys Leu Cys His Arg Gly Tyr Leu Leu Tyr Gly Ile
 340 345 350
 Thr His Cys Gly Asp Val Asp Glu Cys Ser Ile Asn Arg Gly Gly Cys
 355 360 365
 Arg Phe Gly Cys Ile Asn Thr Pro Gly Ser Tyr Gln Cys Thr Cys Pro
 370 375 380
 Ala Gly Gln Gly Arg Leu His Trp Asn Gly Lys Asp Cys Thr Glu Pro
 385 390 395 400
 Leu Lys Cys Gln Gly Ser Pro Gly Ala Ser Lys Ala Met Leu Ser Cys
 405 410 415
 Asn Arg Ser Gly Lys Lys Asp Thr Cys Ala Leu Thr Cys Pro Ser Arg
 420 425 430
 Ala Arg Phe Leu Pro Glu Ser Glu Asn Gly Phe Thr Val Ser Cys Gly
 435 440 445
 Thr Pro Ser Pro Arg Ala Ala Pro Ala Arg Ala Gly His Asn Gly Asn
 450 455 460
 Ser Thr Asn Ser Asn His Cys His Glu Ala Ala Val Leu Ser Ile Lys
 465 470 475 480
 Gln Arg Ala Ser Phe Lys Ile Lys Asp Ala Lys Cys Arg Leu His Leu
 485 490 495
 Arg Asn Lys Gly Lys Thr Glu Glu Ala Gly Arg Ile Thr Gly Pro Gly
 500 505 510
 Gly Ala Pro Cys Ser Glu Cys Gln Val Thr Phe Ile His Leu Lys Cys
 515 520 525
 Asp Ser Ser Arg Lys Gly Lys Gly Arg Arg Ala Arg Thr Pro Pro Gly

530		535		540
Lys Glu Val Thr Arg Leu Thr Leu Glu Leu Glu Ala Glu Val Arg Ala				
545		550		555
Glu Glu Thr Thr Ala Ser Cys Gly Leu Pro Cys Leu Arg Gln Arg Met				560
	565		570	575
Glu Arg Arg Leu Lys Gly Ser Leu Lys Met Leu Arg Lys Ser Ile Asn				
	580		585	590
Gln Asp Arg Phe Leu Leu Arg Leu Ala Gly Leu Asp Tyr Glu Leu Ala				
	595		600	605
His Lys Pro Gly Leu Val Ala Gly Glu Arg Ala Glu Pro Met Glu Ser				
	610		615	620
Cys Arg Pro Gly Gln His Arg Ala Gly Thr Lys Cys Val Ser Cys Pro				
	625		630	635
Gln Gly Thr Tyr Tyr His Gly Gln Thr Glu Gln Cys Val Pro Cys Pro				
	645		650	655
Ala Gly Thr Phe Gln Glu Arg Glu Gly Gln Leu Ser Cys Asp Leu Cys				
	660		665	670
Pro Gly Ser Asp Ala His Gly Pro Leu Gly Ala Thr Asn Val Thr Thr				
	675		680	685
Cys Ala Gly Gln Cys Pro Pro Gly Gln His Ser Val Asp Gly Phe Lys				
	690		695	700
Pro Cys Gln Pro Cys Pro Arg Gly Thr Tyr Gln Pro Glu Ala Gly Arg				
	705		710	715
Thr Leu Cys Phe Pro Cys Gly Gly Gly Leu Thr Thr Lys His Glu Gly				
	725		730	735
Ala Ile Ser Phe Gln Asp Cys Asp Thr Lys Val Gln Cys Ser Pro Gly				
	740		745	750
His Tyr Tyr Asn Thr Ser Ile His Arg Cys Ile Arg Cys Ala Met Gly				
	755		760	765
Ser Tyr Gln Pro Asp Phe Arg Gln Asn Phe Cys Ser Arg Cys Pro Gly				
	770		775	780
Asn Thr Ser Thr Asp Phe Asp Gly Ser Thr Ser Val Ala Gln Cys Lys				
	785		790	795
Asn Arg Gln Cys Gly Gly Glu Leu Gly Glu Phe Thr Gly Tyr Ile Glu				
	805		810	815
Ser Pro Asn Tyr Pro Gly Asn Tyr Pro Ala Gly Val Glu Cys Ile Trp				
	820		825	830
Asn Ile Asn Pro Pro Pro Lys Arg Lys Ile Leu Ile Val Val Pro Glu				
	835		840	845
Ile Phe Leu Pro Ser Glu Asp Glu Cys Gly Asp Val Leu Val Met Arg				
	850		855	860
Lys Asn Ser Ser Pro Ser Ser Ile Thr Thr Tyr Glu Thr Cys Gln Thr				
	865		870	875
Tyr Glu Arg Pro Ile Ala Phe Thr Ala Arg Ser Arg Lys Leu Trp Ile				
	885		890	895
Asn Phe Lys Thr Ser Glu Ala Asn Ser Ala Arg Gly Phe Gln Ile Pro				
	900		905	910
Tyr Val Thr Tyr Asp Glu Asp Tyr Glu Gln Leu Val Glu Asp Ile Val				
	915		920	925
Arg Asp Gly Arg Leu Tyr Ala Ser Glu Asn His Gln Glu Ile Leu Lys				
	930		935	940
Asp Lys Lys Leu Ile Lys Ala Phe Phe Glu Val Leu Ala His Pro Gln				
	945		950	955
Asn Tyr Phe Lys Tyr Thr Glu Lys His Lys Glu Met Leu Pro Lys Ser				
	965		970	975
Phe Ile Lys Leu Leu Arg Ser Lys Val Ser Ser Phe Leu Arg Pro Tyr				
	980		985	990
Lys				

<210> 37
 <211> 138
 <212> PRT
 <213> Homo sapiens

<400> 37
 Met Val Arg Leu Cys Gln Ala Leu Leu Leu Leu Val Ala Thr Val Ala
 1 5 10 15
 Leu Ala Ser Arg Arg Phe Gln Ala Trp Gly Ser Thr Lys Val Val Arg
 20 25 30
 Thr Phe Gln Asp Ile Pro Gln Asn Tyr Val Tyr Val Gln Gln Ala Leu
 35 40 45
 Trp Phe Ala Met Lys Glu Tyr Asn Lys Ala Ser Phe Ser Ile Thr Ser
 50 55 60
 Ser Ala Leu Gly Lys Glu Tyr Lys Leu Lys Val Thr Asp Ser Leu Glu
 65 70 75 80
 Tyr Tyr Ile Glu Val Lys Ile Ala Arg Thr Ile Cys Lys Lys Ile Ser
 85 90 95
 Glu Asp Glu Asn Cys Ala Phe Gln Glu Asp Pro Lys Met Gln Lys Val
 100 105 110
 Val Phe Cys Thr Phe Ile Val Ala Ser Lys Pro Trp Lys Phe Glu Leu
 115 120 125
 Thr Met Leu Lys Lys Gln Cys Lys Asp Met
 130 135

<210> 38
 <211> 241
 <212> PRT
 <213> Homo sapiens

<400> 38
 Met Lys Phe Ile Leu Leu Trp Ala Leu Leu Asn Leu Thr Val Ala Leu
 1 5 10 15
 Ala Phe Asn Pro Asp Tyr Thr Val Ser Ser Thr Pro Pro Tyr Leu Val
 20 25 30
 Tyr Leu Lys Ser Asp Tyr Leu Pro Cys Ala Gly Val Leu Ile His Pro
 35 40 45
 Leu Trp Val Ile Thr Ala Ala His Cys Asn Leu Pro Lys Leu Arg Val
 50 55 60
 Ile Leu Gly Val Thr Ile Pro Ala Asp Ser Asn Glu Lys His Leu Gln
 65 70 75 80
 Val Ile Gly Tyr Glu Lys Met Ile His His Pro His Phe Ser Val Thr
 85 90 95
 Ser Ile Asp His Asp Ile Met Leu Ile Lys Leu Lys Thr.Glu Ala Glu
 100 105 110
 Leu Asn Asp Tyr Val Lys Leu Ala Asn Leu Pro Tyr Gln Thr Ile Ser
 115 120 125
 Glu Asn Thr Met Cys Ser Val Ser Thr Trp Ser Tyr Asn Val Cys Asp
 130 135 140
 Ile Tyr Lys Glu Pro Asp Ser Leu Gln Thr Val Asn Ile Ser Val Ile
 145 150 155 160
 Ser Lys Pro Gln Cys Arg Asp Ala Tyr Lys Thr Tyr Asn Ile Thr Glu
 165 170 175
 Asn Met Leu Cys Val Gly Ile Val Pro Gly Arg Arg Gln Pro Cys Lys
 180 185 190
 Glu Val Ser Ala Ala Pro Ala Ile Cys Asn Gly Met Leu Gln Gly Ile
 195 200 205
 Leu Ser Phe Ala Asp Gly Cys Val Leu Arg Ala Asp Val Gly Ile Tyr

210 215 220
 Ala Lys Ile Phe Tyr Tyr Ile Pro Trp Ile Glu Asn Val Ile Gln Asn
 225 230 235 240
 Asn

<210> 39
 <211> 243
 <212> PRT
 <213> Homo sapiens

<400> 39
 Met Thr Glu Lys Ser Trp Asn Phe Leu Ser Met Leu Leu Phe Pro Val
 1 5 10 15
 Ala Leu Ala Phe Asn Pro Asp Tyr Thr Val Ser Ser Thr Pro Tyr
 20 25 30
 Leu Val Tyr Leu Lys Ser Asp Tyr Leu Pro Cys Ala Gly Val Leu Ile
 35 40 45
 His Pro Leu Trp Val Ile Thr Ala Ala His Cys Asn Leu Pro Lys Leu
 50 55 60
 Arg Val Ile Leu Gly Val Thr Ile Pro Ala Asp Ser Asn Glu Lys His
 65 70 75 80
 Leu Gln Val Ile Gly Tyr Glu Lys Met Ile His His Pro His Phe Ser
 85 90 95
 Val Thr Ser Ile Asp His Asp Ile Met Leu Ile Lys Leu Lys Thr Glu
 100 105 110
 Ala Glu Leu Asn Asp Tyr Val Lys Leu Ala Asn Leu Pro Tyr Gln Thr
 115 120 125
 Ile Ser Glu Asn Thr Met Cys Ser Val Ser Thr Trp Ser Tyr Asn Val
 130 135 140
 Cys Asp Ile Tyr Lys Glu Pro Asp Ser Leu Gln Thr Val Asn Ile Ser
 145 150 155 160
 Val Ile Ser Lys Pro Gln Cys Arg Asp Ala Tyr Lys Thr Tyr Asn Ile
 165 170 175
 Thr Glu Asn Met Leu Cys Val Gly Ile Val Pro Gly Arg Arg Gln Pro
 180 185 190
 Cys Lys Glu Val Ser Ala Ala Pro Ala Ile Cys Asn Gly Met Leu Gln
 195 200 205
 Gly Ile Leu Ser Phe Ala Asp Gly Cys Val Leu Arg Ala Asp Val Gly
 210 215 220
 Ile Tyr Ala Lys Ile Phe Tyr Tyr Ile Pro Trp Ile Glu Asn Val Ile
 225 230 235 240
 Gln Asn Asn

<210> 40
 <211> 483
 <212> PRT
 <213> Homo sapiens

<400> 40
 Met Tyr Pro Gly Trp Pro Gly Gln Gly Met Trp Ala Ser Gly Gln Arg
 1 5 10 15
 Leu Pro Asp Glu Ala Phe Glu Ser Leu Thr Gln Leu Gln His Leu Cys
 20 25 30
 Val Ala His Asn Lys Leu Ser Val Ala Pro Gln Phe Leu Pro Arg Ser
 35 40 45
 Leu Arg Val Ala Asp Leu Ala Ala Asn Gln Val Met Glu Ile Phe Pro
 50 55 60

```

Leu Thr Phe Gly Glu Lys Pro Ala Leu Arg Ser Val Tyr Leu His Asn
65      70      75      80
Asn Gln Leu Ser Asn Ala Gly Leu Pro Pro Asp Ala Phe Arg Gly Ser
      85      90      95
Glu Ala Ile Ala Thr Leu Ser Leu Ser Asn Asn Gln Leu Ser Tyr Leu
      100      105      110
Pro Pro Ser Leu Pro Pro Ser Leu Glu Arg Leu His Leu Gln Asn Asn
      115      120      125
Leu Ile Ser Lys Val Pro Arg Gly Ala Leu Ser Arg Gln Thr Gln Leu
      130      135      140
Arg Glu Leu Tyr Leu Gln His Asn Gln Leu Thr Asp Ser Gly Leu Asp
145      150      155      160
Ala Thr Thr Phe Ser Lys Leu His Ser Leu Glu Tyr Leu Asp Leu Ser
      165      170      175
His Asn Gln Leu Thr Thr Val Pro Ala Gly Leu Pro Arg Thr Leu Ala
      180      185      190
Ile Leu His Leu Gly Arg Asn Arg Ile Arg Gln Val Glu Ala Ala Arg
      195      200      205
Leu His Gly Ala Arg Gly Leu Arg Tyr Leu Leu Leu Gln His Asn Gln
      210      215      220
Leu Gly Ser Ser Gly Leu Pro Ala Gly Ala Leu Arg Pro Leu Arg Gly
225      230      235      240
Leu His Thr Leu His Leu Tyr Gly Asn Gly Leu Asp Arg Val Pro Pro
      245      250      255
Ala Leu Pro Arg Arg Leu Arg Ala Leu Val Leu Pro His Asn His Val
      260      265      270
Ala Ala Leu Gly Ala Arg Asp Leu Val Ala Thr Pro Gly Leu Thr Glu
      275      280      285
Leu Asn Leu Ala Tyr Asn Arg Leu Ala Ser Ala Arg Val His His Arg
      290      295      300
Ala Phe Arg Arg Leu Arg Ala Leu Arg Ser Leu Asp Leu Ala Gly Asn
305      310      315      320
Gln Leu Thr Arg Leu Pro Met Gly Leu Pro Thr Gly Leu Arg Thr Leu
      325      330      335
Gln Leu Gln Arg Asn Gln Leu Arg Met Leu Glu Pro Glu Pro Leu Ala
      340      345      350
Gly Leu Asp Gln Leu Arg Glu Leu Ser Leu Ala His Asn Arg Leu Arg
      355      360      365
Val Gly Asp Ile Gly Pro Gly Thr Trp His Glu Leu Gln Ala Leu Gln
      370      375      380
Met Leu Asp Leu Ser His Asn Glu Leu Ser Phe Val Pro Pro Asp Leu
385      390      395      400
Pro Glu Ala Leu Glu Glu Leu His Leu Glu Gly Asn Arg Ile Gly His
      405      410      415
Val Gly Pro Glu Ala Phe Leu Ser Thr Pro Arg Leu Arg Ala Leu Phe
      420      425      430
Leu Arg Ala Asn Arg Leu His Met Thr Ser Ile Ala Ala Glu Ala Phe
      435      440      445
Leu Gly Leu Pro Asn Leu Arg Val Val Asp Thr Ala Gly Asn Pro Glu
      450      455      460
Gln Val Leu Ile Arg Leu Pro Pro Thr Thr Pro Arg Gly Pro Arg Ala
465      470      475      480
Gly Gly Pro

```

<210> 41
 <211> 605
 <212> PRT
 <213> Homo sapiens

<400> 41

Met	Ala	Glu	Ser	Gly	Leu	Ala	Met	Glu	Gly	Met	Leu	Gln	Ser	Pro	Trp
1				5					10					15	
Arg	Pro	Cys	Ala	Gln	Pro	Gly	Asp	Thr	Leu	Thr	Leu	Pro	Pro	Pro	Gln
			20					25					30		
Trp	Pro	Ser	Leu	Leu	Leu	Leu	Leu	Leu	Pro	Gly	Pro	Pro	Pro	Pro	Val
		35					40				45				
Ala	Gly	Leu	Glu	Asp	Ala	Ala	Phe	Pro	His	Leu	Gly	Glu	Ser	Leu	Gln
	50					55					60				
Pro	Leu	Pro	Arg	Ala	Cys	Pro	Leu	Arg	Cys	Ser	Cys	Pro	Arg	Val	Asp
65					70					75					80
Thr	Val	Asp	Cys	Asp	Gly	Leu	Asp	Leu	Arg	Val	Phe	Pro	Asp	Asn	Ile
				85					90					95	
Thr	Arg	Ala	Ala	Gln	His	Leu	Ser	Leu	Gln	Asn	Asn	Gln	Leu	Gln	Glu
			100					105					110		
Leu	Pro	Tyr	Asn	Glu	Leu	Ser	Arg	Leu	Ser	Gly	Leu	Arg	Thr	Leu	Asn
		115					120					125			
Leu	His	Asn	Asn	Leu	Ile	Ser	Ser	Glu	Gly	Leu	Pro	Asp	Glu	Ala	Phe
	130					135					140				
Glu	Ser	Leu	Thr	Gln	Leu	Gln	His	Leu	Cys	Val	Ala	His	Asn	Lys	Leu
145					150					155					160
Ser	Val	Ala	Pro	Gln	Phe	Leu	Pro	Arg	Ser	Leu	Arg	Val	Ala	Asp	Leu
				165					170					175	
Ala	Ala	Asn	Gln	Val	Met	Glu	Ile	Phe	Pro	Leu	Thr	Phe	Gly	Glu	Lys
			180					185					190		
Pro	Ala	Leu	Arg	Ser	Val	Tyr	Leu	His	Asn	Asn	Gln	Leu	Ser	Asn	Ala
		195					200					205			
Gly	Leu	Pro	Pro	Asp	Ala	Phe	Arg	Gly	Ser	Glu	Ala	Ile	Ala	Thr	Leu
	210					215					220				
Ser	Leu	Ser	Asn	Asn	Gln	Leu	Ser	Tyr	Leu	Pro	Pro	Ser	Leu	Pro	Pro
225				230						235					240
Ser	Leu	Glu	Arg	Leu	His	Leu	Gln	Asn	Asn	Leu	Ile	Ser	Lys	Val	Pro
				245					250					255	
Arg	Gly	Ala	Leu	Ser	Arg	Gln	Thr	Gln	Leu	Arg	Glu	Leu	Tyr	Leu	Gln
			260					265					270		
His	Asn	Gln	Leu	Thr	Asp	Ser	Gly	Leu	Asp	Ala	Thr	Thr	Phe	Ser	Lys
		275					280					285			
Leu	His	Ser	Leu	Glu	Tyr	Leu	Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Thr
	290					295					300				
Val	Pro	Ala	Gly	Leu	Pro	Arg	Thr	Leu	Ala	Ile	Leu	His	Leu	Gly	Arg
305					310					315					320
Asn	Arg	Ile	Arg	Gln	Val	Glu	Ala	Ala	Arg	Leu	His	Gly	Ala	Arg	Gly
				325					330					335	
Leu	Arg	Tyr	Leu	Leu	Leu	Gln	His	Asn	Gln	Leu	Gly	Ser	Ser	Gly	Leu
		340						345					350		
Pro	Ala	Gly	Ala	Leu	Arg	Pro	Leu	Arg	Gly	Leu	His	Thr	Leu	His	Leu
		355					360					365			
Tyr	Gly	Asn	Gly	Leu	Asp	Arg	Val	Pro	Pro	Ala	Leu	Pro	Arg	Arg	Leu
	370					375					380				
Arg	Ala	Leu	Val	Leu	Pro	His	Asn	His	Val	Ala	Ala	Leu	Gly	Ala	Arg
385					390					395					400
Asp	Leu	Val	Ala	Thr	Pro	Gly	Leu	Thr	Glu	Leu	Asn	Leu	Ala	Tyr	Asn
				405					410					415	
Arg	Leu	Ala	Ser	Ala	Arg	Val	His	His	Arg	Ala	Phe	Arg	Arg	Leu	Arg
			420					425					430		
Ala	Leu	Arg	Ser	Leu	Asp	Leu	Ala	Gly	Asn	Gln	Leu	Thr	Arg	Leu	Pro
		435					440					445			
Met	Gly	Leu	Pro	Thr	Gly	Leu	Arg	Thr	Leu	Gln	Leu	Gln	Arg	Asn	Gln

450 455 460
 Leu Arg Met Leu Glu Pro Glu Pro Leu Ala Gly Leu Asp Gln Leu Arg
 465 470 475 480
 Glu Leu Ser Leu Ala His Asn Arg Leu Arg Val Gly Asp Ile Gly Pro
 485 490 495
 Gly Thr Trp His Glu Leu Gln Ala Leu Gln Met Leu Asp Leu Ser His
 500 505 510
 Asn Glu Leu Ser Phe Val Pro Pro Asp Leu Pro Glu Ala Leu Glu Glu
 515 520 525
 Leu His Leu Glu Gly Asn Arg Ile Gly His Val Gly Pro Glu Ala Phe
 530 535 540
 Leu Ser Thr Pro Arg Leu Arg Ala Leu Phe Leu Arg Ala Asn Arg Leu
 545 550 555 560
 His Met Thr Ser Ile Ala Ala Glu Ala Phe Leu Gly Leu Pro Asn Leu
 565 570 575
 Arg Val Val Asp Thr Ala Gly Asn Pro Glu Gln Val Leu Ile Arg Leu
 580 585 590
 Pro Pro Thr Thr Pro Arg Gly Pro Arg Ala Gly Gly Pro
 595 600 605

<210> 42
 <211> 1049
 <212> PRT
 <213> Homo sapiens

<400> 42
 Met Val Thr Arg Glu Leu Phe Phe Leu Phe Ser Pro Gln Phe Phe Ser
 1 5 10 15
 Leu Asn Leu Arg Ser His Thr Arg Ser Thr Met Thr Ser Pro Gln Leu
 20 25 30
 Glu Trp Thr Leu Gln Thr Leu Leu Glu Gln Leu Asn Glu Asp Glu Leu
 35 40 45
 Lys Ser Phe Lys Ser Leu Leu Trp Ala Phe Pro Leu Glu Asp Val Leu
 50 55 60
 Gln Lys Thr Pro Trp Ser Glu Val Glu Glu Ala Asp Gly Lys Lys Leu
 65 70 75 80
 Ala Glu Ile Leu Val Asn Thr Ser Ser Glu Asn Trp Ile Arg Asn Ala
 85 90 95
 Thr Val Asn Ile Leu Glu Glu Met Asn Leu Thr Glu Leu Cys Lys Met
 100 105 110
 Ala Lys Ala Glu Met Met Glu Asp Gly Gln Val Gln Glu Ile Asp Asn
 115 120 125
 Pro Glu Leu Gly Asp Ala Glu Glu Asp Ser Glu Leu Ala Lys Pro Gly
 130 135 140
 Glu Lys Glu Gly Trp Arg Asn Ser Met Glu Lys Gln Ser Leu Val Trp
 145 150 155 160
 Lys Asn Thr Phe Trp Gln Gly Asp Ile Asp Asn Phe His Asp Asp Val
 165 170 175
 Thr Leu Arg Asn Gln Arg Phe Ile Pro Phe Leu Asn Pro Arg Thr Pro
 180 185 190
 Arg Lys Leu Thr Pro Tyr Thr Val Val Leu His Gly Pro Ala Gly Val
 195 200 205
 Gly Lys Thr Thr Leu Ala Lys Lys Cys Met Leu Asp Trp Thr Asp Cys
 210 215 220
 Asn Leu Ser Pro Thr Leu Arg Tyr Ala Phe Tyr Leu Ser Cys Lys Glu
 225 230 235 240
 Leu Ser Arg Met Gly Pro Cys Ser Phe Ala Glu Leu Ile Ser Lys Asp
 245 250 255
 Trp Pro Glu Leu Gln Asp Asp Ile Pro Ser Ile Leu Ala Gln Ala Gln

30/60

Ala Gly His Ile Glu Trp Glu Arg Thr Met Met Leu Met Leu Cys Asp
 740 745 750
 Leu Leu Arg Asn His Lys Cys Asn Leu Gln Tyr Leu Arg Leu Gly Gly
 755 760 765
 His Cys Ala Thr Pro Glu Gln Trp Ala Glu Phe Phe Tyr Val Leu Lys
 770 775 780
 Ala Asn Gln Ser Leu Lys His Leu Arg Leu Ser Ala Asn Val Leu Leu
 785 790 795 800
 Asp Glu Gly Ala Met Leu Leu Tyr Lys Thr Met Thr Arg Pro Lys His
 805 810 815
 Phe Leu Gln Met Leu Ser Leu Glu Asn Cys Arg Leu Thr Glu Ala Ser
 820 825 830
 Cys Lys Asp Leu Ala Ala Val Leu Val Val Ser Lys Lys Leu Thr His
 835 840 845
 Leu Cys Leu Ala Lys Asn Pro Ile Gly Asp Thr Gly Val Lys Phe Leu
 850 855 860
 Cys Glu Gly Leu Ser Tyr Pro Asp Cys Lys Leu Gln Thr Leu Val Leu
 865 870 875 880
 Val Ser Cys Ser Ala Thr Thr Gln Gln Trp Ala Asp Leu Ser Leu Ala
 885 890 895
 Leu Glu Val Asn Gln Ser Leu Thr Cys Val Asn Leu Ser Asp Asn Glu
 900 905 910
 Leu Leu Asp Glu Gly Ala Lys Leu Leu Tyr Thr Thr Leu Arg His Pro
 915 920 925
 Lys Cys Phe Leu Gln Arg Leu Ser Leu Glu Asn Cys His Leu Thr Glu
 930 935 940
 Ala Asn Cys Lys Asp Leu Ala Ala Val Leu Val Val Ser Arg Glu Leu
 945 950 955 960
 Thr His Leu Cys Leu Ala Lys Asn Pro Ile Gly Asn Thr Gly Val Lys
 965 970 975
 Phe Leu Cys Glu Gly Leu Arg Tyr Pro Glu Cys Lys Leu Gln Thr Leu
 980 985 990
 Val Leu Gln Gln Cys Ser Ile Thr Lys Leu Gly Cys Arg Tyr Leu Ser
 995 1000 1005
 Glu Ala Leu Gln Glu Ala Cys Ser Leu Thr Asn Leu Asp Leu Ser Ile
 1010 1015 1020
 Asn Gln Ile Ala Arg Gly Leu Trp Ile Leu Cys Gln Ala Leu Glu Asn
 1025 1030 1035 1040
 Pro Asn Cys Asn Leu Lys His Leu Arg
 1045

<210> 43
 <211> 1062
 <212> PRT
 <213> Homo sapiens

<400> 43
 Met Val Ser Ser Ala Gln Met Gly Phe Asn Leu Gln Ala Leu Leu Glu
 1 5 10 15
 Gln Leu Ser Gln Asp Glu Leu Ser Lys Phe Lys Tyr Leu Ile Thr Thr
 20 25 30
 Phe Ser Leu Ala His Glu Leu Gln Lys Ile Pro His Lys Glu Val Asp
 35 40 45
 Lys Ala Asp Gly Lys Gln Leu Val Glu Ile Leu Thr Thr His Cys Asp
 50 55 60
 Ser Tyr Trp Val Glu Met Ala Ser Leu Gln Val Phe Glu Lys Met His
 65 70 75 80
 Arg Met Asp Leu Ser Glu Arg Ala Lys Asp Glu Val Arg Glu Ala Ala
 85 90 95

Leu- Lys Ser Phe Asn Lys Arg Lys Pro Leu Ser Leu Gly Ile Thr Arg
 100 105 110
 Lys Glu Arg Pro Pro Leu Asp Val Asp Glu Met Leu Glu Arg Phe Lys
 115 120 125
 Thr Glu Ala Gln Ala Phe Thr Glu Thr Lys Gly Asn Val Ile Cys Leu
 130 135 140
 Gly Lys Glu Val Phe Lys Gly Lys Lys Pro Asp Lys Asp Asn Arg Cys
 145 150 155 160
 Arg Tyr Ile Leu Lys Thr Lys Phe Arg Glu Met Trp Lys Ser Trp Pro
 165 170 175
 Gly Asp Ser Lys Glu Val Gln Val Met Ala Glu Arg Tyr Lys Met Leu
 180 185 190
 Ile Pro Phe Ser Asn Pro Arg Val Leu Pro Gly Pro Phe Ser Tyr Thr
 195 200 205
 Val Val Leu Tyr Gly Pro Ala Gly Leu Gly Lys Thr Thr Leu Ala Gln
 210 215 220
 Lys Leu Met Leu Asp Trp Ala Glu Asp Asn Leu Ile His Lys Phe Lys
 225 230 235 240
 Tyr Ala Phe Tyr Leu Ser Cys Arg Glu Leu Ser Arg Leu Gly Pro Cys
 245 250 255
 Ser Phe Ala Glu Leu Val Phe Arg Asp Trp Pro Glu Leu Gln Asp Asp
 260 265 270
 Ile Pro His Ile Leu Ala Gln Ala Arg Lys Ile Leu Phe Val Ile Asp
 275 280 285
 Gly Phe Asp Glu Leu Gly Ala Ala Pro Gly Ala Leu Ile Glu Asp Ile
 290 295 300
 Cys Gly Asp Trp Glu Lys Lys Lys Pro Val Pro Val Leu Leu Gly Ser
 305 310 315 320
 Leu Leu Asn Arg Val Met Leu Pro Lys Ala Ala Leu Leu Val Thr Thr
 325 330 335
 Arg Pro Arg Ala Leu Arg Asp Leu Arg Ile Leu Ala Glu Glu Pro Ile
 340 345 350
 Tyr Ile Arg Val Glu Gly Phe Leu Glu Glu Asp Arg Arg Ala Tyr Phe
 355 360 365
 Leu Arg His Phe Gly Asp Glu Asp Gln Ala Met Arg Ala Phe Glu Leu
 370 375 380
 Met Arg Ser Asn Ala Ala Leu Phe Gln Leu Gly Ser Ala Pro Ala Val
 385 390 395 400
 Cys Trp Ile Val Cys Thr Thr Leu Lys Leu Gln Met Glu Lys Gly Glu
 405 410 415
 Asp Pro Val Pro Thr Cys Leu Thr Arg Thr Gly Leu Phe Leu Arg Phe
 420 425 430
 Leu Cys Ser Arg Phe Pro Gln Gly Ala Gln Leu Arg Gly Ala Leu Arg
 435 440 445
 Thr Leu Ser Leu Leu Ala Ala Gln Gly Leu Trp Ala Gln Thr Ser Val
 450 455 460
 Leu His Arg Glu Asp Leu Glu Arg Leu Gly Val Gln Glu Ser Asp Leu
 465 470 475 480
 Arg Leu Phe Leu Asp Gly Asp Ile Leu Arg Gln Asp Arg Val Ser Lys
 485 490 495
 Gly Cys Tyr Ser Phe Ile His Leu Ser Phe Gln Gln Phe Leu Thr Ala
 500 505 510
 Leu Phe Tyr Thr Leu Glu Lys Glu Glu Glu Glu Asp Arg Asp Gly His
 515 520 525
 Thr Trp Asp Ile Gly Asp Val Gln Lys Leu Leu Ser Gly Val Glu Arg
 530 535 540
 Leu Arg Asn Pro Asp Leu Ile Gln Ala Gly Tyr Tyr Ser Phe Gly Leu
 545 550 555 560
 Ala Asn Glu Lys Arg Ala Lys Glu Leu Glu Ala Thr Phe Gly Cys Arg

33/60

Leu Ile Ile Asp Thr Glu Lys His His Pro Trp Ala Glu Arg Pro Ser
 1045 1050 1055
 Ser His Asp Phe Met Ile
 1060

<210> 44
 <211> 353
 <212> PRT
 <213> Homo sapiens

<400> 44
 Met Thr Ile Phe His Pro Ile Thr Ser Ser Ile Gly Gln Pro Gly Cys
 1 5 10 15
 Gly Pro Lys Cys Lys Glu Thr Pro Leu Glu Leu Val Phe Val Ile Asp
 20 25 30
 Ser Ser Glu Ser Val Gly Pro Glu Asn Phe Gln Ile Ile Lys Asn Phe
 35 40 45
 Val Lys Thr Met Ala Asp Arg Val Ala Leu Asp Leu Ala Thr Ala Arg
 50 55 60
 Ile Gly Ile Ile Asn Tyr Ser His Lys Val Glu Lys Val Ala Asn Leu
 65 70 75 80
 Lys Gln Phe Ser Ser Lys Asp Asp Phe Lys Leu Ala Val Asp Asn Met
 85 90 95
 Gln Tyr Leu Gly Glu Gly Thr Tyr Thr Ala Thr Ala Leu Gln Ala Ala
 100 105 110
 Asn Asp Met Phe Glu Asp Ala Arg Pro Gly Val Lys Lys Val Ala Leu
 115 120 125
 Val Ile Thr Asp Gly Gln Thr Asp Ser Arg Asp Lys Glu Lys Leu Thr
 130 135 140
 Glu Val Val Lys Asn Ala Ser Asp Thr Asn Val Glu Ile Phe Val Ile
 145 150 155 160
 Gly Val Val Lys Lys Asn Asp Pro Asn Phe Glu Ile Phe His Lys Glu
 165 170 175
 Met Asn Leu Ile Ala Thr Asp Pro Glu His Val Tyr Gln Phe Asp Asp
 180 185 190
 Phe Phe Thr Leu Gln Asp Thr Leu Lys Gln Lys Leu Phe Gln Lys Ile
 195 200 205
 Cys Glu Asp Phe Asp Ser Tyr Leu Val Gln Ile Phe Gly Ser Ser Ser
 210 215 220
 Pro Gln Pro Gly Phe Gly Met Ser Gly Glu Glu Leu Ser Glu Ser Thr
 225 230 235 240
 Pro Glu Pro Gln Lys Glu Ile Ser Glu Ser Leu Ser Val Thr Arg Asp
 245 250 255
 Gln Asp Glu Asp Asp Lys Ala Pro Glu Pro Thr Trp Ala Asp Asp Leu
 260 265 270
 Pro Ala Thr Thr Ser Ser Glu Ala Thr Thr Thr Pro Arg Pro Leu Leu
 275 280 285
 Ser Thr Pro Val Asp Gly Ala Glu Asp Pro Arg Cys Leu Glu Ala Leu
 290 295 300
 Lys Pro Gly Asn Cys Gly Glu Tyr Val Val Arg Trp Tyr Tyr Asp Lys
 305 310 315 320
 Gln Val Asn Ser Cys Ala Arg Phe Trp Phe Ser Gly Cys Asn Gly Ser
 325 330 335
 Gly Asn Arg Phe Asn Ser Glu Lys Glu Cys Gln Glu Thr Cys Ile Gln
 340 345 350
 Gly

<210> 45

<211> 448
 <212> PRT
 <213> Homo sapiens

<400> 45

```

Met His Glu Val Ile Glu Ser Asp Tyr Glu Gly Arg Asp Lys Thr Leu
 1      5      10      15
Ser Cys Leu Val Val Gly Val Cys Asp Tyr Ser Thr Arg Met Leu Gly
      20      25      30
Arg Asn Asp His Thr Ala Val Thr Gly Gln Gln Gly Ala Trp Ser Glu
      35      40      45
Ser Ala Ser Leu Asp His Ser Pro Ile Leu Ser Phe Leu Pro Gln Glu
      50      55      60
Phe Pro Ala Asp Arg Asp Gly Ser Leu Ala Leu His Ser Thr Tyr Glu
      65      70      75      80
Ser Leu Arg Leu Ser Ala Ser Ser Trp Thr Val Asn Pro Leu Arg Gly
      85      90      95
Ile Asn Met Met Pro Ser Ser Leu Ala Pro Ser Ser Gln Gly Cys Gly
      100      105      110
Pro Lys Cys Lys Glu Thr Pro Leu Glu Leu Val Phe Val Ile Asp Ser
      115      120      125
Ser Glu Ser Val Gly Pro Glu Asn Phe Gln Ile Ile Lys Asn Phe Val
      130      135      140
Lys Thr Met Ala Asp Arg Val Ala Leu Asp Leu Ala Thr Ala Arg Ile
      145      150      155      160
Gly Ile Ile Asn Tyr Ser His Lys Val Glu Lys Val Ala Asn Leu Lys
      165      170      175
Gln Phe Ser Ser Lys Asp Asp Phe Lys Leu Ala Val Asp Asn Met Gln
      180      185      190
Tyr Leu Gly Glu Gly Thr Tyr Thr Ala Thr Ala Leu Gln Ala Ala Asn
      195      200      205
Asp Met Phe Glu Asp Ala Arg Pro Gly Val Lys Lys Val Ala Leu Val
      210      215      220
Ile Thr Asp Gly Gln Thr Asp Ser Arg Asp Lys Glu Lys Leu Thr Glu
      225      230      235      240
Val Val Lys Asn Ala Ser Asp Thr Asn Val Glu Ile Phe Val Ile Gly
      245      250      255
Val Val Lys Lys Asn Asp Pro Asn Phe Glu Ile Phe His Lys Glu Met
      260      265      270
Asn Leu Ile Ala Thr Asp Pro Glu His Val Tyr Gln Phe Asp Asp Phe
      275      280      285
Phe Thr Leu Gln Asp Thr Leu Lys Gln Lys Leu Phe Gln Lys Ile Cys
      290      295      300
Glu Asp Phe Asp Ser Tyr Leu Val Gln Ile Phe Gly Ser Ser Ser Pro
      305      310      315      320
Gln Pro Gly Phe Gly Met Ser Gly Glu Glu Leu Ser Glu Ser Thr Pro
      325      330      335
Glu Pro Gln Lys Glu Ile Ser Glu Ser Leu Ser Val Thr Arg Asp Gln
      340      345      350
Asp Glu Asp Asp Lys Ala Pro Glu Pro Thr Trp Ala Asp Asp Leu Pro
      355      360      365
Ala Thr Thr Ser Ser Glu Ala Thr Thr Thr Pro Arg Pro Leu Leu Ser
      370      375      380
Thr Pro Val Asp Gly Ala Glu Asp Pro Arg Cys Leu Glu Ala Leu Lys
      385      390      395      400
Pro Gly Asn Cys Gly Glu Tyr Val Val Arg Trp Tyr Tyr Asp Lys Gln
      405      410      415
Val Asn Ser Cys Ala Arg Phe Trp Phe Ser Gly Cys Asn Gly Ser Gly
      420      425      430

```

Asn Arg Phe Asn Ser Glu Lys Glu Cys Gln Glu Thr Cys Ile Gln Gly
 435 440 445

<210> 46
 <211> 493
 <212> PRT
 <213> Homo sapiens

<400> 46
 Met Leu Pro Ala Ala Pro Ser Gly Cys Pro Gln Leu Cys Arg Cys Glu
 1 5 10 15
 Gly Arg Leu Leu Tyr Cys Glu Ala Leu Asn Leu Thr Glu Ala Pro His
 20 25 30
 Asn Leu Ser Gly Leu Leu Gly Leu Ser Leu Arg Tyr Asn Ser Leu Ser
 35 40 45
 Glu Leu Arg Ala Gly Gln Phe Thr Gly Leu Met Gln Leu Thr Trp Leu
 50 55 60
 Tyr Leu Asp His Asn His Ile Cys Ser Val Gln Gly Asp Ala Phe Gln
 65 70 75 80
 Lys Leu Arg Arg Val Lys Glu Leu Thr Leu Ser Ser Asn Gln Ile Thr
 85 90 95
 Gln Leu Pro Asn Thr Thr Phe Arg Pro Met Pro Asn Leu Arg Ser Val
 100 105 110
 Asp Leu Ser Tyr Asn Lys Leu Gln Ala Leu Ala Pro Asp Leu Phe His
 115 120 125
 Gly Leu Arg Lys Leu Thr Thr Leu His Met Arg Ala Asn Ala Ile Gln
 130 135 140
 Phe Val Pro Val Arg Ile Phe Gln Asp Cys Arg Ser Leu Lys Phe Leu
 145 150 155 160
 Asp Ile Gly Tyr Asn Gln Leu Lys Ser Leu Ala Arg Asn Ser Phe Ala
 165 170 175
 Gly Leu Phe Lys Leu Thr Glu Leu His Leu Glu His Asn Asp Leu Val
 180 185 190
 Lys Val Asn Phe Ala His Phe Pro Arg Leu Ile Ser Leu His Ser Leu
 195 200 205
 Cys Leu Arg Arg Asn Lys Val Ala Ile Val Val Ser Ser Leu Asp Trp
 210 215 220
 Val Trp Asn Leu Glu Lys Met Asp Leu Ser Gly Asn Glu Ile Glu Tyr
 225 230 235 240
 Met Glu Pro His Val Phe Glu Thr Val Pro His Leu Gln Ser Leu Gln
 245 250 255
 Leu Asp Ser Asn Arg Leu Thr Tyr Ile Glu Pro Arg Ile Leu Asn Ser
 260 265 270
 Trp Lys Ser Leu Thr Ser Ile Thr Leu Ala Gly Asn Leu Trp Asp Cys
 275 280 285
 Gly Arg Asn Val Cys Ala Leu Ala Ser Trp Leu Asn Asn Phe Gln Gly
 290 295 300
 Arg Tyr Asp Gly Asn Leu Gln Cys Ala Ser Pro Glu Tyr Ala Gln Gly
 305 310 315 320
 Glu Asp Val Leu Asp Ala Val Tyr Ala Phe His Leu Cys Glu Asp Gly
 325 330 335
 Ala Glu Pro Thr Ser Gly His Leu Leu Ser Ala Val Thr Asn Arg Ser
 340 345 350
 Asp Leu Gly Pro Pro Ala Arg Arg Ala Thr Thr Ala Ser Arg Thr Gly
 355 360 365
 Gly Glu Gly Gln His Asp Gly Thr Phe Lys Pro Ala Thr Gly Gly Phe
 370 375 380
 Pro Ala Gly Glu His Ala Lys Asn Pro Val Gln Ile His Lys Val Val
 385 390 395 400

Thr Gly Thr Met Ala Phe Ile Phe Ser Phe Leu Met Val Val Leu Val
 405 410 415
 Leu Tyr Val Ser Trp Lys Cys Phe Pro Ala Ser Leu Arg Gln Leu Arg
 420 425 430
 Gln Cys Phe Val Thr Gln Arg Arg Lys Gln Lys Gln Lys Gln Thr Met
 435 440 445
 His Gln Met Ala Ala Met Ser Ala Gln Glu Tyr Tyr Val Asp Tyr Lys
 450 455 460
 Pro Asn His Ile Glu Gly Ala Leu Val Ile Ile Asn Glu Tyr Gly Ser
 465 470 475 480
 Cys Thr Cys His Gln Gln Pro Ala Arg Glu Cys Glu Val
 485 490

<210> 47
 <211> 548
 <212> PRT
 <213> Homo sapiens

<400> 47
 Met Pro Ala Leu Arg Pro Leu Leu Pro Leu Leu Leu Leu Leu Arg Leu
 1 5 10 15
 Thr Ser Gly Ala Gly Leu Leu Pro Gly Leu Gly Ser His Pro Gly Val
 20 25 30
 Cys Pro Asn Gln Leu Ser Pro Asn Leu Trp Val Asp Ala Gln Ser Thr
 35 40 45
 Cys Glu Arg Glu Cys Ser Arg Asp Gln Asp Cys Ala Ala Ala Glu Lys
 50 55 60
 Cys Cys Ile Asn Val Cys Gly Leu His Ser Cys Val Ala Ala Arg Phe
 65 70 75 80
 Pro Gly Ser Pro Ala Ala Pro Thr Thr Ala Ala Ser Cys Glu Gly Phe
 85 90 95
 Val Cys Pro Gln Gln Gly Ser Asp Cys Asp Ile Trp Asp Gly Gln Pro
 100 105 110
 Val Cys Arg Cys Arg Asp Arg Cys Glu Lys Glu Pro Ser Phe Thr Cys
 115 120 125
 Ala Ser Asp Gly Leu Thr Tyr Tyr Asn Arg Cys Tyr Met Asp Ala Glu
 130 135 140
 Ala Cys Leu Arg Gly Leu His Leu His Ile Val Pro Cys Lys His Val
 145 150 155 160
 Leu Ser Trp Pro Pro Ser Ser Pro Gly Pro Pro Glu Thr Thr Ala Arg
 165 170 175
 Pro Thr Pro Gly Ala Ala Pro Val Pro Pro Ala Leu Tyr Ser Ser Pro
 180 185 190
 Ser Pro Gln Ala Val Gln Val Gly Gly Thr Ala Ser Leu His Cys Asp
 195 200 205
 Val Ser Gly Arg Pro Pro Pro Ala Val Thr Trp Glu Lys Gln Ser His
 210 215 220
 Gln Arg Glu Asn Leu Ile Met Arg Pro Asp Gln Met Tyr Gly Asn Val
 225 230 235 240
 Val Val Thr Ser Ile Gly Gln Leu Val Leu Tyr Asn Ala Arg Pro Glu
 245 250 255
 Asp Ala Gly Leu Tyr Thr Cys Thr Ala Arg Asn Ala Ala Gly Leu Leu
 260 265 270
 Arg Ala Asp Phe Pro Leu Ser Val Val Gln Arg Glu Pro Ala Arg Asp
 275 280 285
 Ala Ala Pro Ser Ile Pro Ala Pro Ala Glu Cys Leu Pro Asp Val Gln
 290 295 300
 Ala Cys Thr Gly Pro Thr Ser Pro His Leu Val Leu Trp His Tyr Asp
 305 310 315 320

Pro Gln Arg Gly Gly Cys Met Thr Phe Pro Ala Arg Gly Cys Asp Gly
 325 330 335
 Ala Ala Arg Gly Phe Glu Thr Tyr Glu Ala Cys Gln Gln Ala Cys Ala
 340 345 350
 Arg Gly Pro Gly Asp Ala Cys Val Leu Pro Ala Val Gln Gly Pro Cys
 355 360 365
 Arg Gly Trp Glu Pro Arg Trp Ala Tyr Ser Pro Leu Leu Gln Gln Cys
 370 375 380
 His Pro Phe Val Tyr Gly Gly Cys Glu Gly Asn Gly Asn Asn Phe His
 385 390 395 400
 Ser Arg Glu Ser Cys Glu Asp Ala Cys Pro Val Pro Arg Thr Pro Pro
 405 410 415
 Cys Arg Ala Cys Arg Leu Arg Ser Lys Leu Ala Leu Ser Leu Cys Arg
 420 425 430
 Ser Asp Phe Ala Ile Val Gly Arg Leu Thr Glu Val Leu Glu Glu Pro
 435 440 445
 Glu Ala Ala Gly Gly Ile Ala Arg Val Ala Leu Glu Asp Val Leu Lys
 450 455 460
 Asp Asp Lys Met Gly Leu Lys Phe Leu Gly Thr Lys Tyr Leu Glu Val
 465 470 475 480
 Thr Leu Ser Gly Met Asp Trp Ala Cys Pro Cys Pro Asn Met Thr Ala
 485 490 495
 Gly Asp Gly Pro Leu Val Ile Met Gly Glu Val Arg Asp Gly Val Ala
 500 505 510
 Val Leu Asp Ala Gly Ser Tyr Val Arg Ala Ala Ser Glu Lys Arg Val
 515 520 525
 Lys Lys Ile Leu Glu Leu Leu Glu Lys Gln Ala Cys Glu Leu Leu Asn
 530 535 540
 Arg Phe Gln Asp
 545

<210> 48
 <211> 286
 <212> PRT
 <213> Homo sapiens

<400> 48
 Met Ala Phe Val Ala Ile Val Val Ser Asn Phe Gly Leu Ser Gly Gln
 1 5 10 15
 Pro His Gly Gly Phe Asn Ser Gln Asp Gln Asn Asp Gln Gly Pro Ser
 20 25 30
 Val Pro Val Ser Leu Leu Asp Arg Thr Thr Gly Gly Gly Ser Ala Leu
 35 40 45
 Cys Phe Leu Ala Gly Ile Asp Tyr Lys Thr Thr Thr Ile Leu Leu Asp
 50 55 60
 Gly Arg Arg Val Lys Leu Glu Leu Trp Asp Thr Ser Gly Gln Gly Arg
 65 70 75 80
 Phe Cys Thr Ile Phe Arg Ser Tyr Ser Arg Gly Ala Gln Gly Ile Leu
 85 90 95
 Leu Val Tyr Asp Ile Thr Asn Arg Trp Ser Phe Asp Gly Ile Asp Arg
 100 105 110
 Trp Ile Lys Glu Ile Asp Glu His Ala Pro Gly Val Pro Arg Ile Leu
 115 120 125
 Val Gly Asn Arg Leu His Leu Ala Phe Lys Arg Gln Val Pro Thr Glu
 130 135 140
 Gln Ala Arg Ala Tyr Ala Glu Lys Asn Cys Met Thr Phe Phe Glu Val
 145 150 155 160
 Ser Pro Leu Cys Asn Phe Asn Val Ile Glu Ser Phe Thr Glu Leu Ser
 165 170 175

Arg Ile Val Leu Met Arg His Gly Met Glu Lys Ile Trp Arg Pro Asn
 180 185 190
 Arg Val Phe Ser Leu Gln Asp Leu Cys Cys Arg Ala Ile Val Ser Cys
 195 200 205
 Thr Pro Val His Leu Ile Asp Lys Leu Pro Leu Pro Val Thr Ile Lys
 210 215 220
 Ser His Leu Lys Ser Phe Ser Met Ala Asn Gly Met Asn Ala Val Met
 225 230 235 240
 Met His Gly Arg Ser Tyr Ser Leu Ala Ser Gly Ala Gly Gly Gly Gly
 245 250 255
 Ser Lys Gly Asn Ser Leu Lys Arg Ser Lys Ser Ile Arg Pro Pro Gln
 260 265 270
 Ser Pro Pro Gln Asn Cys Ser Arg Ser Asn Cys Lys Ile Ser
 275 280 285

<210> 49
 <211> 172
 <212> PRT
 <213> Homo sapiens

<400> 49
 Met Gly Ile Pro Ile Pro Ile Ile Pro His His Pro Gln Ala Arg Val
 1 5 10 15
 Ala Ser Pro Gln Ala Leu Met Asp Lys Trp Pro Trp Lys Ala Ser Ser
 20 25 30
 Ala Ala Pro Gly Phe Cys His His Pro Ser Thr Lys Trp Ser Arg Asp
 35 40 45
 Pro Gly Arg His Pro Glu Ser Pro His Arg Gly Gly Ser Gly Val His
 50 55 60
 Arg Arg Ser Arg Glu Pro Ala Pro His Pro Ala Ser Glu Glu Ser Ser
 65 70 75 80
 Phe Pro Trp Leu Glu Asp Pro Val Met Lys Tyr Val Gly Lys Gly Gly
 85 90 95
 Tyr Asn Cys Thr Leu Ser Lys Thr Glu Phe Leu Ser Phe Met Asn Ala
 100 105 110
 Glu Leu Ala Ala Phe Thr Lys Asn Gln Lys Asp Pro Gly Val Leu His
 115 120 125
 Arg Met Met Lys Lys Leu Gly Thr Asn Asn Asp Gly Gln Leu Asp Phe
 130 135 140
 Ser Glu Phe Leu Asn Leu Ile Gly Gly Leu Ala Met Ala Cys His Asp
 145 150 155 160
 Ser Phe Leu Lys Ala Val Pro Ser Gln Lys Arg Thr
 165 170

<210> 50
 <211> 103
 <212> PRT
 <213> Homo sapiens

<400> 50
 Leu Gln Lys Ser Pro Ala Leu Gln Arg Leu Ser Ile Glu Ser Leu Ile
 1 5 10 15
 Ser Leu Phe Gln Lys Tyr Val Gly Lys Gly Gly Tyr Asn Cys Thr Leu
 20 25 30
 Ser Lys Thr Glu Phe Leu Ser Phe Met Asn Ala Glu Leu Ala Ala Phe
 35 40 45
 Thr Lys Asn Gln Lys Asp Pro Gly Val Leu His Arg Met Met Lys Lys
 50 55 60
 Leu Gly Thr Asn Asn Asp Gly Gln Leu Asp Phe Ser Glu Phe Leu Asn

```

65      70      75      80
Leu Ile Gly Gly Leu Ala Met Ala Cys His Asp Ser Phe Leu Lys Ala
      85      90      95
Val Pro Ser Gln Lys Arg Thr
      100

```

```
<210> 51
<211> 753
<212> PRT
<213> Homo sapiens
```

<400> 51															
Met 1	Arg	Pro	Val	Ser 5	Val	Trp	Gln	Trp	Ser 10	Pro	Trp	Gly	Leu 15	Leu	Leu
Cys	Leu	Leu	Cys 20	Ser	Ser	Cys	Leu	Gly 25	Ser	Pro	Ser	Pro	Ser 30	Thr	Gly
Pro	Glu	Lys 35	Lys	Ala	Gly	Ser	Gln 40	Gly	Leu	Arg	Phe	Arg 45	Leu	Ala	Gly
Phe 50	Pro	Arg	Lys	Pro	Tyr	Glu 55	Gly	Arg	Val	Glu	Ile 60	Gln	Arg	Ala	Gly
Glu 65	Trp	Gly	Thr	Ile 70	Cys	Asp	Asp	Asp	Phe 75	Thr	Leu	Gln	Ala	Ala	His 80
Ile	Leu	Cys	Arg 85	Glu	Leu	Gly	Phe	Thr 90	Glu	Ala	Thr	Gly	Trp 95	Thr	His
Ser	Ala	Lys 100	Tyr	Gly	Pro	Gly	Thr 105	Gly	Arg	Ile	Trp	Leu 110	Asp	Asn	Leu
Ser	Cys 115	Ser	Gly	Thr	Glu	Gln 120	Ser	Val 125	Thr	Glu	Cys	Ala 125	Ser	Arg	Gly
Trp 130	Gly	Asn	Ser	Asp	Cys	Thr 135	His	Asp 140	Glu	Asp	Ala 140	Gly	Val	Ile	Cys
Lys 145	Asp	Gln	Arg	Leu 150	Pro	Gly	Phe	Ser 155	Asp	Ser	Asn 155	Val	Ile	Glu	Val 160
Glu	His	His	Leu 165	Gln	Val	Glu	Glu	Val 170	Arg	Ile	Arg	Pro	Ala	Val 175	Gly
Trp	Gly	Arg 180	Arg	Pro	Leu	Pro	Val 185	Thr	Glu	Gly	Leu	Val 190	Glu	Val	Arg
Leu 195	Pro	Asp	Gly	Trp	Ser	Gln 200	Val	Cys 205	Asp	Lys	Gly	Trp 205	Ser	Ala	His
Asn 210	Ser	His	Val	Val	Cys	Gly 215	Met	Leu	Gly	Phe	Pro 220	Ser	Glu	Lys	Arg
Val 225	Asn	Ala	Ala	Phe 230	Tyr	Arg	Leu	Leu	Ala 235	Gln	Arg	Gln	Gln	His	Ser 240
Phe	Gly	Leu	His 245	Gly	Val	Ala	Cys	Val 250	Gly	Thr	Glu	Ala	His	Leu 255	Ser
Leu	Cys	Ser 260	Leu	Glu	Phe	Tyr	Arg	Ala 265	Asn	Asp	Thr	Ala	Arg 270	Cys	Pro
Gly	Gly	Gly 275	Pro	Ala	Val	Val	Ser 280	Cys	Val	Pro	Gly	Pro 285	Val	Tyr	Ala
Ala	Ser	Ser 290	Gly	Gln	Lys	Lys 295	Gln	Gln	Ser	Lys	Pro 300	Gln	Gly	Glu	
Ala 305	Arg	Val	Arg	Leu	Lys 310	Gly	Gly	Ala	His	Pro 315	Gly	Glu	Gly	Arg	Val 320
Glu	Val	Leu	Lys 325	Ala	Ser	Thr	Trp	Gly	Thr 330	Val	Cys	Asp	Arg	Lys	Trp 335
Asp	Leu	His 340	Ala	Ser	Val	Val	Cys 345	Arg	Glu	Leu	Gly	Phe 350	Gly	Ser	
Ala	Arg	Glu 355	Ala	Leu	Ser	Gly	Ala 360	Arg	Met	Gly	Gln	Gly 365	Met	Gly	Ala
Ile	His	Leu	Ser	Glu	Val	Arg	Cys	Ser	Gly	Gln	Glu	Leu	Ser	Leu	Trp

```

      370      375      380
Lys Cys Pro His Lys Asn Ile Thr Ala Glu Asp Cys Ser His Ser Gln
385      390      395      400
Asp Ala Gly Val Arg Cys Asn Leu Pro Tyr Thr Gly Ala Glu Thr Arg
      405      410      415
Ile Arg Leu Ser Gly Gly Arg Ser Gln His Glu Gly Arg Val Glu Val
      420      425      430
Gln Ile Gly Gly Pro Gly Pro Leu Arg Trp Gly Leu Ile Cys Gly Asp
      435      440      445
Asp Trp Gly Thr Leu Glu Ala Met Val Ala Cys Arg Gln Leu Gly Leu
      450      455      460
Gly Tyr Ala Asn His Gly Leu Gln Glu Thr Trp Tyr Trp Asp Ser Gly
465      470      475      480
Asn Ile Thr Glu Val Val Met Ser Gly Val Arg Cys Thr Gly Thr Glu
      485      490      495
Leu Ser Leu Asp Gln Cys Ala His His Gly Thr His Ile Thr Cys Lys
      500      505      510
Arg Thr Gly Thr Arg Phe Thr Ala Gly Val Ile Cys Ser Glu Thr Ala
      515      520      525
Ser Asp Leu Leu Leu His Ser Ala Leu Val Gln Glu Thr Ala Tyr Ile
      530      535      540
Glu Asp Arg Pro Leu His Met Leu Tyr Cys Ala Ala Glu Glu Asn Cys
545      550      555      560
Leu Ala Ser Ser Ala Arg Ser Ala Asn Trp Pro Tyr Gly His Arg Arg
      565      570      575
Leu Leu Arg Phe Ser Ser Gln Ile His Asn Leu Gly Arg Ala Asp Phe
      580      585      590
Arg Pro Lys Ala Gly Arg His Ser Trp Val Trp His Glu Cys His Gly
      595      600      605
His Tyr His Ser Met Asp Ile Phe Thr His Tyr Asp Ile Leu Thr Pro
      610      615      620
Asn Gly Thr Lys Val Ala Glu Gly His Lys Ala Ser Phe Cys Leu Glu
625      630      635      640
Asp Thr Glu Cys Gln Glu Asp Val Ser Lys Arg Tyr Glu Cys Ala Asn
      645      650      655
Phe Gly Glu Gln Gly Ile Thr Val Gly Cys Trp Asp Leu Tyr Arg His
      660      665      670
Asp Ile Asp Cys Gln Trp Ile Asp Ile Thr Asp Val Lys Pro Gly Asn
      675      680      685
Tyr Ile Leu Gln Val Val Ile Asn Pro Asn Phe Glu Val Ala Glu Ser
      690      695      700
Asp Phe Thr Asn Asn Ala Met Lys Cys Asn Cys Lys Tyr Asp Gly His
705      710      715      720
Arg Ile Trp Val His Asn Cys His Ile Gly Asp Ala Phe Ser Glu Glu
      725      730      735
Ala Asn Arg Arg Phe Glu Arg Tyr Pro Gly Gln Thr Ser Asn Gln Ile
      740      745      750
Ile

```

<210> 52
 <211> 114
 <212> PRT
 <213> Homo sapiens

<400> 52
 Met Glu Ser Ala Ala Gln Leu Gly Pro Gln Val Pro Val Ala Leu Ser
 1 5 10 15
 Trp Met Arg Asp Gln Gly Gln Gly His Cys Ile Thr Thr Leu Cys Cys


```

                20                25                30
Phe Pro Glu Arg Tyr Ala Gly Arg Asp His Asn Ser Cys Lys Leu Ser
      35                40                45
Gln Arg Gly Phe Leu Asn Phe Met Asn Thr Val Leu Val Ala Phe Thr
      50                55                60
Lys Asn Gln Lys Gly Ser Gly Ala Leu Asp Cys Met Met Lys Lys Leu
65                70                75                80
Asp Phe Asn Cys Asp Gly Gln Asp Phe Gln Asp Phe Leu Ser Leu Thr
      85                90                95
Asp Gly Val Ala Val Ala Cys Pro Asp Ser Phe Ile Pro Ala Gly His
      100                105                110
Ala Pro

```

<210> 53
 <211> 106
 <212> PRT
 <213> Homo sapiens

```

      <400> 53
Met Ala Lys Ile Ser Gly Cys Thr Glu Ile Ala Trp Trp Cys Ile Thr
 1                5                10                15
Thr Leu Cys Cys Phe Pro Glu Arg Tyr Ala Gly Arg Asp His Asn Ser
      20                25                30
Cys Lys Leu Ser Gln Arg Gly Phe Leu Asn Phe Met Asn Thr Val Leu
      35                40                45
Val Ala Phe Thr Lys Asn Gln Lys Gly Ser Gly Ala Leu Asp Cys Met
      50                55                60
Met Lys Lys Leu Asp Phe Asn Cys Asp Gly Gln Leu Asp Phe Gln Asp
65                70                75                80
Phe Leu Ser Leu Thr Asp Gly Val Ala Val Ala Cys Pro Asp Ser Phe
      85                90                95
Ile Pro Ala Gly His Ala His Glu Arg Ile
      100                105

```

<210> 54
 <211> 643
 <212> PRT
 <213> Homo sapiens

```

      <400> 54
Met Ala Leu Ala Gly Pro Cys Pro Ser Ser Thr Ala Ser Leu Leu Pro
 1                5                10                15
Ser Thr Gln Ala Leu Pro Thr Ile Asn Ser Phe Leu Lys Ile Ala Ser
      20                25                30
Lys Pro Lys Ser Thr Leu Asp Arg Ala Val Gly Lys Ala Ser Ser Ile
      35                40                45
Leu Ala Leu Lys Ser Arg Ala Ser Ala Lys Arg Ser Val Leu Leu Pro
      50                55                60
Ile Leu Ala Leu Trp Ala Gly Ser Cys Ser Gly Gly Ala Pro Pro Thr
65                70                75                80
Pro Met Gly Leu Ala Thr Leu Gln Leu Leu Pro Ser Pro Pro Gly Ala
      85                90                95
Pro Asp Gly Gln Leu Gln Pro Ile Pro Gly Ile Gly His Pro Asp Lys
      100                105                110
Pro Glu Ala Gly Lys Leu Asp Gln Leu Arg Asp Gln Pro Thr Pro Lys
      115                120                125
Gln Gly Ala Gln Gly Thr Pro Thr Gln Ser Pro Ser Thr Gly Trp Lys
      130                135                140

```

Ala	Leu	Pro	Arg	Pro	Gly	Leu	Ala	Leu	Arg	Lys	Glu	Ser	Pro	Pro	Val
145					150					155					160
Thr	Leu	Glu	Gln	Glu	Gln	Gly	His	Asn	Lys	Gly	Leu	Val	Ala	Glu	Trp
				165					170					175	
Ala	Gln	Pro	Gln	Ala	Thr	Ala	Ala	Met	Arg	Ala	Gly	Ala	Gly	Lys	Pro
			180					185					190		
Glu	Ala	Leu	Lys	Leu	Arg	Pro	Trp	Gln	Ala	Gly	Arg	Asp	Pro	Gln	Ala
		195					200					205			
Gln	Glu	Gly	Ala	Ala	Val	Thr	Glu	Glu	Asp	Gln	Gly	Gln	Arg	Thr	Gly
	210					215					220				
Gly	Arg	Glu	Asp	Lys	Gly	Arg	Gly	Leu	Lys	Pro	Arg	Arg	Pro	Pro	Lys
225				230						235					240
Gly	Thr	Ser	His	Gln	Pro	Gly	Leu	Arg	Ile	Arg	Arg	Pro	Gln	Lys	Asp
			245						250					255	
Arg	Ser	Arg	Gly	Gln	Gly	Gly	Gly	Gly	Ser	Thr	Ser	Lys	Thr	Pro	Gly
			260					265					270		
His	Gly	Trp	Lys	Arg	Pro	Gly	Ser	Thr	His	Gly	His	Arg	His	Arg	His
	275						280					285			
Ala	Asp	Leu	Gly	Thr	Thr	Gln	Gln	Ala	Met	Pro	Ser	Leu	Pro	Ala	Ser
	290					295					300				
Cys	Leu	Leu	Ala	Gln	Ala	Val	Ile	Ala	Cys	Gly	Asn	Val	Lys	Met	Lys
305				310						315					320
His	Val	Pro	Ala	Leu	Thr	His	Pro	Gly	Leu	Thr	Thr	Leu	Tyr	Leu	Ala
			325						330					335	
Glu	Asn	Glu	Ile	Ala	Lys	Ile	Pro	Ala	His	Thr	Phe	Leu	Gly	Leu	Pro
			340					345					350		
Asn	Leu	Glu	Trp	Leu	Asp	Leu	Ser	Lys	Asn	Lys	Leu	Asp	Pro	Arg	Gly
	355						360					365			
Leu	His	Pro	His	Ala	Phe	Lys	Asn	Leu	Met	Arg	Leu	Lys	Arg	Leu	Asn
	370					375					380				
Leu	Val	Gly	Asn	Ser	Leu	Thr	Thr	Val	Pro	Ala	Leu	Pro	Ala	Ser	Leu
385				390						395					400
Gln	Glu	Leu	Lys	Leu	Asn	Asp	Asn	Leu	Leu	Gln	Gly	Leu	Gln	Gly	Ser
			405						410					415	
Ser	Phe	Arg	Gly	Leu	Ser	Gln	Leu	Leu	Thr	Leu	Glu	Glu	Leu	His	Leu
			420					425					430		
Gly	Thr	Asn	Leu	Ile	Glu	Glu	Val	Ala	Glu	Gly	Ala	Leu	Ser	His	Ile
	435						440						445		
His	Ser	Leu	Ser	Val	Leu	Val	Leu	Ser	His	Asn	Trp	Leu	Gln	Glu	His
	450					455					460				
Trp	Leu	Ala	Pro	Arg	Ala	Trp	Ile	His	Leu	Pro	Lys	Leu	Glu	Thr	Leu
465				470						475					480
Asp	Leu	Ser	Tyr	Asn	Arg	Leu	Val	His	Val	Pro	Arg	Phe	Leu	Pro	Arg
			485						490					495	
Gly	Leu	Arg	Arg	Leu	Thr	Leu	His	His	Asp	His	Ile	Glu	Arg	Ile	Pro
			500					505					510		
Gly	Tyr	Ala	Phe	Ala	His	Met	Lys	Pro	Gly	Leu	Glu	Phe	Leu	His	Leu
	515						520					525			
Ser	His	Asn	Arg	Leu	Gln	Ala	Asp	Gly	Ile	His	Ser	Val	Ser	Phe	Leu
	530					535					540				
Gly	Leu	Arg	Ala	Ser	Leu	Ala	Glu	Leu	Leu	Leu	Asp	His	Asn	Gln	Val
545				550						555					560
Gln	Ala	Ile	Pro	Arg	Gly	Leu	Leu	Gly	Leu	Lys	Gly	Leu	Gln	Val	Leu
			565					570						575	
Gly	Leu	Ser	His	Asn	Arg	Ile	Arg	Gln	Val	Pro	Leu	Asn	Ser	Ile	Cys
			580					585					590		
Asp	Met	Arg	Val	Ala	Gln	Asp	Ser	Asn	Leu	Thr	Ser	Thr	His	Leu	Glu
	595						600					605			
Asn	Asn	Leu	Ile	Asp	Arg	Arg	Arg	Ile	Pro	Pro	Thr	Ala	Phe	Ser	Cys

610 615 620
 Thr Arg Ala Tyr His Ser Val Val Leu Gln Pro Gln Arg Arg Gly Glu
 625 630 635 640
 Glu Gly Ser

<210> 55
 <211> 653
 <212> PRT
 <213> Homo sapiens

<400> 55
 Met Ala Gly Cys Pro Gly Thr Gly Gln Ser Gly Gln Gln Glu Tyr His
 1 5 10 15
 Ser Pro Gly Ala His Pro Ala Lys Arg Ser Val Leu Leu Pro Ile Leu
 20 25 30
 Ala Leu Trp Ala Gly Ser Cys Ser Gly Gly Ala Pro Pro Thr Pro Met
 35 40 45
 Gly Leu Ala Thr Leu Gln Leu Leu Pro Ser Pro Pro Gly Ala Pro Asp
 50 55 60
 Gly Gln Leu Gln Pro Ile Pro Gly Ile Gly His Pro Asp Lys Pro Glu
 65 70 75 80
 Ala Gly Lys Leu Asp Gln Leu Arg Asp Gln Pro Thr Pro Lys Gln Gly
 85 90 95
 Ala Gln Gly Thr Pro Thr Gln Ser Pro Ser Thr Gly Trp Lys Ala Leu
 100 105 110
 Pro Arg Pro Gly Leu Ala Leu Arg Lys Glu Ser Pro Pro Val Thr Leu
 115 120 125
 Glu Gln Glu Gln Gly His Asn Lys Gly Leu Val Ala Glu Trp Ala Gln
 130 135 140
 Pro Gln Ala Thr Ala Ala Met Arg Ala Gly Ala Gly Lys Pro Glu Ala
 145 150 155 160
 Leu Lys Leu Arg Pro Trp Gln Ala Gly Arg Asp Pro Gln Ala Gln Glu
 165 170 175
 Gly Ala Ala Val Thr Glu Glu Asp Gln Gly Gln Arg Thr Gly Gly Arg
 180 185 190
 Glu Asp Lys Gly Arg Gly Leu Lys Pro Arg Arg Pro Pro Lys Gly Thr
 195 200 205
 Ser His Gln Pro Gly Leu Arg Ile Arg Arg Pro Gln Lys Asp Arg Ser
 210 215 220
 Arg Gly Gln Gly Gly Gly Ser Thr Ser Lys Thr Pro Gly His Gly
 225 230 235 240
 Trp Lys Arg Pro Gly Ser Thr His Gly His Arg His Arg His Ala Asp
 245 250 255
 Leu Gly Thr Thr Gln Gln Ala Met Pro Ser Leu Pro Ala Ser Cys Leu
 260 265 270
 Leu Ala Gln Ala Val Ile Ala Cys Gly Asn Val Lys Met Lys His Val
 275 280 285
 Pro Ala Leu Thr His Pro Gly Leu Thr Thr Leu Tyr Leu Ala Glu Asn
 290 295 300
 Glu Ile Ala Lys Ile Pro Ala His Thr Phe Leu Gly Leu Pro Asn Leu
 305 310 315 320
 Glu Trp Leu Asp Leu Ser Lys Asn Lys Leu Asp Pro Arg Gly Leu His
 325 330 335
 Pro His Ala Phe Lys Asn Leu Met Arg Leu Lys Arg Leu Asn Leu Val
 340 345 350
 Gly Asn Ser Leu Thr Thr Val Pro Ala Leu Pro Ala Ser Leu Gln Glu
 355 360 365
 Leu Lys Leu Asn Asp Asn Leu Leu Gln Gly Leu Gln Gly Ser Ser Phe

370	375	380
Arg Gly Leu Ser Gln Leu Thr Leu Glu Val Glu Gly Asn Gln Leu		
385	390	395
Arg Asp Arg Asp Ile Ser Pro Leu Ala Phe Gln Pro Leu Cys Ser Leu		400
	405	410
Leu Tyr Leu Arg Leu Asp Arg Asn Arg Leu Arg Ala Ile Pro Arg Gly		415
	420	425
Leu Pro Ser Ser Leu Gln Glu Leu His Leu Gly Thr Asn Leu Ile Glu		430
	435	440
Glu Val Ala Glu Gly Ala Leu Ser His Ile His Ser Leu Ser Val Leu		445
	450	455
Val Leu Ser His Asn Trp Leu Gln Glu His Trp Leu Ala Pro Arg Ala		460
465	470	475
Trp Ile His Leu Pro Lys Leu Glu Thr Leu Asp Leu Ser Tyr Asn Arg		480
	485	490
Leu Val His Val Pro Arg Phe Leu Pro Arg Gly Leu Arg Arg Leu Thr		495
	500	505
Leu His His Asp His Ile Glu Arg Ile Pro Gly Tyr Ala Phe Ala His		510
	515	520
Met Lys Pro Gly Leu Glu Phe Leu His Leu Ser His Asn Arg Leu Gln		525
	530	535
Ala Asp Gly Ile His Ser Val Ser Phe Leu Gly Leu Arg Ala Ser Leu		540
545	550	555
Ala Glu Leu Leu Leu Asp His Asn Gln Val Gln Ala Ile Pro Arg Gly		560
	565	570
Leu Leu Gly Leu Lys Gly Leu Gln Val Leu Gly Leu Ser His Asn Arg		575
	580	585
Ile Arg Gln Val Pro Leu Asn Ser Ile Cys Asp Met Arg Val Ala Gln		590
	595	600
Asp Ser Asn Leu Thr Ser Thr His Leu Glu Asn Asn Leu Ile Asp Arg		605
	610	615
Arg Arg Ile Pro Pro Thr Ala Phe Ser Cys Thr Arg Ala Tyr His Ser		620
625	630	635
Val Val Leu Gln Pro Gln Arg Arg Gly Glu Glu Gly Ser		640
	645	650

<210> 56

<211> 305

<212> PRT

<213> Homo sapiens

<400> 56

Met Gly Ala Arg Gly Ala Leu Leu Leu Ala Leu Leu Leu Ala Arg Ala	
1	5
Gly Leu Gly Lys Pro Glu Ser Gln Glu Glu Glu Leu Leu Ser Glu Ala	10
	20
Cys Gly His Arg Glu Ile His Ala Leu Val Ala Gly Gly Val Glu Ser	25
	30
Ala Arg Gly Arg Trp Pro Trp Gln Ala Ser Leu Arg Leu Arg Arg Arg	35
	40
His Arg Cys Gly Gly Ser Leu Leu Ser Arg Arg Trp Val Leu Ser Ala	45
65	50
Ala His Cys Phe Gln Lys His Tyr Tyr Pro Ser Glu Trp Thr Val Gln	55
	60
Leu Gly Glu Leu Thr Ser Arg Pro Thr Pro Trp Asn Leu Arg Ala Tyr	65
	70
Ser Ser Arg Tyr Lys Val Gln Asp Ile Ile Val Asn Pro Asp Ala Leu	75
	80
Gly Val Leu Arg Asn Asp Ile Ala Leu Leu Arg Leu Ala Ser Ser Val	85
	90
	95
	100
	105
	110
	115
	120
	125

130 135 140
 Thr Tyr Asn Ala Tyr Ile Gln Pro Ile Cys Ile Glu Ser Ser Thr Phe
 145 150 155 160
 Asn Phe Val His Arg Pro Asp Cys Trp Val Thr Gly Trp Gly Leu Ile
 165 170 175
 Ser Pro Ser Gly Thr Pro Leu Pro Pro Tyr Asn Leu Arg Glu Ala
 180 185 190
 Gln Val Thr Ile Leu Asn Asn Thr Arg Cys Asn Tyr Leu Phe Glu Gln
 195 200 205
 Pro Ser Ser Arg Ser Met Ile Trp Asp Ser Met Phe Cys Ala Gly Ala
 210 215 220
 Glu Asp Gly Ser Val Asp Thr Cys Lys Gly Asp Ser Gly Gly Pro Leu
 225 230 235 240
 Val Cys Asp Lys Asp Gly Leu Trp Tyr Gln Val Gly Ile Val Ser Trp
 245 250 255
 Gly Met Asp Cys Gly Gln Pro Asn Arg Pro Gly Val Tyr Thr Asn Ile
 260 265 270
 Ser Val Tyr Phe His Trp Ile Arg Arg Val Met Ser His Ser Thr Pro
 275 280 285
 Arg Pro Asn Pro Ser Gln Leu Leu Leu Leu Leu Ala Leu Leu Trp Ala
 290 295 300
 Pro
 305

<210> 57
 <211> 387
 <212> PRT
 <213> Homo sapiens

<400> 57
 Met Arg Val Thr Trp Asn His Gly Pro Pro Cys Pro Ser Pro Asp Ser
 1 5 10 15
 Leu Thr Ile Thr Cys Asn Tyr Gly Asn Gly Gly Cys Gln His Ser Cys
 20 25 30
 Glu Asp Thr Asp Thr Gly Pro Thr Cys Gly Cys His Gln Lys Tyr Ala
 35 40 45
 Leu His Ser Asp Gly Arg Thr Cys Ile Glu Lys Asp Glu Ala Ala Ile
 50 55 60
 Glu Arg Ser Gln Phe Asn Ala Thr Ser Val Ala Asp Val Asp Lys Arg
 65 70 75 80
 Val Lys Arg Arg Leu Leu Met Ala Pro Pro Asp Trp Gly Gln Lys Leu
 85 90 95
 Gly Leu Phe Gln Leu Gly Ala Pro Pro Gln Gly Thr Ala Gln Gly Leu
 100 105 110
 Ala Gln Ser Gly Ser Met Glu Ser Leu Leu Ile Asn Leu Val Ile Glu
 115 120 125
 His Asn Ser Leu Asp Thr Ser Ala Val Leu Val Thr Leu Thr Leu Pro
 130 135 140
 Cys Pro Asp Ser Val Trp Ser Val Gly Glu Ala Ser Ala His Thr Asp
 145 150 155 160
 Ser Ala Ala Leu Trp Gly Arg Ser Pro Gly Val Ser Ala Leu Pro Thr
 165 170 175
 Ser Trp Arg Arg Lys Pro Gly His Gln Arg Val Gln Thr Ser Arg Pro
 180 185 190
 Arg Arg Leu Ser Arg Pro Pro Gln Val Cys Phe Arg Val Gly Glu Ile
 195 200 205
 Pro His Glu Ala Ile Met Ser Ala Pro Glu Thr Cys Ala Val Asn Asn
 210 215 220
 Gly Gly Cys Asp Arg Thr Cys Lys Asp Thr Ala Thr Gly Val Arg Cys

```

225      230      235      240
Ser Cys Pro Val Gly Phe Thr Leu Gln Pro Asp Gly Lys Thr Cys Lys
      245      250      255
Asp Ile Asn Glu Cys Leu Val Asn Asn Gly Gly Cys Asp His Phe Cys
      260      265      270
Arg Asn Thr Val Gly Ser Phe Glu Cys Gly Cys Arg Lys Gly Tyr Lys
      275      280      285
Leu Leu Thr Asp Glu Arg Thr Cys Gln Asp Ile Asp Glu Cys Ser Phe
      290      295      300
Glu Arg Thr Cys Asp His Ile Cys Ile Asn Ser Pro Gly Ser Phe Gln
305      310      315      320
Cys Leu Cys His Arg Gly Tyr Ile Leu Tyr Gly Thr Thr His Cys Gly
      325      330      335
Asp Val Asp Glu Cys Ser Met Ser Asn Gly Ser Cys Asp Gln Gly Cys
      340      345      350
Val Asn Thr Lys Gly Ser Tyr Glu Cys Val Cys Pro Pro Gly Arg Arg
      355      360      365
Leu His Trp Asn Gly Lys Asp Cys Val Gly Arg Gly Ser Leu Leu Leu
      370      375      380
Gly Tyr Gly
385

```

```

<210> 58
<211> 964
<212> PRT
<213> Homo sapiens

```

```

      <400> 58
Met Gly Ala Ala Val Arg Trp His Leu Cys Val Leu Leu Ala Leu
1      5      10      15
Gly Thr Arg Gly Arg Leu Ala Gly Gly Ser Gly Leu Pro Gly Ser Val
      20      25      30
Asp Val Asp Glu Cys Ser Glu Gly Thr Asp Asp Cys His Ile Asp Ala
      35      40      45
Ile Cys Gln Asn Thr Pro Lys Ser Tyr Lys Cys Leu Cys Lys Pro Gly
      50      55      60
Tyr Lys Gly Glu Gly Lys Gln Cys Glu Asp Ile Asp Glu Cys Glu Asn
      65      70      75      80
Asp Tyr Tyr Asn Gly Gly Cys Val His Glu Cys Ile Asn Ile Pro Gly
      85      90      95
Asn Tyr Arg Cys Thr Cys Phe Asp Gly Phe Met Leu Ala His Asp Gly
      100      105      110
His Asn Cys Leu Asp Val Asp Glu Cys Gln Asp Asn Asn Gly Gly Cys
      115      120      125
Gln Gln Ile Cys Val Asn Ala Met Gly Ser Tyr Glu Cys Gln Cys His
      130      135      140
Ser Gly Phe Phe Leu Ser Asp Asn Gln His Thr Cys Ile His Arg Ser
      145      150      155      160
Asn Glu Gly Met Asn Cys Met Asn Lys Asp His Gly Cys Ala His Ile
      165      170      175
Cys Arg Glu Thr Pro Lys Gly Gly Val Ala Cys Asp Cys Arg Pro Gly
      180      185      190
Phe Asp Leu Ala Gln Asn Gln Lys Asp Cys Thr Leu Thr Cys Asn Tyr
      195      200      205
Gly Asn Gly Gly Cys Gln His Ser Cys Glu Asp Thr Asp Thr Gly Pro
      210      215      220
Thr Cys Gly Cys His Gln Lys Tyr Ala Leu His Ser Asp Gly Arg Thr
      225      230      235      240
Cys Ile Glu Thr Cys Ala Val Asn Asn Gly Gly Cys Asp Arg Thr Cys

```

245 250 255
 Lys Asp Thr Ala Thr Gly Val Arg Cys Ser Cys Pro Val Gly Phe Thr
 260 265 270
 Leu Gln Pro Asp Gly Lys Thr Cys Lys Asp Ile Asn Glu Cys Leu Val
 275 280 285
 Asn Asn Gly Gly Cys Asp His Phe Cys Arg Asn Thr Val Gly Ser Phe
 290 295 300
 Glu Cys Gly Cys Arg Lys Gly Tyr Lys Leu Leu Thr Asp Glu Arg Thr
 305 310 315 320
 Cys Gln Asp Ile Asp Glu Cys Ser Phe Glu Arg Thr Cys Asp His Ile
 325 330 335
 Cys Ile Asn Ser Pro Gly Ser Phe Gln Cys Leu Cys His Arg Gly Tyr
 340 345 350
 Ile Leu Tyr Gly Thr Thr His Cys Gly Asp Val Asp Glu Cys Ser Met
 355 360 365
 Ser Asn Gly Ser Cys Asp Gln Gly Cys Val Asn Thr Lys Gly Ser Tyr
 370 375 380
 Glu Cys Val Cys Pro Pro Gly Arg Arg Leu His Trp Asn Gly Lys Asp
 385 390 395 400
 Cys Val Glu Thr Gly Lys Cys Leu Ser Arg Ala Lys Thr Ser Pro Arg
 405 410 415
 Ala Gln Leu Ser Cys Ser Lys Ala Gly Gly Val Glu Ser Cys Phe Leu
 420 425 430
 Ser Cys Pro Ala His Thr Leu Phe Val Pro Asp Ser Glu Asn Ser Tyr
 435 440 445
 Val Leu Ser Cys Gly Val Pro Gly Pro Gln Gly Lys Ala Leu Gln Lys
 450 455 460
 Arg Asn Gly Thr Ser Ser Gly Leu Gly Pro Ser Cys Ser Asp Ala Pro
 465 470 475 480
 Thr Thr Pro Ile Lys Gln Lys Ala Arg Phe Lys Ile Arg Asp Ala Lys
 485 490 495
 Cys His Leu Arg Pro His Ser Gln Ala Arg Ala Lys Glu Thr Ala Arg
 500 505 510
 Gln Pro Leu Leu Asp His Cys His Val Thr Phe Val Thr Leu Lys Cys
 515 520 525
 Asp Ser Ser Lys Lys Arg Arg Arg Gly Arg Lys Ser Pro Ser Lys Glu
 530 535 540
 Val Ser His Ile Thr Ala Glu Phe Glu Ile Glu Thr Lys Met Glu Glu
 545 550 555 560
 Ala Ser Asp Thr Cys Glu Ala Asp Cys Leu Arg Lys Arg Ala Glu Gln
 565 570 575
 Ser Leu Gln Ala Ala Ile Lys Thr Leu Arg Lys Ser Ile Gly Arg Gln
 580 585 590
 Gln Phe Tyr Val Gln Val Ser Gly Thr Glu Tyr Glu Val Ala Gln Arg
 595 600 605
 Pro Ala Lys Ala Leu Glu Gly Gln Gly Ala Cys Gly Ala Gly Gln Val
 610 615 620
 Leu Gln Asp Ser Lys Cys Val Ala Cys Gly Pro Gly Thr His Phe Gly
 625 630 635 640
 Gly Glu Leu Gly Gln Cys Val Ser Cys Met Pro Gly Thr Tyr Gln Asp
 645 650 655
 Met Glu Gly Gln Leu Ser Cys Thr Pro Cys Pro Ser Ser Asp Gly Leu
 660 665 670
 Gly Leu Pro Gly Ala Arg Asn Val Ser Glu Cys Gly Gly Gln Cys Ser
 675 680 685
 Pro Gly Phe Phe Ser Ala Asp Gly Phe Lys Pro Cys Gln Ala Cys Pro
 690 695 700
 Val Gly Thr Tyr Gln Pro Glu Pro Gly Arg Thr Gly Cys Phe Pro Cys
 705 710 715 720

Gly Gly Gly Leu Leu Thr Lys His Glu Gly Thr Thr Ser Phe Gln Asp
 725 730 735
 Cys Glu Ala Lys Val His Cys Ser Pro Gly His His Tyr Asn Thr Thr
 740 745 750
 Thr His Arg Cys Ile Arg Cys Pro Val Gly Thr Tyr Gln Pro Glu Phe
 755 760 765
 Gly Gln Asn His Cys Ile Thr Cys Pro Gly Asn Thr Ser Thr Asp Phe
 770 775 780
 Asp Gly Ser Thr Asn Val Thr His Cys Lys Asn Gln His Cys Gly Gly
 785 790 795 800
 Glu Leu Gly Asp Tyr Thr Gly Tyr Ile Glu Ser Pro Asn Tyr Pro Gly
 805 810 815
 Asp Tyr Pro Ala Asn Ala Glu Cys Val Trp His Ile Ala Pro Pro Pro
 820 825 830
 Lys Arg Arg Ile Leu Ile Val Val Pro Glu Ile Phe Leu Pro Ile Glu
 835 840 845
 Asp Glu Cys Gly Asp Val Leu Val Met Arg Lys Ser Ala Ser Pro Thr
 850 855 860
 Ser Ile Thr Thr Tyr Glu Thr Cys Gln Thr Tyr Glu Arg Pro Ile Ala
 865 870 875 880
 Phe Thr Ser Arg Ser Arg Lys Leu Trp Ile Gln Phe Lys Ser Asn Glu
 885 890 895
 Gly Asn Ser Gly Lys Gly Phe Gln Val Pro Tyr Val Thr Tyr Asp Gly
 900 905 910
 Lys Ile His Cys Leu His Gly Pro Leu Cys Thr Ala Gln Ala Gly Pro
 915 920 925
 Trp Arg His Arg Asp Glu Ser His Val Pro Ala Leu Arg Glu Leu Arg
 930 935 940
 Pro Gly Arg Tyr Arg Pro Gly Ser Arg Thr Asn Thr Val Arg Gly Gln
 945 950 955 960
 Ser Gln Thr Gly

<210> 59
 <211> 213
 <212> PRT
 <213> Homo sapiens

<400> 59
 Ala Met Val Leu Pro Ser Tyr Ser Lys Ser Glu Gly Gly Ser Leu Leu
 1 5 10 15
 Asp Ile Tyr Cys Leu Leu Thr Tyr Trp Met Glu Val Val Pro Thr Leu
 20 25 30
 Leu Ala Glu Thr Lys Ile Pro Ala Thr Asp Val Ala Asp Ala Ser Leu
 35 40 45
 Asn Glu Cys Ser Ser Thr Glu Arg Lys Gln Asp Val Val Leu Leu Phe
 50 55 60
 Val Thr Leu Ser His Thr Gln Pro Pro Leu Phe His Leu Pro Tyr Val
 65 70 75 80
 Gln Lys Pro Leu Ile Ser Asn Val Glu Gln Leu Ile Leu Gly Ile Pro
 85 90 95
 Gly Gln Asn Arg Arg Glu Ile Gly His Gly Gln Asp Ile Phe Pro Ala
 100 105 110
 Glu Lys Leu Cys His Leu Gln Asp Arg Lys Val Asn Leu His Arg Ala
 115 120 125
 Ala Trp Gly Glu Cys Ile Val Ala Pro Lys Thr Leu Ser Phe Ser Tyr
 130 135 140
 Cys Gln Gly Thr Cys Pro Ala Leu Asn Ser Glu Leu Arg His Ser Ser
 145 150 155 160

Phe Glu Cys Tyr Lys Arg Ala Val Pro Thr Cys Pro Trp Leu Phe Gln
 165 170 175
 Thr Cys Arg Pro Thr Met Val Arg Leu Phe Ser Leu Met Val Gln Asp
 180 185 190
 Asp Glu His Lys Met Ser Val His Tyr Val Asn Thr Ser Leu Val Glu
 195 200 205
 Lys Cys Gly Cys Ser
 210

<210> 60
 <211> 189
 <212> PRT
 <213> Homo sapiens

<400> 60
 Asx Met Glu Val Val Pro Thr Leu Leu Ala Glu Thr Lys Ile Pro Ala
 1 5 10 15
 Thr Asp Val Ala Asp Ala Ser Leu Asn Glu Cys Ser Ser Thr Glu Arg
 20 25 30
 Lys Gln Asp Val Val Leu Leu Phe Val Thr Leu Ser His Thr Gln Pro
 35 40 45
 Pro Leu Phe His Leu Pro Tyr Val Gln Lys Pro Leu Ile Ser Asn Val
 50 55 60
 Glu Gln Leu Ile Leu Gly Ile Pro Gly Gln Asn Arg Arg Glu Ile Gly
 65 70 75 80
 His Gly Gln Asp Ile Phe Pro Ala Glu Lys Leu Cys His Leu Gln Asp
 85 90 95
 Arg Lys Val Asn Leu His Arg Ala Ala Trp Gly Glu Cys Ile Val Ala
 100 105 110
 Pro Lys Thr Leu Ser Phe Ser Tyr Cys Gln Gly Thr Cys Pro Ala Leu
 115 120 125
 Asn Ser Glu Leu Arg His Ser Ser Phe Glu Cys Tyr Lys Arg Ala Val
 130 135 140
 Pro Thr Cys Pro Trp Leu Phe Gln Thr Cys Arg Pro Thr Met Val Arg
 145 150 155 160
 Leu Phe Ser Leu Met Val Gln Asp Asp Glu His Lys Met Ser Val His
 165 170 175
 Tyr Val Asn Thr Ser Leu Val Glu Lys Cys Gly Cys Ser
 180 185

<210> 61
 <211> 740
 <212> PRT
 <213> Homo sapiens

<400> 61
 Met Gly Asp Ser Gly Ala Glu Ala Val Gly Gly Gly Gly Thr Tyr Thr
 1 5 10 15
 Asp Gly Pro Val Leu Leu Leu Tyr Ala Gly Glu Leu Leu Leu Pro Gln
 20 25 30
 Glu Thr Thr Val Glu Leu Ser Cys Gly Val Gly Pro Leu Gln Val Ile
 35 40 45
 Leu Gly Pro Glu Gln Ala Ala Val Leu Asn Cys Ser Leu Gly Ala Ala
 50 55 60
 Ala Ala Gly Pro Pro Thr Arg Val Thr Trp Ser Lys Asp Gly Asp Thr
 65 70 75 80
 Leu Leu Glu His Asp His Leu His Leu Leu Pro Asn Gly Ser Leu Trp
 85 90 95
 Leu Ser Gln Pro Leu Ala Pro Asn Gly Ser Asp Glu Ser Val Pro Glu

51/60

Leu Gln Pro Asn Lys Val Tyr Arg Val Arg Ile Ser Ala Gly Thr Ala
 580 585 590
 Ala Gly Phe Gly Ala Pro Ser Gln Trp Met His His Arg Thr Pro Ser
 595 600 605
 Met His Asn Gln Ser His Val Pro Phe Ala Pro Ala Glu Leu Lys Val
 610 615 620
 Gln Ala Lys Met Glu Ser Leu Val Val Ser Trp Gln Pro Pro Pro His
 625 630 635 640
 Pro Thr Gln Ile Ser Gly Tyr Lys Leu Tyr Trp Arg Glu Val Gly Ala
 645 650 655
 Glu Glu Glu Ala Asn Gly Asp Arg Leu Pro Gly Gly Arg Gly Asp Gln
 660 665 670
 Ala Trp Asp Val Gly Pro Val Arg Leu Lys Lys Lys Val Lys Gln Tyr
 675 680 685
 Glu Leu Thr Gln Leu Val Pro Gly Arg Leu Tyr Glu Val Lys Leu Val
 690 695 700
 Ala Phe Asn Lys His Glu Asp Gly Tyr Ala Ala Val Trp Lys Gly Lys
 705 710 715 720
 Thr Glu Lys Ala Pro Ala Pro Gly Glu Gly Gly Gly Arg Arg Arg
 725 730 735
 Gly Gly Leu Arg
 740

<210> 62
 <211> 1250
 <212> PRT
 <213> Homo sapiens

<400> 62
 Met Ala Arg Gly Asp Ala Gly Arg Gly Arg Gly Leu Leu Ala Leu Thr
 1 5 10 15
 Phe Cys Leu Leu Ala Ala Arg Gly Glu Leu Leu Leu Pro Gln Glu Thr
 20 25 30
 Thr Val Glu Leu Ser Cys Gly Val Gly Pro Leu Gln Val Ile Leu Gly
 35 40 45
 Pro Glu Gln Ala Ala Val Leu Asn Cys Ser Leu Gly Ala Ala Ala Ala
 50 55 60
 Gly Pro Pro Thr Arg Val Thr Trp Ser Lys Asp Gly Asp Thr Leu Leu
 65 70 75 80
 Glu His Asp His Leu His Leu Leu Pro Asn Gly Ser Leu Trp Leu Ser
 85 90 95
 Gln Pro Leu Ala Pro Asn Gly Ser Asp Glu Ser Val Pro Glu Ala Val
 100 105 110
 Gly Val Ile Glu Gly Asn Tyr Ser Cys Leu Ala His Gly Pro Leu Gly
 115 120 125
 Val Leu Ala Ser Gln Thr Ala Val Val Lys Leu Ala Thr Leu Ala Asp
 130 135 140
 Phe Ser Leu His Pro Glu Ser Gln Thr Val Glu Glu Asn Gly Thr Ala
 145 150 155 160
 Arg Phe Glu Cys His Ile Glu Gly Leu Pro Ala Pro Ile Ile Thr Trp
 165 170 175
 Glu Lys Asp Gln Val Thr Leu Pro Glu Glu Pro Arg Leu Ile Val Leu
 180 185 190
 Pro Asn Gly Val Leu Gln Ile Leu Asp Val Gln Glu Ser Asp Ala Gly
 195 200 205
 Pro Tyr Arg Cys Val Ala Thr Asn Ser Ala Arg Gln His Phe Ser Gln
 210 215 220
 Glu Ala Leu Leu Ser Val Ala His Arg Gly Ser Leu Ala Ser Thr Arg
 225 230 235 240

Gly Gln Asp Val Val Ile Val Ala Ala Pro Glu Asn Thr Thr Val Val
 245 250 255
 Ser Gly Gln Ser Val Val Met Glu Cys Val Ala Ser Ala Asp Pro Thr
 260 265 270
 Pro Phe Val Ser Trp Val Arg Gln Asp Gly Lys Pro Ile Ser Thr Asp
 275 280 285
 Val Ile Val Leu Gly Arg Thr Asn Leu Leu Ile Ala Asn Ala Gln Pro
 290 295 300
 Trp His Ser Gly Val Tyr Val Cys Arg Ala Asn Lys Pro Arg Thr Arg
 305 310 315 320
 Asp Phe Ala Thr Ala Ala Ala Glu Leu Arg Val Leu Ala Ala Pro Ala
 325 330 335
 Ile Thr Gln Ala Pro Glu Ala Leu Ser Arg Thr Arg Ala Ser Thr Ala
 340 345 350
 Arg Phe Val Cys Arg Ala Ser Gly Glu Pro Arg Pro Ala Leu Arg Trp
 355 360 365
 Leu His Asn Gly Ala Pro Leu Arg Pro Asn Gly Arg Val Lys Val Gln
 370 375 380
 Gly Gly Gly Gly Ser Leu Val Ile Thr Gln Ile Gly Leu Gln Asp Ala
 385 390 395 400
 Gly Tyr Tyr Gln Cys Val Ala Glu Asn Ser Ala Gly Met Ala Cys Ala
 405 410 415
 Ala Ala Ser Leu Ala Val Val Val Arg Glu Gly Leu Pro Ser Ala Pro
 420 425 430
 Thr Arg Val Thr Ala Thr Pro Leu Ser Ser Ser Ala Val Leu Val Ala
 435 440 445
 Trp Glu Arg Pro Glu Met His Ser Glu Gln Ile Ile Gly Phe Ser Leu
 450 455 460
 His Tyr Gln Lys Ala Arg Gly Met Asp Asn Val Glu Tyr Gln Phe Ala
 465 470 475 480
 Val Asn Asn Asp Thr Thr Glu Leu Gln Val Arg Asp Leu Glu Pro Asn
 485 490 495
 Thr Asp Tyr Glu Phe Tyr Val Val Ala Tyr Ser Gln Leu Gly Ala Ser
 500 505 510
 Arg Thr Ser Thr Pro Ala Leu Val His Thr Leu Asp Asp Val Pro Ser
 515 520 525
 Ala Ala Pro Gln Leu Ser Leu Ser Ser Pro Asn Pro Ser Asp Ile Arg
 530 535 540
 Val Ala Trp Leu Pro Leu Pro Pro Ser Leu Ser Asn Gly Gln Val Val
 545 550 555 560
 Lys Tyr Lys Ile Glu Tyr Gly Leu Gly Lys Glu Asp Gln Ile Phe Ser
 565 570 575
 Thr Glu Val Arg Gly Asn Glu Thr Gln Leu Met Leu Asn Ser Leu Gln
 580 585 590
 Pro Asn Lys Val Tyr Arg Val Arg Ile Ser Ala Gly Thr Ala Ala Gly
 595 600 605
 Phe Gly Ala Pro Ser Gln Trp Met His His Arg Thr Pro Ser Met His
 610 615 620
 Asn Gln Ser His Val Pro Phe Ala Pro Ala Glu Leu Lys Val Gln Ala
 625 630 635 640
 Lys Met Glu Ser Leu Val Val Ser Trp Gln Pro Pro Pro His Pro Thr
 645 650 655
 Gln Ile Ser Gly Tyr Lys Leu Tyr Trp Arg Glu Val Gly Ala Glu Glu
 660 665 670
 Glu Ala Asn Gly Asp Arg Leu Pro Gly Gly Arg Gly Asp Gln Ala Trp
 675 680 685
 Asp Val Gly Pro Val Arg Leu Lys Lys Lys Val Lys Gln Tyr Glu Leu
 690 695 700
 Thr Gln Leu Val Pro Gly Arg Leu Tyr Glu Val Lys Leu Val Ala Phe

705 710 715 720
 Asn Lys His Glu Asp Gly Tyr Ala Ala Val Trp Lys Gly Lys Thr Glu
 725 730 735
 Lys Ala Pro Ala Pro Asp Met Pro Ile Gln Arg Gly Pro Pro Leu Pro
 740 745 750
 Pro Ala His Val His Ala Glu Ser Asn Ser Ser Thr Ser Ile Trp Leu
 755 760 765
 Arg Trp Lys Lys Pro Asp Phe Thr Thr Val Lys Ile Val Asn Tyr Thr
 770 775 780
 Val Arg Phe Ser Pro Trp Gly Leu Arg Asn Ala Ser Leu Val Thr Tyr
 785 790 795 800
 Tyr Thr Ser Ser Gly Glu Asp Ile Leu Ile Gly Gly Leu Lys Pro Phe
 805 810 815
 Thr Lys Tyr Glu Phe Ala Val Gln Ser His Gly Val Asp Met Asp Gly
 820 825 830
 Pro Phe Gly Ser Val Val Glu Arg Ser Thr Leu Pro Asp Arg Pro Ser
 835 840 845
 Thr Pro Pro Ser Asp Leu Arg Leu Ser Pro Leu Thr Pro Ser Thr Val
 850 855 860
 Arg Leu His Trp Cys Pro Pro Thr Glu Pro Asn Gly Glu Ile Val Glu
 865 870 875 880
 Tyr Leu Ile Leu Tyr Ser Ser Asn His Thr Gln Pro Glu His Gln Trp
 885 890 895
 Thr Leu Leu Thr Thr Gln Gly Asn Ile Phe Ser Ala Glu Val His Gly
 900 905 910
 Leu Glu Ser Asp Thr Arg Tyr Phe Phe Lys Met Gly Ala Arg Thr Glu
 915 920 925
 Val Gly Pro Gly Pro Phe Ser Arg Leu Gln Asp Val Ile Thr Leu Gln
 930 935 940
 Glu Lys Leu Ser Asp Ser Leu Asp Met His Ser Val Thr Gly Ile Ile
 945 950 955 960
 Val Gly Val Cys Leu Gly Leu Leu Cys Leu Leu Ala Cys Met Cys Ala
 965 970 975
 Gly Leu Arg Arg Ser Pro His Arg Glu Ser Leu Pro Gly Leu Ser Ser
 980 985 990
 Thr Ala Thr Pro Gly Asn Pro Ala Leu Tyr Ser Arg Ala Arg Leu Gly
 995 1000 1005
 Pro Pro Ser Pro Pro Ala Ala His Glu Leu Glu Ser Leu Val His Pro
 1010 1015 1020
 His Pro Gln Asp Trp Ser Pro Pro Pro Ser Asp Val Glu Asp Arg Ala
 1025 1030 1035 1040
 Glu Val His Ser Leu Met Gly Gly Gly Val Ser Glu Gly Arg Ser His
 1045 1050 1055
 Ser Lys Arg Lys Ile Ser Trp Ala Gln Pro Ser Gly Leu Ser Trp Ala
 1060 1065 1070
 Gly Ser Trp Ala Gly Cys Glu Leu Pro Gln Ala Gly Pro Arg Pro Ala
 1075 1080 1085
 Leu Thr Arg Ala Leu Leu Pro Pro Ala Gly Thr Gly Gln Thr Leu Leu
 1090 1095 1100
 Leu Gln Ala Leu Val Tyr Asp Ala Ile Lys Gly Asn Gly Arg Lys Lys
 1105 1110 1115 1120
 Ser Pro Pro Ala Cys Arg Asn Gln Val Glu Ala Glu Val Ile Val His
 1125 1130 1135
 Ser Asp Phe Ser Ala Ser Asn Gly Asn Pro Asp Leu His Leu Gln Asp
 1140 1145 1150
 Leu Glu Pro Glu Asp Pro Leu Pro Pro Glu Ala Pro Asp Leu Ile Ser
 1155 1160 1165
 Gly Val Gly Asp Pro Gly Gln Gly Ala Ala Trp Leu Asp Arg Glu Leu
 1170 1175 1180

Gly Gly Cys Glu Leu Ala Ala Pro Gly Pro Asp Arg Leu Thr Cys Leu
 1185 1190 1195 1200
 Pro Glu Ala Ala Ser Ala Ser Cys Ser Tyr Pro Asp Leu Gln Pro Gly
 1205 1210 1215
 Glu Val Leu Glu Glu Thr Pro Gly Asp Ser Cys Gln Leu Lys Ser Pro
 1220 1225 1230
 Cys Pro Leu Gly Ala Ser Pro Gly Leu Pro Arg Ser Pro Val Ser Ser
 1235 1240 1245
 Ser Ala
 1250

<210> 63
 <211> 634
 <212> PRT
 <213> Homo sapiens

<400> 63
 Met Ala Gln Gly Val Leu Trp Ile Leu Leu Gly Leu Leu Leu Trp Ser
 1 5 10 15
 Asp Pro Gly Thr Ala Ser Leu Pro Leu Leu Met Asp Ser Val Ile Gln
 20 25 30
 Ala Leu Ala Glu Leu Glu Gln Lys Val Pro Ala Ala Lys Thr Arg His
 35 40 45
 Thr Ala Ser Ala Trp Leu Met Ser Ala Pro Asn Ser Gly Pro His Asn
 50 55 60
 Arg Leu Tyr His Phe Leu Leu Gly Ala Trp Ser Leu Asn Ala Thr Glu
 65 70 75 80
 Leu Asp Pro Cys Pro Leu Ser Pro Glu Leu Leu Gly Leu Thr Lys Glu
 85 90 95
 Val Ala Arg His Asp Val Arg Glu Gly Lys Glu Tyr Gly Val Val Leu
 100 105 110
 Ala Pro Asp Gly Ser Thr Val Ala Val Glu Pro Leu Leu Ala Gly Leu
 115 120 125
 Glu Ala Gly Leu Gln Gly Arg Arg Val Ile Asn Leu Pro Leu Asp Ser
 130 135 140
 Met Ala Ala Pro Trp Glu Thr Gly Asp Thr Phe Pro Asp Val Val Ala
 145 150 155 160
 Ile Ala Pro Asp Val Arg Ala Thr Ser Ser Pro Gly Leu Arg Asp Gly
 165 170 175
 Ser Pro Asp Val Thr Thr Ala Asp Ile Gly Ala Asn Thr Pro Asp Ala
 180 185 190
 Thr Lys Gly Cys Pro Asp Val Gln Ala Ser Leu Pro Asp Ala Lys Ala
 195 200 205
 Lys Ser Pro Pro Thr Met Val Asp Ser Leu Leu Ala Val Thr Leu Ala
 210 215 220
 Gly Asn Leu Gly Leu Thr Phe Leu Arg Gly Ser Gln Thr Gln Ser His
 225 230 235 240
 Pro Asp Leu Gly Thr Glu Gly Cys Trp Asp Gln Leu Ser Ala Pro Arg
 245 250 255
 Thr Phe Thr Leu Leu Asp Pro Lys Ala Ser Leu Leu Thr Met Ala Phe
 260 265 270
 Leu Asn Gly Ala Leu Asp Gly Val Ile Leu Gly Asp Tyr Leu Ser Arg
 275 280 285
 Thr Pro Glu Pro Arg Pro Ser Leu Ser His Leu Leu Ser Gln Tyr Tyr
 290 295 300
 Gly Ala Gly Val Ala Arg Asp Pro Gly Phe Arg Ser Asn Phe Arg Arg
 305 310 315 320
 Gln Asn Gly Ala Ala Leu Thr Ser Ala Ser Ile Leu Ala Gln Gln Val
 325 330 335

Trp Gly Thr Leu Val Leu Leu Gln Arg Leu Glu Pro Val His Leu Gln
 340 345 350
 Leu Gln Cys Met Ser Gln Glu Gln Leu Ala Gln Val Ala Ala Asn Ala
 355 360 365
 Thr Lys Glu Phe Thr Glu Ala Phe Leu Gly Cys Pro Ala Ile His Pro
 370 375 380
 Arg Cys Arg Trp Gly Ala Ala Pro Tyr Arg Gly Arg Pro Lys Leu Leu
 385 390 395 400
 Gln Leu Pro Leu Gly Phe Leu Tyr Val His His Thr Tyr Val Pro Ala
 405 410 415
 Pro Pro Cys Thr Asp Phe Thr Arg Cys Ala Ala Asn Met Arg Ser Met
 420 425 430
 Gln Arg Tyr His Gln Asp Thr Gln Gly Trp Gly Asp Ile Gly Tyr Ser
 435 440 445
 Phe Val Val Gly Ser Asp Gly Tyr Val Tyr Glu Gly Arg Gly Trp His
 450 455 460
 Trp Val Gly Ala His Thr Leu Gly His Asn Ser Arg Gly Phe Gly Val
 465 470 475 480
 Ala Ile Val Gly Asn Tyr Thr Ala Ala Leu Pro Thr Glu Ala Ala Leu
 485 490 495
 Arg Thr Val Arg Asp Thr Leu Pro Ser Cys Ala Val Arg Ala Gly Leu
 500 505 510
 Leu Arg Pro Asp Tyr Ala Leu Leu Gly His Arg Gln Leu Val Arg Thr
 515 520 525
 Asp Cys Pro Gly Asp Ala Leu Phe Asp Leu Leu Arg Thr Trp Pro His
 530 535 540
 Phe Thr Ala Val Ser Leu Arg Ser Leu His Tyr Thr Ala Arg Arg Pro
 545 550 555 560
 Ser Val Tyr Thr Ser Ser Thr Arg Pro Leu Pro Pro Ala Cys Asn Ser
 565 570 575
 Cys Ala Arg Thr Ala Ser Ala Arg Pro Pro Thr Ser Arg Arg His Val
 580 585 590
 Tyr Ser Gly Asn Leu Gly Pro Ala Phe Ala Gly His Ser Ala Gly Asn
 595 600 605
 Ile Pro Asp Pro Val Thr Ser Ala Tyr Ala Ala Ser Ala Gln Pro Gln
 610 615 620
 Thr Gln Pro Ala Cys Pro Phe Pro Ser Ser
 625 630

<210> 64
 <211> 576
 <212> PRT
 <213> Homo sapiens

<400> 64
 Met Ala Gln Gly Val Leu Trp Ile Leu Leu Gly Leu Leu Leu Trp Ser
 1 5 10 15
 Asp Pro Gly Thr Ala Ser Leu Pro Leu Leu Met Asp Ser Val Ile Gln
 20 25 30
 Ala Leu Ala Glu Leu Glu Gln Lys Val Pro Ala Ala Lys Thr Arg His
 35 40 45
 Thr Ala Ser Ala Trp Leu Met Ser Ala Pro Asn Ser Gly Pro His Asn
 50 55 60
 Arg Leu Tyr His Phe Leu Leu Gly Ala Trp Ser Leu Asn Ala Thr Glu
 65 70 75 80
 Leu Asp Pro Cys Pro Leu Ser Pro Glu Leu Leu Gly Leu Thr Lys Glu
 85 90 95
 Val Ala Arg His Asp Val Arg Glu Gly Lys Glu Tyr Gly Val Val Leu
 100 105 110

Ala Pro Asp Gly Ser Thr Val Ala Val Glu Pro Leu Leu Ala Gly Leu
 115 120 125
 Glu Ala Gly Leu Gln Gly Arg Arg Val Ile Asn Leu Pro Leu Asp Ser
 130 135 140
 Met Ala Ala Pro Trp Glu Thr Gly Asp Thr Phe Pro Asp Val Val Ala
 145 150 155 160
 Ile Ala Pro Asp Val Arg Ala Thr Ser Ser Pro Gly Leu Arg Asp Gly
 165 170 175
 Ser Pro Asp Val Thr Thr Ala Asp Ile Gly Ala Asn Thr Pro Asp Ala
 180 185 190
 Thr Lys Gly Cys Pro Asp Val Gln Ala Ser Leu Pro Asp Ala Lys Ala
 195 200 205
 Lys Ser Pro Pro Thr Met Val Asp Ser Leu Leu Ala Val Thr Leu Ala
 210 215 220
 Gly Asn Leu Gly Leu Thr Phe Leu Arg Gly Ser Gln Thr Gln Ser His
 225 230 235 240
 Pro Asp Leu Gly Thr Glu Gly Cys Trp Asp Gln Leu Ser Ala Pro Arg
 245 250 255
 Thr Phe Thr Leu Leu Asp Pro Lys Ala Ser Leu Leu Thr Met Ala Phe
 260 265 270
 Leu Asn Gly Ala Leu Asp Gly Val Ile Leu Gly Asp Tyr Leu Ser Arg
 275 280 285
 Thr Pro Glu Pro Arg Pro Ser Leu Ser His Leu Leu Ser Gln Tyr Tyr
 290 295 300
 Gly Ala Gly Val Ala Arg Asp Pro Gly Phe Arg Ser Asn Phe Arg Arg
 305 310 315 320
 Gln Asn Gly Ala Ala Leu Thr Ser Ala Ser Ile Leu Ala Gln Gln Val
 325 330 335
 Trp Gly Thr Leu Val Leu Leu Gln Arg Leu Glu Pro Val His Leu Gln
 340 345 350
 Leu Gln Cys Met Ser Gln Glu Gln Leu Ala Gln Val Ala Ala Asn Ala
 355 360 365
 Thr Lys Glu Phe Thr Glu Ala Phe Leu Gly Cys Pro Ala Ile His Pro
 370 375 380
 Arg Cys Arg Trp Gly Ala Ala Pro Tyr Arg Gly Arg Pro Lys Leu Leu
 385 390 395 400
 Gln Leu Pro Leu Gly Phe Leu Tyr Val His His Thr Tyr Val Pro Ala
 405 410 415
 Pro Pro Cys Thr Asp Phe Thr Arg Cys Ala Ala Asn Met Arg Ser Met
 420 425 430
 Gln Arg Tyr His Gln Asp Thr Gln Gly Trp Gly Asp Ile Gly Tyr Ser
 435 440 445
 Phe Val Val Gly Ser Asp Gly Tyr Val Tyr Glu Gly Arg Gly Trp His
 450 455 460
 Trp Val Gly Ala His Thr Leu Gly His Asn Ser Arg Gly Phe Gly Val
 465 470 475 480
 Ala Ile Val Gly Asn Tyr Thr Ala Ala Leu Pro Thr Glu Ala Ala Leu
 485 490 495
 Arg Thr Val Arg Asp Thr Leu Pro Ser Cys Ala Val Arg Ala Gly Leu
 500 505 510
 Leu Arg Pro Asp Tyr Ala Leu Leu Gly His Arg Gln Leu Val Arg Thr
 515 520 525
 Asp Cys Pro Gly Asp Ala Leu Phe Asp Leu Leu Arg Thr Trp Pro His
 530 535 540
 Phe Thr Ala Thr Val Lys Pro Arg Pro Ala Arg Ser Val Ser Lys Arg
 545 550 555 560
 Ser Arg Arg Glu Pro Pro Pro Arg Thr Leu Pro Ala Thr Asp Leu Gln
 565 570 575

<210> 65
 <211> 734
 <212> PRT
 <213> Homo sapiens

<400> 65
 Met Trp Gly Leu Leu Ala Leu Ala Ala Phe Ala Pro Ala Val Gly
 1 5 10 15
 Pro Ala Leu Gly Ala Pro Arg Asn Ser Val Leu Gly Leu Ala Gln Pro
 20 25 30
 Gly Thr Thr Lys Val Pro Gly Ser Thr Pro Ala Leu His Ser Ser Pro
 35 40 45
 Ala Gln Pro Pro Ala Glu Thr Ala Asn Gly Thr Ser Glu Gln His Val
 50 55 60
 Arg Ile Arg Val Ile Lys Lys Lys Val Ile Met Lys Lys Arg Lys
 65 70 75 80
 Lys Leu Thr Leu Thr Arg Pro Thr Pro Leu Val Thr Ala Gly Pro Leu
 85 90 95
 Val Thr Pro Thr Pro Ala Gly Thr Leu Asp Pro Ala Glu Lys Gln Glu
 100 105 110
 Thr Gly Cys Pro Pro Leu Gly Leu Glu Ser Leu Arg Val Ser Asp Ser
 115 120 125
 Arg Leu Glu Ala Ser Ser Ser Gln Ser Phe Gly Leu Gly Pro His Arg
 130 135 140
 Gly Arg Leu Asn Ile Gln Ser Gly Leu Glu Asp Gly Asp Leu Tyr Asp
 145 150 155 160
 Gly Ala Trp Cys Ala Glu Glu Gln Asp Ala Asp Pro Trp Phe Gln Val
 165 170 175
 Asp Ala Gly His Pro Thr Arg Phe Ser Gly Val Ile Thr Gln Gly Arg
 180 185 190
 Asn Ser Val Trp Arg Tyr Asp Trp Val Thr Ser Tyr Lys Val Gln Phe
 195 200 205
 Ser Asn Asp Ser Arg Thr Trp Trp Gly Ser Arg Asn His Ser Ser Gly
 210 215 220
 Met Asp Ala Val Phe Pro Ala Asn Ser Asp Pro Glu Thr Pro Val Leu
 225 230 235 240
 Asn Leu Leu Pro Glu Pro Gln Val Ala Arg Phe Ile Arg Leu Leu Pro
 245 250 255
 Gln Thr Trp Leu Gln Gly Gly Ala Pro Cys Leu Arg Ala Glu Ile Leu
 260 265 270
 Ala Cys Pro Val Ser Asp Pro Asn Asp Leu Phe Leu Glu Ala Pro Ala
 275 280 285
 Ser Gly Ser Ser Asp Pro Leu Asp Phe Gln His His Asn Tyr Lys Ala
 290 295 300
 Met Arg Lys Leu Met Lys Gln Val Gln Glu Gln Cys Pro Asn Ile Thr
 305 310 315 320
 Arg Ile Tyr Ser Ile Gly Lys Ser Tyr Gln Gly Leu Lys Leu Tyr Val
 325 330 335
 Met Glu Met Ser Asp Lys Pro Gly Glu His Glu Leu Gly Glu Pro Glu
 340 345 350
 Val Arg Tyr Val Ala Gly Met His Gly Asn Glu Ala Leu Gly Arg Glu
 355 360 365
 Leu Leu Leu Leu Leu Met Gln Phe Leu Cys His Glu Phe Leu Arg Gly
 370 375 380
 Asn Pro Arg Val Thr Arg Leu Leu Ser Glu Met Arg Ile His Leu Leu
 385 390 395 400
 Pro Ser Met Asn Pro Asp Gly Tyr Glu Ile Ala Tyr His Arg Gly Ser
 405 410 415
 Glu Leu Val Gly Trp Ala Glu Gly Arg Trp Asn Asn Gln Ser Ile Asp

```

      420              425              430
Leu Asn His Asn Phe Ala Asp Leu Asn Thr Pro Leu Trp Glu Ala Gln
      435              440              445
Asp Asp Gly Lys Val Pro His Ile Val Pro Asn His His Leu Pro Leu
      450              455              460
Pro Thr Tyr Tyr Thr Leu Pro Asn Ala Thr Val Ala Pro Glu Thr Arg
465      470      475      480
Ala Val Ile Lys Trp Met Lys Arg Ile Pro Phe Val Leu Ser Ala Asn
      485      490      495
Leu His Gly Gly Glu Leu Val Val Ser Tyr Pro Phe Asp Met Thr Arg
      500      505      510
Thr Pro Trp Ala Ala Arg Glu Leu Thr Pro Thr Pro Asp Asp Ala Val
      515      520      525
Phe Arg Trp Leu Ser Thr Val Tyr Ala Gly Ser Asn Leu Ala Met Gln
      530      535      540
Asp Thr Ser Arg Arg Pro Cys His Ser Gln Asp Phe Ser Val His Gly
545      550      555      560
Asn Ile Ile Asn Gly Ala Asp Trp His Thr Val Pro Gly Ser Met Asn
      565      570      575
Asp Phe Ser Tyr Leu His Thr Asn Cys Phe Glu Val Thr Val Glu Leu
      580      585      590
Ser Cys Asp Lys Phe Pro His Glu Asn Glu Leu Pro Gln Glu Trp Glu
      595      600      605
Asn Asn Lys Asp Ala Leu Leu Thr Tyr Leu Glu Gln Val Arg Met Gly
      610      615      620
Ile Ala Gly Val Val Arg Asp Lys Asp Thr Glu Leu Gly Ile Ala Asp
625      630      635      640
Ala Val Ile Ala Val Asp Gly Ile Asn His Asp Val Thr Thr Ala Trp
      645      650      655
Gly Gly Asp Tyr Trp Arg Leu Leu Thr Pro Gly Asp Tyr Met Val Thr
      660      665      670
Ala Ser Ala Glu Gly Tyr His Ser Val Thr Arg Asn Cys Arg Val Thr
      675      680      685
Phe Glu Glu Gly Pro Phe Pro Cys Asn Phe Val Leu Thr Lys Thr Pro
      690      695      700
Lys Gln Arg Leu Arg Glu Leu Leu Ala Ala Gly Ala Lys Val Pro Pro
705      710      715      720
Asp Leu Arg Arg Arg Leu Glu Arg Leu Arg Gly Gln Lys Asp
      725      730

```

<210> 66
 <211> 358
 <212> PRT
 <213> Homo sapiens

```

      <400> 66
Met Pro Glu Asp Val Arg Glu Lys Lys Glu Asn Leu Leu Leu Asn Ser
  1              5              10              15
Glu Arg Ser Thr Arg Leu Leu Thr Lys Thr Ser His Ser Gln Gly Gly
      20      25      30
Asp Gln Ala Leu Ser Lys Ser Thr Gly Ser Pro Thr Glu Lys Leu Ile
      35      40      45
Glu Lys Arg Gln Gly Ala Lys Thr Val Phe Asn Lys Phe Ser Asn Met
      50      55      60
Asn Trp Pro Val Asp Ile His Pro Leu Asn Lys Ser Leu Val Lys Asp
      65      70      75      80
Asn Lys Trp Lys Lys Thr Glu Glu Thr Gln Glu Lys Arg Arg Ser Phe
      85      90      95
Leu Gln Glu Phe Cys Lys Lys Tyr Gly Gly Val Ser His His Gln Ser

```

59/60

60/60

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72961 A3

(51) International Patent Classification⁷: C12N 15/12.
C07K 1/00, 14/00

S. [US/US]: 4138 Presidential Drive, Lafayette Hill, PA 19444 (US). LAI, Ying-Ta [—/US]: 516 Spruce Avenue, Upper Darby, PA 19082 (US).

(21) International Application Number: PCT/US01/09226

(22) International Filing Date: 22 March 2001 (22.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/192.158 24 March 2000 (24.03.2000) US
60/192.668 28 March 2000 (28.03.2000) US
60/200.166 27 April 2000 (27.04.2000) US

(74) Agents: GIMMI, Edward, R. et al.: SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicants (*for all designated States except US*): SMITHKLINE BEECHAM CORPORATION [US/US]: One Franklin Plaza, Philadelphia, PA 19103 (US). SMITHKLINE BEECHAM P.L.C. [GB/GB]: New Horizons Court, Great West Road, Brentford, Middlesex TW8 9EP (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): AGARWAL, Pankaj [IN/US]: 251 West DeKalb Pike, King of Prussia, PA 19406 (US). MURDOCH, Paul, R. [GB/GB]: New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). RIZVI, Safia, K. [PK/US]: 4617 Pine Street, Philadelphia, PA 19143 (US). SMITH, Randall, F. [US/US]: 4138 Presidential Drive, Lafayette Hill, PA 19444 (US). XIANG, Zhaoying [CN/US]: 2413 Ridgeway, Fort Lee, NJ 07024 (US). KABNICK, Karen,

Published:

— with international search report

(88) Date of publication of the international search report:
20 June 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS

(57) Abstract: Polypeptides and polynucleotides of the genes set forth in Table I and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing polypeptides and polynucleotides of the genes set forth in Table I in diagnostic assays.

WO 01/72961 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/09226

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/12; C07K 1/00, 14/00

US CL : 536/23.5, 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5, 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN (Bioscience); East (all databases); sequence search, search terms: slit, leucine-rich repeat.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No. :
Y	Database GenEmbl, Accession Number AC009625, Whitehead Institute/MIT Center for Genome Research, Cambridge, MA, BIRREN et al. 26 August 1999.	1
A, P	Database Geneseq, Accession Number AAB07469, ZYMOGENETICS INC., A human leucine-rich repeat protein designated Zlrr3, WO200042184-A1, 20 JULY 2000, see sequence comparison, closest sequence homology.	1
A	WO 00/42184 A1 (ZYMOGENETICS INC.) 20 July 2000 (20-07-00), see entire document, especially SEQ ID NO:41.	1

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 NOVEMBER 2001

Date of mailing of the international search report

01 FEB 2002

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Dorthea Lawrence
HOLLY SCHNIZER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/09226

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NAKAYAMA et al. Identification of High-Molecular Weight Proteins with multiple EGF-like Motifs by Motif-Trap Screening. Genomics, 1998, Vol. 51, pp. 27-34.	1
A	BROSE et al. Slit Proteins Bind Robo Receptors and Have an Evolutionarily Conserved Role in Repulsive Axon Guidance. Cell. 19 March 1999, Vol. 96, pp. 795-806.	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/09226

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 5-7
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claims 5-7 are not searchable because of improper claim dependencies.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/09226

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim 1, in part, drawn to the special technical feature of a polypeptide of SEQ ID NO:34.

Groups 2-33, claim 1, in part, drawn to the special technical feature of one of the 32 polypeptides of SEQ ID NOs: 35-66, respectively. If any of these groups are elected, Applicant must provide elected SEQ ID NO.

Groups 34-66, claim(s) 2-4, in part, drawn to the special technical feature of one of the 33 polynucleotides of SEQ ID NOs: 1-33, respectively. If any of these groups are elected, Applicant must provide the elected SEQ ID NO.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The nucleic acid molecules with the sequences set forth in SEQ ID NOs: 1-33 have different structural and functional features, therefore SEQ ID NO:1 will be searched. Applicants must pay appropriate fees for a search of each of the other SEQ ID NOs.

The polypeptides comprising SEQ ID NOS: 34-66 have different structural and functional features, therefore SEQ ID NO:34 will be searched. Applicants must pay appropriate fees for a search of each of the other SEQ ID NOs.

The inventions listed as Groups do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

There is no apparent shared common core structure and no apparent shared art recognized function. For example, the polypeptides and polynucleotides were isolated from different tissues, expressed in different tissues, and the polynucleotides encode polypeptides with varying function (various growth factors, matrix proteins, and proteases, for example).

Claims 5-7 are not searchable because of improper claim dependencies.

THIS PAGE BLANK (USPTO)